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ABSTRACT
THE ROLE AND REGULATION OF INHIBITOR OF KAPPA B KINASE (IκK)
IN THE IMPAIRED MONOCYTE RESPONSE
Norman J.Galbraith
November 10th, 2016
Trauma, major surgery and systemic infection can lead to a
subsequent immunosuppressed state which can predispose patients to
nosocomial infection and death. Approximately a sixth of patients will have
impaired monocyte function, as determined by decreased HLA-DR expression
or decreased TNF-α production in response to ex-vivo lipopolysaccharide
(LPS) stimulation. This project aimed to develop an in-vitro model of impaired
monocyte function using isolated monocytes from healthy volunteers, to study
the effect of monocyte impairment on IκK signaling, and determine the role of
IκK in the impaired monocyte response. These studies have provided the
following results:
1. Monocytes treated with low dose LPS (10 ng/mL) exposure exhibit an

impaired inflammatory response to a subsequent 100 ng/mL LPS
challenge. Levels of TNF-α and IL-10 production, as well as monocyte
HLA-DR expression, were decreased in the impaired monocyte
compared with its naïve counterpart.

v

2. Impaired monocytes that exhibited this impaired response were found

to have decreased NFκB activation. In addition, while total levels of
IκK-α and IκK-β were similar between naïve and impaired conditions,
decreased IκK phosphorylation was observed in the impaired
monocyte.
3. Loss of IκK function studies using IκK-16 (a specific IκK inhibitor)

showed that decreases in both TNF-α and IL-10 production were
attributable to decreased IκK activation, demonstrating a causal
relationship between IκK function and the monocyte cytokine response.
However, HLA-DR expression was not dependent on IκK function,
suggesting that other signaling pathways may also be altered in
monocyte impairment that may affect HLA-DR expression.
4. The impaired monocyte phenotype also results in decreased

chemokine production (such as MCP-1 and IP-10) and growth factor
secretion (such as GM-CSF).

Our data highlight the importance of IκK function in the host defense response
to infective stimuli, but also demonstrate the effects of negative feedback
regulation following a primary stimulus. Excessive IκK stimulation, or indeed
suppression of IκK activity, is likely to be detrimental to the surgical patient.
Future studies of IκK function in the surgical patient, as well as translating
potential therapies to modulate the IκK pathway, could ameliorate monocyte
impairment and decrease the susceptibility to infection in the surgical patient.
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CHAPTER I
GENERAL INTRODUCTION
Major insults to the body, such as trauma, surgery or infection, can lead to a
complex and sometimes harmful inflammatory response. The systemic
release of DAMPs and PAMPs stimulate toll-like receptors to cause an initial
upregulation of pro-inflammatory cytokines which is met with a downregulation
of antigen presenting proteins 1. A loss of this fine balance can result in
impaired monocyte function which is typified by decreased cytokine
production (e.g. tumor-necrosis factor alpha (TNF-α)) and decreased HLA-DR
expression 2,3. Monocyte impairment, which is seen in approximately a sixth of
patients after such an insult, has repeatedly predicted infective complications
and mortality 4.
The pathophysiological response underpinning this form of
immunosuppression is complex and poorly understood (Figure 1). The
commonly held belief is that as a result of the initial stimulation, such as from
lipopolysaccharide (LPS), negative feedback molecules increase which
inhibits toll-like receptor signaling, thus preventing the propagation of any
potential responses from subsequent stimuli 5. Numerous observations from
clinical studies and from animal and in-vitro models suggest that important
intracellular inflammatory signaling pathways such as nuclear factor kappa-B
(NFκB) are subsequently suppressed, resulting in a decreased cytokine
response 6,7.

1

Due to such an incomplete understanding of how host defenses respond to an
endotoxin challenge, there are no early, reliable validated markers for
identifying and predicting patients with monocyte impairment who are at risk
of complications at the time of writing 8. Furthermore, there are no clinically
proven adjunctive immune therapies to improve mortality by augmentation of
monocyte function in this subset of surgical patients 9.
The purpose of this work is to develop a model of impaired monocyte function
in order to understand the changes in inflammatory signaling pathways that
result in a suppressed monocyte inflammatory response, and specifically the
role and regulation of Inhibitor of Kappa-B Kinase (IκK), a critical link between
toll-like receptor signaling and NFκB activation in this setting.

2

3

Figure 1. The immune response in the critically-ill surgical patient.

NET

reoperations

Legend to Figure 1.

Surgical insults such as trauma, major infection and surgery itself leads to
poorly understood pro-inflammatory and compensatory anti-inflammatory
mechanisms. Approximately a sixth of patients will develop impaired
monocyte function. This immunopathology is a contributory factor to the death
of some surgical patients, and remains a potentially modifiable aspect of
surgical care. Challenges remain in defining which patient, which adjuvant to
give, when and for how long to deliver it. A better understanding of this
complex immune response could help answer these questions.
(Adapted from Krezalek et al, Shock, 2016

4

10

).

CHAPTER II
THE SIGNIFICANCE OF MONOCYTE IMPAIRMENT IN THE SURGICAL
PATIENT

a. Background
Significant insults to the body such as trauma, major surgery and overt sepsis
of other origins are associated with the release of danger associated
molecular patterns and/or pathogen associated molecular patterns. In the
surgical patient, these can range from gram negative bacterial of enteric origin
to intracellular proteins and mitochondrial DNA from cell necrosis as a result
of major trauma. These molecules act as agonists to numerous receptors,
such as toll-like receptors, expressed on the surface of circulating and fixed
leukocytes. Systemic release of signaling molecules, including cytokines and
acute phase proteins lead the systemic inflammatory response with a
subsequent cascade of host defense dysregulation. If this phase is excessive
or prolonged, it is thought by some to lead to harmful consequences, including
multi-organ failure and death. The traditionally taught tri-phasic model of
death following trauma describes many patients who survive the initial insult
then suffer later infections in a setting of immune suppression, engendering
the term “immunoparalysis” 11-14. This chapter aims to give an overview of
what we believe to be a central component of this process: monocyte
impairment in the surgical patient. In this chapter, the work of often large

5

groups is identified by the first and/or senior author of the reference. Table 1
is a list of abbreviations.
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Table 1. List of abbreviations.
A20
BCL

See TNFAIP
B-cell CLL lymphoma

MKP1
MyD88

CaCP29

Monoclonal antibody targeting the
complement cascade
Chemokine (C-C motif) ligand

NEMO

CD
(14/16)
CLP

Cluster differentiation

NK cells

Cecal ligation and puncture

NOD

CREB

cyclic AMP responsive element binding
protein
Chemokine (C-X-C motif) ligand

P65

PBMC
PD-1
PD-L1

GM-CSF

Danger associated molecular patterns
Enzyme linked immunosorbent assay
Granulocyte colony stimulating factor
Glyceraldehyde 3-phosphate
dehydrogenase
Granulocyte-macrophage stimulating factor

Pathogen associated molecular
patterns
Peripheral blood mononuclear cells
Programmed cell death 1
Programmed cell death ligand 1

Poly (I:C)

Polyinosinic:polycytidylic acid

GUSB
HLA-DR

Glucuronidase Beta
Human leukocyte antigen DR

PPAR

Peroxisome proliferation-activated
receptor

HMGB1

High mobility group box 1

HRPT

Hypoxanthine Phosphoribosyltransferase

RAGE

receptor for advanced glycation endproducts

ICU

Intensive care unit

RAW 264.7

IFN
IL (1, 6,
10, 12)
IRAK

Interferon
Interleukin

RCT
RNA

Name of a commonly used murine
macrophage cell line
Randomized controlled trial
Ribonucleic acid

IL-1β receptor associated kinase

ROI/ROS

IRF
IκB

Interferon regulatory factor
Inhibitor of κB

SOCS
STAT

IκK

Inhibitor of κB kinase

TAK1

JAK
LPS
LTA

Janus kinase
Lipopolysaccharide
Lipoteichoic acid

MAPK
MCP-1
MD-2

Mitogen-activated protein kinase
Monocyte chemotactic protein-1
Lymphocyte antigen 96

TCR
TH (1/2)
THP1 &
U937
THR
TLR
TNFAIP

MDP
MHC

Muramyl dipeptide
Major histocompatibility complex

TNF-α
TRAF6

MIG

Monokine inducible by interferon-γ

TRIF

CCL

CXCL
DAMP
ELISA
G-CSF
GAPDH

NFκB

PAMP

7

MAPK phosphatase-1
Myeloid differentiation primary
response gene 88
NFκB essential modulator
Nuclear factor kappa-light-chain
enhancer of activated B cells
Natural killer cells
Nucleotide-binding oligomerization
domain
A subunit of the NFκB complex

Reactive oxygen
intermediates/species
Suppressor of cytokine signaling
Signal transducer and activator of
transcription
Transforming growth factor betaactivating kinase 1
T-cell receptor
T-helper
Names of commonly used human
monocytic cell lines
Total hip replacement
Toll-like receptor
Tumor necrosis factor alpha inducible
protein
Tumor necrosis factor alpha
Tumor necrosis factor receptor
associated factor
Toll/IL-1 receptor domain-containing
adaptor-inducing interferon- β

Figure 2. Monocyte HLA-DR expression and outcomes in trauma patients.

.

Outcomes are labeled as an uncomplicated recovery (O), survivors with posttraumatic infection (□) and non-survivors (∆). Note the patient trajectory
between groups becomes apparent only by day 4-6 after injury, based on this
marker.
(From Hershman et al, Br J Surg, 1990. 15)
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Systematic observations of host defense mechanisms in ill patients
prompted the recognition of the importance of the impaired monocyte,
contrary to their null hypothesis 4. Specifically, a subset of approximately 15%
of patients exhibited subnormal monocyte function and were at higher risk of
developing infection and of death

15

. This is illustrated in Figure 2, where

differences in monocyte HLA-DR expression, a cell surface marker, become
increasingly predictive of a patients outcome after days 4-6 following major
trauma.
The ultimate goal for laboratory and clinical investigators is not just to
identify such “high risk” patients, but also to augment host defenses. This
principle is illustrated in Figure 3, where the addition of muramyl dipeptide
(MDP) in a rat model of a contaminated wound promotes containment, as
opposed to permissive progression to bacteremia and subsequent systemic
deleterious consequences 16.
The central factor that determines a patient’s fate following a major
insult remains unclear. In a group of patients given the same equivalent insult,
many will be “aces” and survive, but a subset will be “dogs” and not survive
(Fry DE, unpublished). Firstly, genetic predisposition can lead to subnormal
host defenses. Secondly, the heterogeneous nature of an insult and its
severity can also be decisive and thirdly, epigenetic changes, such as in
microRNA (miRNA), may significantly result in post-translational modification
of important pro- and anti-inflammatory signaling. Finally, prompt and attentive
supportive care with timely surgical intervention and precise non-operative
care can massively shift the balance for some patients.

9

10

A

B

C

Figure 3. Muramyl dipeptide (MDP) augmentation of bacterial containment in a model of wound contamination.

Legend to Figure 3.

Infection in skeletal muscle is contained better by MDP (●) than by placebo
(O). As time passes from 6 hours after contamination in A, note MDP
produces constant levels of localized bacteria where placebo treated animals
experienced escape of bacteria into blood by 48 hours (C). This experiment
exemplifies the potential clinical benefit from immune enhancement.
(Adapted from Polk et al, Infect Immun, 1990. 16)
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b. The role of the healthy monocyte
The monocyte is central to the innate immune system in the surgical patient.
Its key roles are cytokine production, antigen presentation, and phagocytosis
(Figure 4). Early recognition of PAMPs & DAMPs from invading microbes and
damaged tissue activate monocytes through surface receptors such as
extracellular toll like receptors, and intracellular receptors such as NOD-like
receptors, RAGE receptors and certain toll-like receptors.
This leads to the infiltration of neutrophils, traditionally the first
leukocyte on the scene. These polymorphonuclear cells have the most potent
phagocytic ability, which are followed by infiltrating circulating monocytes due
to chemokines. These can differentiate and thus expand the numbers of
tissue macrophages. Throughout this process, monocytes secrete cytokines
which have systemic consequences on remote organs such as the liver,
gastrointestinal system and endothelium, especially that in lung parenchyma.
Furthermore, this cell-to-cell communication leads to a crucial link to the
adaptive immune system through complex T-cell interactions. The monocyte,
and other antigen presenting cells, allow fragments of invading bacteria, such
as LPS, to be processed in vesicles and externalized through MHC II
complexes, such as HLA-DR, that bind to T-cell receptors on receptive Tcells. This bi-directional interaction can also further promote
monocyte/macrophage activation through endogenous IFN-γ from T-cells and
natural killer cells. However, in patients with a subnormal immune system or
persistent antigen stimulation, this process can be blunted through the
promotion of negative co-stimulatory molecules such as PD-1/PD-L1 surface
molecules.
12

Figure 4. Basic monocyte functions.

The monocyte is a highly important circulating leukocyte which links the innate
to adaptive immune systems. Its primary functions include cytokine production
(such as TNF-α, IL-10, IL-1β and IL-12), antigen presentation (through major
histocompatibility complexes such as HLA-DR) and phagocytosis. Impairment
of the first two functions have been correlated with poor outcomes in surgical
patients, thus we believe that they are the two most clinically relevant
functions to study.
Original figure by Norman Galbraith and Samuel Walker (student).
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Invading microbes initially evoke a T-helper (Th) 1 response from CD4 T-cells.
In this type of response, T-cells secrete IFN-γ and IL-2, further promoting and
activating monocytes and macrophages in a pro-inflammatory manner. While
this response is linked to the “M1” pro-inflammatory macrophage, the
alternative Th2 response (associated with allergens and Helminths) secretes
IL-10 and IL-4 promoting the “M2” anti-inflammatory macrophage.
Cytokines are secreted proteins, acting in a paracrine manner to influence
the differentiation and response of surrounding immune cells. Of a multitude
of cytokines that monocytes secrete, the most clinically studied (and their
function) include;


Pro-inflammatory cytokines
o TNF-α - promotes inflammation and endothelial activation
o IL-6 - acute phase response promoting fever and T/B cell growth
o IL-1β - fever, activation of monocytes, macrophages, T-cell
activation



Anti-inflammatory cytokines
o

IL-10 - suppresses monocyte function

Cytokines influencing monocyte behavior are discussed below. While
monocytes do phagocytize bacterial pathogens, defects in its phagocytic
ability appearing to be less important in the fate of the surgical patient when
compared to altered cytokine release and antigen presentation.
Monocytes are now considered to be of three main types 17:

14

1. The classical monocyte accounts for the vast majority of
circulating monocytes, expressing high CD14, medium HLA-DR
expression, but no CD16 expression (CD14++ CD16-). These cells
produce both TNF-α and IL-10.
2. Non-classical monocytes express lower levels of CD14, but high
CD16 and HLA-DR (CD14+CD16++). They secrete TNF-α but not
IL-10.
3. Finally intermediate monocytes express high levels of CD14, but
low CD16. (CD14++ CD16+). This subset has gained increasing
recognition over the last 5 years and is noted to have increased IL10 production. Interestingly, they have been correlated with sepsis,
myocardial infarction and early, but not metastatic colorectal cancer
18

.

It is worth noting that monocytes, macrophages and dendritic cells are all
myeloid derived with largely similar expression of toll-like receptors. While this
body of work focuses on the monocyte, many of the concepts discussed
regarding physiology, pathology and therapy can be extended to all the
above.

15

c. Clinical scenarios and the monocyte response
Major trauma & burns
As post-traumatic and indeed all critical care improved, it became apparent
that some survivors of major trauma were susceptible to later infection.
Evidence grew that this may be a consequence of depressed host defenses
19

. Our systematic study of various facets of the innate immune system

revealed that monocyte antigen presenting ability was highly predictive of
infection following major trauma 4. It was apparent that not only absolute
monocyte HLA-DR expression, but the ability to up-regulate this MHC II
surface marker in response to endotoxin exposure was also predictive of
morbidity and mortality. Since then, studies focusing on HLA-DR expression
as a marker of monocyte function demonstrate that this remains consistently
predictive for poor outcomes following trauma as well as folowing burns
(Table 2 2,4,15,20-33). Increasingly, CD14+ HLA-DR- cells are described as
“myeloid derived suppressor cells” and this phenotype has also been
observed in the orthopedic patient following intramedullary nailing following
fracture of the tibia 34.
The revolution of cytokine related research prompted another aspect of
monocyte function to be examined – ex-vivo cytokine production in response
to endotoxin exposure, both in “whole blood” and in isolated peripheral blood
mononuclear cells. In general, early high IL-6 production and subsequent
lower TNF-α production appears to characterize this dysregulation

35

.

Furthermore, the role of the anti-inflammatory IL-10 has long been debated,
but it remains clear that IL-10 acts to inhibit pro-inflammatory pathways. While

16

a homeostatic balance is critical, IL-10 can promote a suppressed monocyte
phenotype 36.

17

Table 2. Salient observations from selected papers relating monocyte function
to clinical outcome.
SENIOR
AUTHOR

KEY
OBSERVATION

CLINICAL SETTING

OUTCOME

JOURNAL, YEAR

HLA-DR

Septic shock

Mortality

Intens. Care M.
2006
Crit Care, 2007

20

MONNERET
VENET

21

HLA-DR

Burns

Septic shock

LAHIRI

22

TLR4/5

Elective
hepatopancreatobiliary
surgery

Ann. Surg, 2015

HLA-DR

Trauma

Systemic
inflammatory
response
syndrome
Mortality

HLA-DR

Trauma

Infection

Am. J. Surg, 1991

TNF-α

Trauma

Sepsis & multiorgan failure

Shock 2006

HLA-DR
LPS induced
HLA-DR

Trauma

Infection
Mortality

British Journal of
Surgery, 1990

HLA-DR

Pancreatitis

Secondary
infection

Hepatogastroenterology 2013

STAT3, CREB,
NFκB

Elective THR

Recovery,
function, pain

Sci. Trans. Med.
2014

IL-6

Elective
gastrointestinal
surgery

Post-operative
infection

Ann. Surg. 2015

IL-10

Trauma

Septic events

Ann. Surg. 1997

IL-6, IL-10

Trauma

Mortality

Acta Anaesth.
Scand. 2009

HLA-DR

Pediatric lung
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Findings of the Inflammation and the Host Response to Injury Large Scale
Collaborative Research Program relating to monocyte function
A highly funded multi-center project, the “Glue Grant”, aimed to take a
‘systems approach’ to the host inflammatory response to trauma and burns,
primarily focusing on gene expression studies1. This design was to lessen the
reductionist approach of multiple groups focusing on one single aspect of the
host defenses which was seen as likely to fail given the redundancy of the
immune system. It is worth noting that the patients studied were critically ill;
generally being hypotensive, having received blood products, and
demonstrating some form of organ dysfunction. Selected papers from this
effort pertaining to monocyte impairment are discussed below.
Xaio et al 1 sequentially studied peripheral blood leukocyte genome
wide expression of mRNA in 167 severely injured trauma patients up to 28
days after injury. In addition, patients with greater than 20% burns and healthy
individuals were analyzed. A change in over 80% of gene expression, termed
a “genomic storm”, was observed. This response to trauma was non-specific,
with 98% of the same genomic changes seen in burn patients, and 88% of
that seen in experimental endotoxemia. A complicated recovery was
associated with the up-regulation of innate immunity genes including IL-6 and
IL-10, with a simultaneous down-regulation of adaptive immunity genes such
as those relating to antigen presentation. Importantly, they demonstrated that
contrary to conventional thinking, leukocyte genomic responses of both proand anti-inflammatory pathways were simultaneous, rather than a so-called

1

The Glue Grant: Inflammatory and the host response to injury (PI: Tompkins RG). National Institute
of General Medical Sciences.
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“second hit” or insult causing the anti-inflammatory component 1. Laudanski et
al examined both monocyte and T-cell pathways of 18 trauma patients using
high throughput screening of gene expression 37. Interestingly, the response
to trauma was very specific to the cell type, with only 11% of pathways
common to both monocytes and T-cells, such as a down-regulation of the
transcription factor NFκB. This further demonstrated a down-regulation of
antigen presentation genes such as HLA-DR and CD86, with an increase in
monocyte negative co-stimulatory genes such as PD-L2. In keeping with the
down-regulation of antigen presenting pathways in monocytes, T-cells
demonstrated molecular choreography with reciprocal increases in genes
relating to apoptosis and anergy 37.
In a more recent study from the same dataset, 8% of the 1595 subjects
included had proven gram negative bacteremia. These 127 patients had an
increased risk of mortality (21%), compared with those without infection
(11%). Gene expression of these patients was compared with those who did
not contract infection, showing certain pro-inflammatory pathways to be
similar 12 hours following injury. However, at 96 hours after injury IL-1β and
IL-2RB were markedly decreased in those who died. Furthermore, expression
of genes relating to monocytes such as HLA-DR and CD163 was similarly
increased at 12 hours after injury, but at 96 hours a significant decrease in
gene expression were apparent in the group who went on to develop gram
negative bacteremia 38. This project has increased our understanding of the
pathways involved in host defenses following major trauma. Perhaps not
surprisingly given the recognition of such complexity, the surgeon remains illequipped to confidently or specifically modulate this response.
20

Inflammatory networks following trauma
Since the prior project came to an end, other groups have adopted a ‘systems
biology’ approach to better understand inflammatory networks after major
trauma. The Pittsburgh group studied 472 survivors of blunt trauma for
circulating plasma cytokines and chemokines. The findings were analyzed
using emerging computational methods reflecting that various patterns were
demonstrable in the first 24 hours, much earlier than the diagnosis of infection
made 7 days after injury. Serum markers that were significantly elevated in
patients who later developed infection include HMGB1, IL-6 and IL-1RA, to
name a few. Dynamic Bayesian networks inferred that IL-6 was affected by
various chemokines, such as MCP-1 and MIG 39,40.
Major elective surgery
Major abdominal operations, and general anesthesia, have long been
associated with post-operative immunosuppression. Factors such as
increasing age, prevalence of diabetes mellitus and immunosuppressive
medications (neoadjuvant chemotherapy, glucocorticoids and monoclonal
antibodies such as anti-TNF-α antibodies) increase the relevance of this
concept today. However, the prevalence of impaired monocyte function also
extends to the patients of neurosurgeons, transplant surgeons and cardiac
surgeons 41-43. More recently, Albertsmeier showed that major abdominal
surgery leads to an expansion of CD14+ HLA-DR- cells. This group of
monocytes secreted TNF-α and IL-6, but when co-cultured with T-cells led to
decreased T-cell IFN-γ secretion 44. Studies in the last few years have
demonstrated how surgical approaches can also influence monocyte
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behavior, as discussed later. Furthermore, dysregulation of pro-inflammatory
pathways in monocyte subsets, such as NFκB in intermediate monocytes, led
to higher TLR and IL-6 expression that was associated with increased
infective complications 22,26.
Overt sepsis
Major infection, namely severe sepsis and septic shock, is the most common
clinical event associated with monocyte impairment. While the majority of
studies use flow cytometry to quantify either the percentage of monocytes
expressing HLA-DR, or mean fluorescence intensity, more recent studies
show that gene expression of HLA-DR is also predictive of infective
complications 21,45. Furthermore, bench to bedside studies of monocyte
impairment reveal dysregulated gene expression patterns, including genes
such as S100A8/9, TNFAIP6 and IRAK-M (as well as TNF-α, IL-10 and HLADR) which have been suggested to “monitor efficacy” of IFN-γ therapy 46-48.
There has been increased interest over the past decade in the
differential expression of negative co-stimulatory molecules in septic patients.
This has been in part due to the recognition of T-cell anergy and apoptosis as
a driver of immune suppression, which is also observed in some cancers

49

.

Monocyte co-stimulatory antigens such as CD86 and PD-L1 correspond to Tcell CD28 & PD-1 respectively, which may be considered “on” and “off”
switches in addition to the central HLA-DR–T-cell receptor (TCR) interaction.
The potential importance of negative co-stimulatory molecules has been
highlighted by reported improved mortality in murine models of surgical sepsis
from PD-1/PD-L1 blockade 50,51. Various clinical observations have found
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increased monocyte PD-L1 as well as increased T-cell PD-1 expression in
infected patients. In one study of 64 patients with septic shock, of which 42%
had an abdominal source, had increased expression of monocyte PD-L1 and
T-cell PD-1 compared to healthy controls, which was also predictive of
secondary nosocomial infection 33. In another study of 90 critically ill surgical
patients, blood samples within 24 hours of admission to the ICU showed
increased monocyte PD-1 expression, correlating with APACHE II scores

52

.

In addition, certain PD-1 polymorphisms have been associated with higher
mortality in a study of 221 patients diagnosed with sepsis or septic shock, in
which lung infections were the most common source of infection 53.

d. Patient factors influencing monocyte function
The practicing surgeon caring for sick surgical patients may adversely
influence monocyte function unknowingly, as summarized in Table 3 54-63.
Experimental models have shown that protecting patients from unintentional
hypothermia may promote the pro-inflammatory response through increased
miRNA-155 expression and subsequent higher TNF-α and lower IL-10
production 54. The once popular very precise glucose control in critical care
environments may risk harmful hypoglycemic episodes, but also blunt the
cytokine and bactericidal properties of the monocyte

55

. Supplemental oxygen,

to an inspired oxygen concentration of 80% appears to have mixed effects on
the monocyte and in particular increases reactive oxygen species 56. The
immunosuppressive effects of blood transfusion have been recognized for
many years, but recent studies implicate small circulating biomolecules, such
as protein-bound or exosomal miRNAs that may also inhibit monocyte HLA23

DR expression 58. The role of minimally invasive surgery on monocyte
function has remained controversial 64. Recent studies have suggested that
minimally invasive surgery, such as laparoscopic or robotic approaches, are
less immunosuppressive, as compared to major open colorectal and liver
surgery 59-63.
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Table 3. Clinical factors influencing monocyte function.

Clinical factor

Parameter

Impact

Selected references

Temperature (hyperthermia)

TNF-α

Increase

Billeter, FASEB, 2014
54

TNF-α
Reactive oxygen
species
TNF-α
Reactive oxygen
species
LPS induced TNF-α
IL-6

Increase
Decrease

Qadan, JACS, 2010 55

Decrease
Increase

Qadan,
Anaesthesiology, 2010

Laparoscopic (over open total
mesorectal excision)

HLA-DR
IL-6

Increase
Decrease

Robotic (over open
colectomy)

HLA-DR (equivalent
to laparoscopic)

Increase

Shibata, Tech.
Coloproc. 2015 60

Laparoscopic (over open liver
resection)

HLA-DR

Increase

Chopra, JSLS, 2013 61

Laparoscopic (over open
contaminated
cholecystectomy)

HLA-DR

Increase

Sista, WJGS, 2013 62

Laparoscopic (better than
open colectomy,
independent of fast-track)

HLA-DR

Increase

Veenhof, Ann. Surg.,
2012 63

Glucose (hyperglycemia)

Oxygen (supplemental)

Blood Transfusion
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56

Decrease

Muszynski,
Transfusion, 2014 &
2015 57,58
Veenhof, Int. J.
Colorec. Dis, 2011 59

e. Defining and studying the impaired monocyte
Clinical studies have shown that monocyte impairment, also described as
“endotoxin tolerance”, is not common in most surgical patients and pertains to
only some previously unsuspected patients. Therefore, it becomes difficult to
adequately power and fund clinical studies to examine mechanisms behind
this pathology.
Over the last 15 years, both in-vitro and in-vivo murine models have been
used to study endotoxin tolerance. Endotoxin tolerance was discovered by
Beeson, who found that repeated injection of endotoxin led to a progressively
decreased febrile response 65. We now know that exposure to endotoxin,
often LPS, stimulates various negative regulators to inhibit a subsequent
response when compared to a naïve cell. This has been shown to be akin to
the impaired monocyte response seen in the critically ill surgical patient 7. We
consider monocyte impairment and endotoxin tolerance in monocytes to be a
very similar phenomenon. Various studies have shown “cross-tolerance”, in
that the same molecular mechanisms behind such impairment also occur with
other so called “priming” agents including:


PAMPs/DAMPs
o Lipoteichoic acid (TLR2)
o Poly (I:C) (TLR3)
o High mobility box group 1 (TLR2 & 4)



Cytokines
o IL-1β
o IL-6
26

o TNF-α
o IL-10 5
Common models include isolated primary cells such as CD14
monocytes and PBMCs as well as cell lines such as THP1 and U937
monocytes, and RAW 264.7 macrophages. In-vivo models expose mice to low
dose intraperitoneal LPS, followed either by ex-vivo stimulation, or in-vivo
cecal ligation and puncture. Human in-vivo models have used subcutaneous
LPS, followed by ex-vivo leukocyte stimulation 66. The most accepted in-vitro
outcome of the LPS pre-treated “impaired” cell is reduced TNF-α production
compared to naïve cells, measured either by supernatant protein secretion by
ELISA or gene expression of TNF-α mRNA. Other cytokines have been
reported variably 5. Although reported less frequently, this approach is thought
to represent monocytes with reduced antigen presenting capability 67,68.
Pathophysiological mechanisms behind the impairment of the
monocyte response are complex and influence various molecular pathways
(Figure 5 5). In toll-like receptor signaling, the MyD88-dependent pathway is
inhibited at various levels such as sMyD88 and IRAK-M that inhibits TRAF6.
Furthermore, A20 increases and thus inhibits TRAF6 via deubiquitination. It is
at this level that Pellino-1, a positive regulator, is decreased in impaired cells
69

. Recently monocyte impairment has also been associated with disruption of

the interaction between IRAK1 and IκK-γ (also known as NEMO) although the
level and function of IκK-α and –β are relatively unknown 70.
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Figure 5. Negative regulators involved in monocyte impairment (endotoxin tolerance).

Legend for Figure 5.

Homeostatic mechanisms to prevent excessive inflammation and promote the
resolution of the response are in part regulated by intracellular negative
regulator molecules. These regulators act to suppress and downregulate the
production and/or activation of key pro-inflammatory pathways. Note a
number of epigenetic mechanisms that control toll-like receptor signaling
exist, such as post-transcriptional silencing by microRNA-146a, and A20
which promotes the deubiquintation of TRAF-6.
(Modified from Biswas, Frontiers in Immunology, 2009 5.)
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The initial LPS stimulation decreases the degradation of IκB in impaired
monocytes, which act as the “brakes” in the NFκB pathway. Therefore, there
is decreased p65 phosphorylation and subsequent translocation to the
nucleus, in part explaining the decreased gene expression of proinflammatory cytokines. Furthermore, the non-canonical NFκB pathway has
been reported to be involved, with impaired cells having increased expression
of RelB, c-Jun and the homodimer of p50-p50 of NFκB rather than the more
commonly expressed p-65-p50 heterodimer 71.
The MAPK pathway is also dysregulated, with evidence of decreased
TAK1 phosphorylation in impaired cells, which leads to decreased MAPK p38
phosphorylation 70. Other known negative regulators that are not discussed
here include SOCS1, SOCS3, BCL3, PPAR-γ and CREB 5.
MicroRNAs (miRNAs) are short, non-coding RNA molecules involved in
post-transcriptional regulation of gene expression. Various miRNAs are
dysregulated in monocyte impairment, with miRNA-146a being the most
studied. This increases as a physiological response to LPS, and subsequently
inhibits TRAF6 and IRAK1. Murine knock-out or antagomiR-mediated
inhibition of miRNA-146a rescues the impaired response. Further miRNAs
shown to influence monocyte impairment include let-7a, miR-223, -221, -9, 150 and -1325.
However, despite the manipulation of numerous negative regulators
demonstrated in-vitro to improve the monocyte response, none of these are
known to have gained scientific momentum or reached the bedside. Such
complexity highlights the redundant nature of our evolved immune system.
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Furthermore, murine studies of sepsis, such as those using models of cecal
ligation and puncture (CLP), have for many years raised unfulfilled hope in
potential immunotherapies for the impaired monocyte, but have not yet
translated to clinical success. One reason for this might be that not all of the
immune system is conserved from mice to man. Murine models are overtly
oversimplified - there are no additional variables such as blood transfusion,
fluid resuscitation, antibiotic therapy and other co-morbidity. Finally, genetic
variations in patients are obviously not represented in the narrow pool of mice
and cell lines.

f. Inhibitor of κB Kinase (IκK) – the known and unknowns governing
the gateway from TLR to NFκB

IκK is an intracellular protein complex involved in the canonical pathway of the
NFκB pro-inflammatory signaling pathway. The complex is made up primarily
of 3 subunits; IκK-α, IκK-β and IκK-γ (also known as NEMO) (Figure 6) . The
first two subunits are considered catalytic subunits which are primarily
involved in the propagation of a response from upstream signals, often
secondary to stimulation by IL-1β, TNF-α or a TLR ligand such as LPS.
IκK-α (also known as IκK-1 or CHUK) is involved in both the
canonical pathway with IκK-β, but also plays a role in the non-canonical
signaling pathway in response to ligands such as lymphotoxin B, which
activates NFκB inducing kinase (NIK) to phosphorylate IκK-α. This in turn
cleaves p52 and RelB as a heterodimer from the p100 NFκB subunit.
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IκK-β (IκK2) is considered the main active subunit in the canonical
NFκB pathway. This subunit is bound to IκK-α, and through activation of a
variety of upstream pathways (most commonly through MyD88/TRAF-6/TAK1) both the α and β subunits can be phosphorylated. It should be noted that
upstream input signals for IκK phosphorylation are extraordinarily complex
with various levels of regulation from related kinases and phosphatases. It
has been shown that IκK phosphorylation is not dependent on TAK-1 alone,
with over 15 potential input sources 72,73 Phosphorylation of the α & -β
subunits leads to a conformational change allowing the complex to undertake
its primary role of phosphorylating IκB, as its name suggests. IκB
phosphorylation is the critical step in NFκB activation. IκB act as the “brakes”
in this pathway, and once phosphorylation occurs IκB then undergoes
ubiquitination and subsequent proteosomal degradation. This allows the main
active NFκB complex comprising of the p65 (RelA) and p50 heterodimer to be
“released”, where it translocates from the cytoplasm to the nucleus. Here,
NFκB promotes the transcription of pro-inflammatory genes such as TNF-α,
IL-10, IL-6 among many others.
The IκK-γ (NEMO) subunit is considered a regulatory unit, rather
than a catalytic unit, meaning that it chaperones the α and β subunits from
TRAF-6 and TAK-1 towards the NFκB subunit following activation. A fourth
IκK subunit, IκK-ε (Also termed IκK-i) exists but this subunit is part of a
separate signaling cascade, along with TBK1, that activates the transcription
factor IRF3 to promote type I interferon production. Experimental evidence
suggests that IκK-β and IκK-γ are critical for NFκB activation in order to mount
a sufficient pro-inflammatory response against stimuli 73.
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Figure 6. Inhibitor of κB Kinase (IκK) pathway in the activation of NFκB

The classical pathway of IκK is activated by various DAMPs and PAMPs such
as LPS. Phosphorylation of the IκK-α and/or –β subunits activates the IκK
complex, which directly phosphorylates IκBα. This leads to the degradation of
these “brakes” releasing the p65/p50 heterodimer (the key active canonical
NFκB subunits) to become phosphorylated themselves and translocate the
nucleus for the transcription of pro-inflammatory genes.
(Adapted from Luo et al, Journal of Clinical Investigation, 2005
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74

).

Clinical implications of IκK
Numerous studies over the years have investigated the
dysregulation of cytokines that are dependent on IκK & NFκB, such as TNF-α
and IL-6, which are predictive of poor outcomes in surgical patients 28,31. More
recent studies have shown that excessive early NFκB stimulation is predictive
of mortality in CLP models and predictive of systemic inflammatory response
syndromes (SIRS) following major elective surgery75, 76. These differences in
the magnitude of activation may be surrogate markers for excessive early
stimulation of IκK, upstream to NFκB in this pathway, however, few studies
have examined IκK activation itself in surgical patients.
The Inflammation and the Host Response to Injury studies have
been discussed earlier. In such high throughput genomic studies where
thousands of mRNA levels are measured sequentially, reports did reveal
some significant changes in IκK mRNA levels in trauma patients. Specifically,
Laudanski et al examined cell-specific mRNA expression in monocytes and Tcells isolated from trauma patients 37. IκK-β was downregulated and IκK-ε was
upregulated in the monocyte when compared to healthy controls. Upstream of
IκK, NIK was also upregulated. T-cells demonstrated a similar pattern of IκK-β
downregulation. IκK-α was not different and IκK-γ was upregulated compared
to healthy controls.
Various studies of in-vitro and in-vivo models have
demonstrated IκK phosphorylation in response to LPS and CLP, respectively
77

. There has been increasing attention towards IκK blockers as a potential

therapeutic target to prevent excessive inflammation. Of interest, one IκK
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blocker, SAR113945, was used in a phase II trial via intra-articular injection
for osteoarthritis in Germany (clinicaltrials.gov).
In 2013, Coldewey and colleagues used another IκK blocker
(IκK-16) in a mouse model of peritonitis 78. They found that IκK-16 was
effective in preventing the degradation of IκB, limiting inflammation and
decreasing lung injury caused by the infection. A group from China in 2014
found that IκK-16 was effective in reducing end organ failure in a rat model of
ventilator-assisted lung injury 79.
More recently, Sordi et al used IκK-16 by intraperitoneal
injection in a rat model of hemorrhagic shock. The phosphorylation of IκK was
successfully inhibited, with corresponding decreases in pro-inflammatory
cytokines. Treated rats had reduced lung injury, and also renal and hepatic
markers of organ failure were lessened 77. In 2016, the same group reported
the application of IκK-16 in a murine model of sepsis, using both LPS and
CLP, with pre-existing renal impairment (by nephrectomy). This demonstrated
improvements in sepsis-associated myocardial dysfunction 80.
One lesson from history tells us that the therapeutic approach to
immune modulation should not aim to simply prevent or “turn off” inflammation
as this may have unrecognized harmful effects. Li et al examined the effect of
IκK inhibition on other aspects of host defenses in a mouse model of CLP 81.
The benefits of decreased pulmonary edema were seen with IκK inhibition,
and treatment of cultured macrophages did not negatively influence
phagocytosis of bacteria or decrease colony forming units in blood, lung or
peritoneal fluid. Mortality, however, was unchanged.
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In general, IκK appears to be a critical step in mounting a
sufficient inflammatory response to an infective challenge. However,
excessive stimulation appears to lead to exaggerated release of cytokines
and downstream organ dysfunction. These undesireable consequences can
be prevented in surgically relevant animal models of sepsis and shock, which
makes IκK-16 an attractive therapeutic approach. However, we do not know
how IκK function is affected in the context of monocyte impairment, where
immune suppression is part of the pathophysiological problem. In addition, we
do not understand the exact role of IκK in cytokine and antigen presentation
functions, and whether the same benefits of IκK modulation will be seen when
translating this approach to the human inflammatory response.
In summary, the monocyte is a master regulator of the immune
response following major insults to the body through its important roles in
cytokine production and antigen presentation. The functions of these roles are
influenced by a variety of patient factors and by various clinical scenarios.
There is a significant body of evidence that major physiological insults such as
trauma can lead to excessive depression to the responsiveness to LPS and
HLA-DR expression which results in an increased risk of infection and death.
The function and role of IκK in monocyte impairment is not clear. We believe
this complex and clinically relevant phenomenon is worthy of detailed study.

Please note that the text of this chapter has been published in a review. 8
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CHAPTER III
PAST, PRESENT AND FUTURE OF AUGMENTATION OF MONOCYTE
FUNCTION IN THE SURGICAL PATIENT

a. Background
Sepsis is a clinical condition in a patient that has changes in systemic
parameters combined with a proven source of infection. However, the
underlying pathophysiology occurs in response to the dissemination of
bacteria or other PAMPs/DAMPs into the bloodstream. This stimulates toll-like
receptors to produce an inflammatory response, governed NFκB and MAPK
p38 pathways to promote cytokine and chemokine release that results in the
clinical signs and symptoms that many junior physicians recognize. A very
similar response is seen following major trauma. Through the “Surviving
Sepsis Campaign” there has been increased prompt recognition of the early
phases of sepsis, with the aim of early goal-directed therapy such as titrated
fluid boluses, appropriate intravenous antibiotic administration and closer
monitoring of hourly urine outputs and serial lactate measurements. However,
the later phases of a major insult such as major trauma, burns, or major
infection that may include components of immunosuppression remain
oblivious to many clinicians. The simultaneous down-regulation of antigen
presenting genes and those pertaining to adaptive immunity may result in
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reduced HLA-DR expression, decreased TNF-α production in response to
lipopolysaccharide (LPS) exposure and also T-cell anergy. This phenomenon,
discussed in the previous chapter, does not yet have as widely accepted
corrective or adjunctive therapy, although numerous credible laboratories
pursue the subject in their own ways.
A major flaw in many of these studies, including our group’s previous
work, is the failure to define what is the most appropriate threshold in the
laboratory to define impaired monocyte function and the most meaningful
duration of that impairment. While low monocyte HLA-DR expression is
commonly cited as the most commonly used predictive marker of surgical
infection, reports have been variable in part due to a lack of standardization
between laboratories. Newer methods of calibration to calculate the number of
HLA-DR antibodies per cell have somewhat improved upon this problem

82,83

.

Various studies have aimed to boost immune function by increasing the
proportion of normal, activated monocytes (such as with interferon-gamma,
GM-CSF or other agents), but this has failed thus far to consistently show a
reduction in mortality 3,84,85. One of the biggest challenges has been in
defining and identifying this subset of patients, which has in parallel stimulated
the field of endotoxin tolerance research 5,7. This principle is illustrated in
Figure 7, where the monocyte previously stimulated by LPS has a decreased
responsiveness to a subsequent LPS challenge. The role of potential therapy
is demonstrated in Figure 8, an in-vivo model of endotoxin tolerance. Here,
one can see the augmentation of TNF-α production when interferon-gamma is
given subcutaneously. This chapter aims to address the evidence and lessons
learned from previous trials in therapies aimed at restoring monocyte function,
38

and to discuss current and future approaches to this clinically important
conundrum.
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Figure 7. Principle of in-vitro studies of the impaired monocyte.

The naïve monocyte with no previous exposure to endotoxin represents a
healthy response to a challenge, such as LPS, with a high level of TNF-α
production (seen in green). By comparison, the impaired monocytes with
early, low dose exposure to LPS mount an initial response characterized by
high TNF-α levels but then becomes refractory to a subsequent LPS
challenge, characterized by a blunted, lower level of TNF-α levels (seen in
red) when compared against its naïve counterpart.
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Figure 8. Human in-vivo monocyte impairment.

This figure demonstrates human in-vivo monocyte impairment in response to
subcutaneous LPS administration. Compared to the first LPS dose (day 1),
there is decreased monocyte responsiveness with decreased TNF-α
production demonstrated above, to a second dose (day 7). Note partial
reversal with IFN-γ & GM-CSF, when given between doses.
(Adapted from Leentjens et al, Am J Respir Crit Care Med, 2012
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86

).

b. Clinical evidence for therapies:
IFN-γ
Polk et al, Am. J. Surg. 1992 (Trauma) 85
IFN-γ has safely been used in humans for other clinical indications such as
malignancy. A pilot clinical trial of 15 patients who were treated with IFN-γ
following major trauma demonstrated increased monocyte HLA-DR
expression, albeit in a narrowly focused study. This was followed by a larger
prospective randomized controlled trial of 201 patients enrolled with an injury
severity score over 20 with bacterial contamination. Recombinant IFN-γ (100
µg) was given subcutaneously for 10 consecutive days, among 4 medical
centers. HLA-DR expression was augmented for the duration of IFN-γ
treatment; however, levels quickly returned to that of the placebo group after
treatment cessation at day 10 (Figure 9). Patients were followed up to 90
days and it was noted that a quarter of infections occurred after day 11. Fewer
patients required an operation for infection and mortality appeared lower in
the IFN-γ treatment group, although this was not statistically significant. Fever
was experienced in 93% of treated patients as a side effect of therapy. The
authors later concluded that future trials might consider administering doses
on alternate days over a longer duration, with the aim of reducing febrile side
effects yet extending therapy 87. Interestingly, this was a keystone of
concurrent parallel work by Dries et al 84.
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Figure 9. Effect of IFN-γ on monocyte HLA-DR expression in severely
traumatized patients.

For the duration of treatment, the interferon-γ treated group (inverted
triangles) benefit from increased monocyte HLA-DR expression (mean
fluorescence intensity) compared to the placebo group (circles). However,
note the rapid return of monocyte HLA-DR to a similar level to the placebo
group after the final dose of the regimen (given on day 10 post-injury, see red
arrow).
(Adapted from Polk et al, Am. J. Surg., 1992 85).
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Dries et al, Arch. Surg 1994 (Trauma) 84
A second randomized controlled trial was undertaken in parallel, with
416 patients across 9 centers randomized to IFN-γ or placebo. Again, severe
trauma was the indication, but the major difference in design was that doses
were given on alternate days, for 20 days rather than 10 days. The
differences between this and the previous trial are discussed at length
elsewhere 87. The major findings were that all-cause mortality was similar, but
infection related deaths were lower in the treatment group (3% IFN-γ vs. 9%
placebo). The authors noted an unusually high mortality rate in the placebo
group in a single hospital that contributed this large imbalance. Interestingly,
the treatment group did have a longer ICU stay than placebo, perhaps
attributable to investigation of the febrile reaction to therapy. The excess
death rates in the placebo arm in the leading enrolling institutions has not
been solved intellectually or technically.
Docke et al, Nature Medicine, 1997 (Sepsis) 3
In 1997, Docke et al used IFN-γ in 9 patients diagnosed with sepsis
and impaired monocyte function. This “monocyte deactivation” was defined as
patients with less than 30% HLA-DR positive monocytes for 2 consecutive
days, in the context of Bone’s criteria for sepsis 88. Therapy was continued
until HLA-DR expression was restored for 2 consecutive days, or 8 days total.
Therapy also boosted ex-vivo TNF-α production when compared to 26
historical controls. This novel approach appeared to help clear infection in 8 of
the 9 patients included. The mortality rate for the treatment group was
reduced from 58% in similar patients to 33%, this study was too small to draw
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conclusions on mortality. This approach of treating only patients with evidence
of monocyte impairment was promising for larger studies. These authors
appear not to have performed or contributed to other trials to enhance the
power of this 9-patient trial.
Wasserman et al, Crit Care Med, 1998 (Burns) 89
This phase III randomized double-blinded trial compared subcutaneous
IFN-γ in 109 burn patients compared with 107 patients receiving placebo.
These patients had severe burns, scoring at least 7 using the abbreviated
burn index. Therapy was started in the first 4 days after thermal injury and
continued daily until 90 days, hospital discharge, or wound closure. IFN-γtreated patients had equivalent rates of major infection and death. The
putative benefits of therapy could have been masked by including patients
with no evidence of monocyte impairment and the inclusion of older, severely
burned patients, likely to die regardless of intervention.
Nakos et al, Crit Care Med 2002 (Trauma) 90
In 2002, Nakos et al studied mechanically ventilated trauma patients
with a decreased alveolar macrophage HLA-DR of less than 30%, obtained
through bronchoscopy (compromising 21 of 52 patients). Patients were
randomized to inhaled recombinant IFN-γ (11 patients) versus placebo (10
patients). Injury severity score was 40 and 43 respectively in these groups.
The treatment group received inhaled IFN-γ three times a day. Investigators
found HLA-DR expression increased from a 16.4% to 44% in the follow up
bronchoscopy on day 3 post injury. This compared with persistence of low
HLA-DR in the placebo group. In addition, there was a decrease in IL-10
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concentration in bronchoalveolar fluid and decreased rates of ventilatorassociated pneumonia compared to placebo. It is not clear whether the
inhaled delivery allowed IFN-γ to have significant systemic effects. Mortality
remained unchanged. This important trial needs to be repeated; the study of
alveolar macrophages with inhaled IFN-γ “therapy” is unique.
Schinkel et al, Shock, 2001 & Licht et al, J. Interfer. Cytoki. Res. 2003
(Major elective surgery) 91,92
The Faist group (both papers) screened 209 patients undergoing major
surgery for pre-operative immunosuppression, as defined by a negative
delayed type hypersensitivity skin test 91. Of these, 46 anergic patients (22%)
were randomized to pre-operative parenteral IFN-γ administration (-7, -5, and
-3 pre-operative days). Visceral, gynecological, vascular, and thoracic
operations were included and were said to be physiologically equivalent in
each group. There was a significant increase in peripheral monocyte HLA-DR,
serum IL-1 and IL-8. LPS induced TNF-α was also augmented. A subsequent
report from the same group in 2003 reported that treated patients
demonstrated increased IL-2R levels and decreased IL-4 levels, without an
effect on IL-10 or lymphocyte proliferation, suggesting a shift to a Th1
phenotype. The authors cited a generally low number of infectious
complications and were unable to demonstrate any real differences in
morbidity and mortality. There are many examples of bias in these trials of
dually reported patients that could warrant repeating the trial in more depth
and breadth, particularly to the extent that skin testing does or does not reflect
monocyte function.
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GM-CSF
Meisel et al, Am J Respir Crit Care Med, 2009 (Sepsis) 93
This prospective, randomized double blinded trial using granulocytemacrophage colony stimulating factor (GM-CSF) was undertaken in very ill
patients, requiring the presence of severe sepsis or septic shock for inclusion.
More specifically, patients were required to have depressed monocyte HLADR expression for two consecutive days. This yielded 38 patients from a total
of 135 who were screened for impaired monocyte function. Pneumonia was
the leading cause of sepsis, accounting for 60% of the 38 patients, while
peritonitis was responsible for 30%. Following 8 days of treatment, all 19
patients in the treatment arm demonstrated increased monocyte HLA-DR
expression, as well as restored ex-vivo TNF-α secretion. Furthermore,
increased T-cell and monocyte counts increased, accompanied by a decrease
in IL-10. Such patients had shorter time of ventilation and shorter ICU stays,
however mortality was 16% in the GM-CSF group vs. 21% in the placebo
group, this did not reach statistical significance.
Leentjens et al, Am J Resp Crit Care Med, 2012(Experimental endotoxemia)86
Leentjens et al successfully induced impaired monocyte function in
healthy volunteers with low dose intravenous LPS. Eighteen males were
randomized to receive IFN-γ, GM-CSF or placebo for 3 alternate day doses,
followed by a second LPS dose on day 7. The placebo group had an initial
increase in the cytokine levels of TNF-α, IL-6, IL-10 and IL-1RA after the first
LPS dose, but after the second dose a reduction in TNF-α production was
seen, in keeping with in-vitro monocyte models (Figure 8). Following the
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second LPS dose, there was a trend of lower IL-10 but this did not reach
statistical significance. HLA-DR expression decreased following the first dose
of LPS, but appeared to recover prior to a subsequent similar depression in
response to the second LPS dose. Compared to placebo, IFN-γ increased
TNF-α and HLA-DR, with decreased IL-10, and was more effective than GMCSF in achieving monocyte activation.
Spies et al, PLoS One, 2015 (Major Elective Surgery)
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This recent randomized controlled trial examined the role of continuous
intravenous infusion of GM-CSF in elective esophageal and pancreatic
resections in preventing post-operative infection. Crucially, only patients with
empirically proven low monocyte HLA-DR expression measured on postoperative day 1 were eligible. While we have discussed using a single
observation to trigger immunoadjuvant therapy, more than one subnormal
value could ascertain the deficiency more clearly. Sixty-one patients in total
were included, equally distributed into a GM-CSF group, influenza vaccination
and placebo. As expected, the GM-CSF treated group developed significantly
higher monocyte HLA-DR expression compared with placebo. However, daily
HLA-DR measurements were used to assess the response and as soon as
the treated patients reached the threshold of 10,000 monoclonal antibodies
(mAb) per cell, therapy was stopped. Therefore, duration of this
immunoadjuvant was short, lasting between 1-3 days of continuous
intravenous infusion. The result of this was a rapid return of monocyte HLADR to the depressed levels of the other two groups by post-operative day 5.
Note the similarity of this “post-treatment dip” to our group’s prior interferongamma study, as demonstrated in Figure 9. Spies et al reported a shorter
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number of “infection days” in the GM-CSF treated patients, but the postoperative infection rate was similar between groups. The learning point may
be that single monocyte HLA-DR measurement of response may not be an
optimum marker of treatment effect. In addition, the immunological benefits
from GM-CSF appear transient (at least in circulating monocytes) and
therefore therapy probably should continue to at least 7-14 days based on
several other studies when the peak of post-operative infection rates might
occur.
The decision to include an arm of influenza vaccine and its apparent
association with increased delirium detracts from the clarity of this work.

G-CSF
Schneider et al, Ann. Surg, 2004 (Major Elective Surgery) 95
Prophylaxis with granulocyte colony stimulating factor (G-CSF) was
given pre-operatively in patients undergoing major extirpative surgery. Sixty
patients were divided equally into three arms; two different G-CSF regimens
and placebo. In the first regimen, subcutaneous G-CSF was given on
perioperative days -2, 1 and 3, compared with the second regimen with a
dose on day -2, with smaller subsequent doses on the following 5 days.
Operations included colectomy, gastrectomy, Whipple
pancreatoduodenectomy, esophagectomy, and liver and lung resection.
Patients who received G-CSF had increased TNF-α production, HLA-DR
expression and exhibited decreased lymphocyte anergy. This led to both
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decreased rates and severity of infection in the treatment group. Interestingly,
the authors stated that, in their opinion, monocyte deactivation was
irreversible, and that this therapy exerted its effects by increasing the
functioning number of leukocytes. While this study included an odd collection
of extensive operations, the differences described are worthy of future work.

Bo et al, L. Crit Care 2011 (Sepsis)
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In 2001, Bo et al undertook a meta-analysis of 12 RCTs using either GCSF or GM-CSF in sepsis. This included a total of 2380 patients. The vast
majority of studies included did not target therapy specifically for those with
impaired monocyte function. While this study demonstrated a trend of lower
deaths in the treatment groups, there were no statistically significant
differences in 28-day mortality for either immunoadjuvant. That being said, in
three trials of G-CSF and one trial of GM-CSF, both agents appeared to
significantly reverse infection.
Alternative approaches
While beyond the scope of this chapter, there have been various
alternative approaches for immunomodulation even including extra-corporeal
blood and plasma filtration. Early work has shown that endotoxin filtration
combined with immune stimulation improves survival in a murine model of
sepsis 97. Endotoxin filtration, such as with polymyxin B cartridges, have been
accepted therapy in Japan in severe sepsis with approval also for many years
in Europe, as discussed by Esteban et al 98. Furthermore, cytokine filters
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(such as CYTOSORB®) have the potential for filtering “harmful” proinflammatory cytokines. This principle is probably oversimplified, and
elucidating optimum timing, if any, will be very difficult. Nevertheless, there is
not yet acceptable evidence at present for its use in USA.

c. Challenges of therapy
Providing the patient with a reliable immunoadjuvant to treat the underlying
pathophysiology of a major insult, whether it specifically addresses monocyte
impairment or other aspects of the response, remains an old conundrum yet
to be resolved.
Spontaneous insults such as major trauma, burns or sepsis are a
difficult issue to control for in a prospective, randomized fashion. With such
heterogeneity, ensuring equal distribution between treatment and placebo
groups is difficult, as discussed. Furthermore, each patient will have
numerous treatments ranging from antibiotics, fluid therapy, inotropic support
and potentially mechanical ventilation, not to mention source control. With so
many variables, proving that the addition of a single adjuvant can make a
statistically significant improvement in mortality becomes difficult.
Many studies may initially show improvement with short term
outcomes, yet when one examines 90 day mortality it often remains
unchanged 99. Timing is a major issue not just for follow up, but also with the
introduction, duration and cessation of therapy given the changing immune
milieu from initial insult to prolonged recovery as discussed earlier.
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The immune system is redundant, which is likely a product of evolution.
With so many different positive and negative effects of various inflammatory
pathways, changing or altering one protein is not likely to ultimately change
the outcome for a given patient. Indeed, it may have unrecognized negative
consequences, such as those seen in early corticosteroid and anti-TNF-α
therapeutic trials. Compare this, however, with the common use of brief
perioperative antibiotic prophylaxis for clean-contaminated elective
operations. Antibiotics were in use by surgeons for more than 20 years before
definitive clinical proof was accomplished; this is now the most common use
of antibiotic agents in the world. In retrospect the persuasive experiment was
the pre-operative antibiotic dose 100.
Although not specifically aimed at monocyte function, a meta-analysis
of the effects of immune adjuvants in the context of sepsis is shown in Figure
10 101.
Early approaches, specifically for sepsis, targeted the apparent
exuberant pro-inflammatory response, the so called “cytokine storm.” The
rational for a therapeutic target was the predominance of TNF-α, IL-6 and IL1β production from innate immune cells such as monocytes, leading to
endothelial activation and the release of acute phase proteins contributing to
vasodilation, shock, acute respiratory distress syndrome and multi-organ
failure. Furthermore, blockage or binding of LPS may be able to lower the
PAMP load to limit the foregoing cascade. A simple “dampening” of the
immune system with corticosteroid therapy has remained controversial.
Moreover, this approach has never convincingly improved mortality. The only
FDA approved sepsis therapy was detracogin alpha (Xigris®), a form of
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activated protein C. Despite the initial success of the PROWESS trial,
concerns for its efficacy and bleeding side effects lead to the subsequent
PROWESS-SHOCK trial in 2012. Those investigators concluded that 28 and
90 day mortality were not significantly different, leading to subsequent
withdrawal of FDA approval 99.
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Figure 10. Therapeutic efficacy of mediator-targeted therapy for sepsis.

Therapeutic efficacy of mediator-targeted therapy for sepsis. This metaanalysis demonstrates relative risks and confidence intervals of various
immune modulators are plotted based on the probability of death compared to
the untreated controls. A relative risk of 1 indicates no difference in survival,
and a relative risk of less than 1 indicates that the therapy has a decreased
probability of death, thus is superior to untreated controls. Unfortunately,
when many of these therapies were expanded to larger studies or different
populations, the potential to improve mortality was not fulfilled.
(Modified from Marshall DC, Trends Mol. Med., 2013
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).

Eritoran is a synthetic lipid A antagonist to MD-2-TLR4 that was
recently used in a randomized controlled trial of 1961 patients diagnosed with
severe sepsis. This followed previous strategies targeting endotoxemia (such
as lipid A antibodies). In this large phase III trial, the placebo group had a
mortality of 27%, much lower than the 40% anticipated by investigators.
Furthermore, patients with gram positive infection actually appeared to do
worse than placebo. In contrast to a smaller phase II trial preceding it, there
was no decrease in 28-day or 1 year mortality 102.

d. The future of monocyte biology in the surgical patient
Since the continued failure of clinical trials to show a mortality benefit
between major trauma and sepsis, consensus in the literature seems to be
moving towards ever more targeted therapy 20,21,49,103. For example, treating
only those patients with depressed monocyte HLA-DR with IFN-γ, rather than
non-specifically treating all patients. Such a strategy surely reduces the
denominator, thus enhancing the demonstrable positive effects of putative
treatments.
This approach, therefore, needs a biomarker that would accurately
represent the underlying immune phenotype, be present early enough to allow
the benefit of therapy, and also respond to therapy in order to guide treatment
response.
In many diseases, miRNAs have been found to be stable and reliable
markers in various conditions, including cancer. Furthermore, various studies
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have identified miRNAs that are dysregulated in patients with sepsis

104-107

.

More recent studies have implicated miRNAs in the host defense to trauma
108-110

. In general, these studies have not been correlated to underlying

monocyte phenotype. It remains unclear if these markers could fulfill some of
our criteria. For example some miRNAs such as miRNA-133a have been
linked to increased mortality in sepsis 111. In-vitro studies using cell lines have
shown that manipulation of such miRNAs could abrogate monocyte
impairment; but as it stands there appears to be no immediate miRNA-based
immunotherapy planned for human trials.
It has been postulated that negative co-stimulatory markers such as
PD-L1 are increased in patients with sepsis. There are few trials
demonstrating this phenotype in major elective surgery or trauma. However,
the apparent success with anti-PD-1 & anti-PD-L1 based therapy for
malignant melanoma in humans may indicate that such therapy could be
utilized for trauma or septic patients exhibiting this immune phenotype.
e. Future immunoadjuvants
It is not just PD-1 based therapies that are targeting T-cell defects in
sepsis patients. Recent murine studies of sepsis models promise that IL-7 and
IL-15 monoclonal antibodies increase the activity and function of T-cells. This
may in turn increase endogenous IFN-γ and restore the healthy monocyte-Tcell interaction. However, much more research is required before this can
reach human clinical trials. The current list of registered trials for trauma and
sepsis relating to monocyte function is summarized in Table 4
(clinicaltrials.gov).
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Table 4. Current trials relating to monocyte function (clinicaltrials.gov).
Trial number

Centre

Type

Setting

Intervention

Status

NCT01649921

Radbound,
Netherlands

Interventional

Sepsis

IFN-γ

Recruiting

NCT02361528

Lyon, France

Interventional

Sepsis (& low
HLA-DR)

GM-CSF

Not yet
open

NCT01653665

Newcastle, UK

Interventional

Sepsis (&
PMN <50%)

GM-CSF

Completed

NCT01495637

Ohio, USA

Interventional

Pediatric
Trauma

GM-CSF

Recruiting

NCT01161745

Changhai,
China

Observational
(for PD-1/PDL1)

Sepsis

N/A

Completed

NCT02246595

Jena, Germany

Interventional

Septic shock

CaCP29

Recruiting

NCT01378169

Paris, France

Observational
(Monocyte
microRNA)

Sepsis

N/A

Unknown

NCT02576459

Bristol-Myers
Squibb, Site not
specified, USA

Interventional

Septic shock

Anti-PD-L1

Not yet
open

NCT02186522

Edinburgh, UK

Observational

Sepsis

N/A

Not yet
open

Last accessed July, 2016.
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f. Conclusion
The predisposition and response of the immune system as a factor in the
outcome of the surgical patient remains as relevant in 2016 as it ever has. As
high-throughput systems approaches to trauma and sepsis, such as the
Inflammation and the Host Response to Injury Project, continues we
recognize an increased level of complexity with more and more molecules
associated with poor outcomes such as nosocomial infection and indeed
death. The field has progressed well beyond a rudimentary pro- or antiinflammatory response to a given insult. Yet the same challenges remain.
With this increased knowledge, how can the physician hijack the immune
system to improve the outcome of a patient? The question of what therapy
might be optimum, and the timing and duration of this, remains.
In a previous chapter, it was discussed how there may be different
components to a patient who has impaired host defenses, and indeed one
biomarker, or therapy may not fit all. For example, perhaps interferon-gamma
or GM-CSF is the right adjuvant for the patient with proven impaired monocyte
function, and anti-PD-1 therapy might be appropriate for the patient with
proven T-cell anergy with elevated PD-1 expression. In this chapter, one of
the most promising agents is still interferon-gamma, but the persuasive trial
that is adequately powered and targeted to those with impaired monocyte
function has not been done. Much of the failed translation of pre-clinical
studies to human trials for certain therapies may be in part due to the limits of
murine research, the complex genetic and post-translational variation in our
patients, and an incomplete understanding of how our very redundant immune
system responds.
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At present, there is insufficient evidence for the use of interferongamma, G-CSF or GM-CSF in the adjuvant setting for major trauma, surgery
or overt infection. Furthermore, new therapies, with apparent success in the
oncologic setting, have yet to be trialed. Currently registered trials discussed
here will hopefully answer some of these questions. We believe that while
mortality has yet to be convincingly reduced with the use of such agents, the
approach of targeting patients with proven monocyte impairment for the right
duration, whatever that might be, holds potential in improving outcomes in
some of our patients.
In summary, this chapter has shown that corrective therapy to restore
monocyte function in surgical patients has gained considerable traction for 30
years, but no convincing improvements in mortality rates have been
demonstrated. Furthermore, these clinical considerations highlight the
incomplete understanding of how the immune response can become
“maladaptive”. In order to achieve the ultimate goal of reliably identifying
patients with impaired monocyte function and to correct this defect to improve
outcomes, there is a need for better understanding the mechanisms by which
the impairment takes place. Therefore, the work in this dissertation focuses on
understanding how an insult such as endotoxin exposure might change
intracellular signaling and lead to a suppression of the human monocyte
inflammatory response.

Please note that the text of this chapter has been published in a review.
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CHAPTER IV
HYPOTHESIS, SPECIFIC AIMS AND EXPERIMENTAL PLAN

A.

Key Objective

To develop a clinically relevant in-vitro model of monocyte impairment and
study the defects in underlying signaling that lead to the suppression of proinflammatory cytokine production which may predispose critically-ill surgical
patients to nosocomial infection and death.
B.

Hypothesis

LPS induced monocyte impairment occurs through sustained feedback
inhibition of IκK, leading to decreased TNF-α production, also represented by
decreased HLA-DR expression & increased IL-10 production.
This dissertation focuses on TNF-α as a valid marker of monocyte function.
C.

Specific aims

1.

Develop a model of monocyte impairment, in which low dose

endotoxin exposure leads to altered cytokine responses, analogous to that
seen in some trauma and complex surgical patients.
2.

Investigate whether decreases in the cytokine response of the

impaired monocyte is due to inhibition of IκK, leading to subsequent
decreases in NFκB activation.
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3.

Determine which cytokines other than TNF-α and IL-10 are impaired,

and determine the influence of IκK on their production.
D.

Experimental Plan

The purpose of this project was to develop a model of monocyte impairment
using isolated human monocytes. We anticipated that the in-vitro model would
allow monocytes to have suppressed cytokine responses, specifically
decreased TNF-α production, and decreased HLA-DR expression,
recapitulating the defect seen in the critically-ill surgical patient.
We then examined the underlying signaling mechanisms, starting with
differences in TNF-α gene expression (mRNA) between naïve monocytes and
those which are impaired. We then worked proximally in the signaling
pathway to examine the differences in NFκB function and then IκK function.
We anticipated decreased activation of both complexes of this important
pathway in the impaired monocyte. This was indeed the case, therefore we
then examined upstream circuitry of IκK to investigate dysregulation in toll-like
receptor (TLR) signaling as well as miRNA’s which regulate this complex
network. Finally, we took a global view of a wide variety of cytokine and
chemokine levels to determine which other functions are suppressed as part
of monocyte impairment, and the role of IκK in their production through its
inhibition.
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Figure 11. Summary of hypothesis.

Impaired
Monocyte
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e. Methods
i. Monocyte isolation
Approval was given by the University of Louisville Institutional Review Board
(IRB) (“Study of Immunological and Genetic Markers in Hospitalized and
Ambulatory Subjects”, 0.0018) and written informed consent was obtained
from all donors. The age of donors ranged from 18 – 54 years. A pool of 18
donors (10 male) in total were used for donation, although between 4 and 10
donors were used for a given experiment. Exclusion criteria included acute
illness, anti-inflammatory medications, diabetes mellitus and any
immunosuppressive conditions.
Up to 25 mL of venous blood was collected in EDTA Vacuntainer
tubes (Becton Dickinson, Frankin Lakes, NJ). The collected blood was then
incubated with CD14 magnetic microbeads and primary human monocytes
isolated using a positive selection magnetic cell sorting technique according to
manufacturer’s instructions (Miltenyi Biotec, Auburn, CA). In brief, after 15 min
incubation with the microbeads, cells were washed with MACS Separation
Buffer, resuspended and run through magnetic columns. Columns were then
washed three times to eliminate non-monocyte material, before cells were
eluted with MACS Elution Buffer. Cells were then counted to check for total
number, purity and viability of the isolate using Trypan Blue staining.
Primary monocytes were then cultured in 1640 RPMI medium (MP
Biomedical, Solon, OH) with 10% heat-inactivated Fetal Bovine Serum, 2 nM
L-Glutamine, antibiotic (100 IU/mL penicillin and 100 µg/mL streptomycin) and
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anti-mycotic (250 ng/mL amphotericin B). All the above were purchased from
Thermo Scientific, Waltham, MA. Monocytes were cultured at 37°C in a
humidified incubator at 5% carbon dioxide concentration. Cells were cultured
either at 0.25 x 106 cells/mL after initial isolation or 0.5 x 106 cells/mL after
resuspension at 17 hrs depending on the experimental conditions. Fifty mL
polypropylene tubes were used for these single cell suspension experiments
(VWR, Westchester, PA).
Lipopolysaccharide (LPS) from E.Coli 0111:B4 was used for cell
stimulation, at doses of either 10 ng/mL or 100 ng/mL depending on
experimental conditions which were based on preliminary experiments
(Sigma-Aldrich, St. Louis, MO).

ii. In-vitro induced monocyte impairment
To develop impaired monocytes, the following steps were undertaken;
cultured cells from a given donor were divided into separate tubes and rested
for 1 h. At 1 h, “naïve” monocytes were cultured in media only, however
“impaired” cells were given low dose LPS (10 ng/mL) at this time. Cells were
then cultured in parallel for a further 16 h. At the 17 h time point, cells were
centrifuged at 1800 rpm, counted and resuspended in fresh media. This step
ensured that each condition had equal concentrations of viable monocytes for
comparison. Cells at all conditions were then given a high dose, LPS
challenge (100 ng/mL) to determine monocyte responsiveness.
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iii. Cytokine assays
Two series of cytokine assays were used to determine cytokine supernatant
protein concentrations. Following cell culture incubations, tubes were
centrifuged at 2000 rpm for 10 mins to ensure an acellular supernatant. This
supernatant was then aspirated and stored at -80°C until subsequent
analysis. For individual key cytokines, TNF-α, IL-10 and IL-6 concentrations
were quantified by enzyme-linked immunosorbent assay (ELISA) kits
(eBiosciences, San Diego, CA). ELISA assays were run in 96 well plates in
accordance with manufacturer’s instructions. A standard curve was generated
using recombinant TNF-α, IL-10 or IL-6 as appropriate. Activity was measured
using a SpectraMax Plus384 spectrophotometer at a 450 nm wavelength. All
samples were measured in duplicate.
For multiplex cytokine experiments, 25 µL of supernatant sample
were used per well in duplicate in pre-mixed 96 well plates using magnetic
beads for 29 different cytokines and chemokines as per manufacturers
recommendations (Milliplex Human Cytokine/Chemokine 29-Plex Magnetic
Bead kit, EMD Millipore, Billerica, MA). Recombinant pre-mixed beads were
used to create a standard curve. Quality controls 1 & 2 were used. Plates
were run using a Luminex MAGPIX instrument (EMD Millipore, MA).
iv. Flow cytometry
Monocyte cell culture samples containing 100,000 cells were washed twice in
Phosphate Buffered Saline (PBS) by centrifugation and resuspended in 100 µl
of PBS. Cells were stained with fluorescein isothiocyanate (FITC)-labeled
anti-human CD14+ and phycoerythrin (PE)-labeled anti-HLA-DR antibodies
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(BD Biosciences, La Jolla, CA). Cells were stained for 25 minutes, before two
further PBS washes and fixation in 300 µL of 1% paraformaldehyde solution
until subsequent analysis. Flow cytometric analysis was undertaken using a
FACS Calibur flow cytometer (Becton Dickinson, San Diego, CA). A minimum
of 3,000 gated events were acquired for each sample. Cell Quest software
was used to determine cell purity (based on CD14 and HLA-DR positivity) and
mean fluorescence intensity (MFI).
For phosflow analyses for determination of pathway activation by intracellular
protein phosphorylation, 100,000 cells were fixed with 3.2% formalehyde and
washed twice after culture with stain buffer (PBS containing fetal bovine
serum 2%) and permeabilized with 100% methanol for 30 min at -20C. Cells
were then resuspended in 100 µL stain buffer and incubated for 1 h in the
dark with either phospho-p65 or phospho-p38 MAPK (BD Biosciences, La
Jolla, CA). Finally, cells were then washed twice with stain buffer and run
fresh within 2 h of stimulation using the FACS Calibur as described above.
v. RNA isolation
In order to obtain RNA, after a given time point of cell culture, cells
were pelleted and stored in 300 µL of lysis buffer at -80°C. RNA was extracted
using the MirVana RNA extraction kit (Thermo Fisher Scientific, Waltham,
MA).
For quality control testing, RNA purity and concentration was
measured using the Nanodrop N-1000 (Agilent Biosystems, Santa Clara, CA).
Samples were only used if they fulfilled the quality control criteria of 1.8 – 2.2
purity, based on the ratio of absorbance at 260 nm and 280 nm (A260/A280
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ratio). This excluded samples of poor, unreliable quality that were at risk of
containing contaminating DNA, protein or other organic compounds.
vi. mRNA measurements
To determine the expression of individual genes of interest, RNA was diluted
to 2 ng/µL concentration and used to synthesize complimentary DNA (cDNA)
by reverse transcription (High Capacity cDNA Reverse Transcription kit, Life
Technologies, Foster City, CA).
Quantitative real time polymerase chain reaction (qRT-PCR) was undertaken
with Taqman® 20X specific mRNA primers, such as those for TNF-α, using
18S as an internal control. Samples were run in duplicate in a 96 well plate
using Taqman® Universal Mastermix (all of the above from Life Technologies,
Foster City, CA).
For data analysis, a ΔRn (normalized reporter value i.e. signal) threshold of
0.1 was chosen based on the linear part of the gene expression curve. Fold
changes were calculated using the ΔΔCT method 112.
For TLR signaling, pre-coated mRNA profiler plates were used (Taqman®
Array Human Toll Pathway, Core Components, Life Technologies, Foster
City, CA). Each of the 48 wells received 3 ng of cDNA (44 wells with gene of
interest, 4 of internal controls). Taqman® Universal Mastermix was used to
make a reaction volume of 10 µL per well. For these experiments, a
combination of 18S, GAPDH, and Beta2-Microglobulin were used for internal
controls. The StepOne Plus RealTime-PCR-System instrument was used for
qRT-PCR (Applied Biosystems®, Foster City, CA).
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vii.miRNA measurements
For microRNA screening, Taqman® Microfluidic Low Density Array Cards
were used with a total of 1500 ng of diluted RNA per card, divided between
384 wells (Card A, Life Technologies, Foster City, CA). Once samples were
loaded (100 µL per port), cards were sealed and centrifuged at 2000 rpm for 2
mins. They were then run using a ViiA™ 7 Real-Time PCR System (Applied
Biosystems®, Foster City, CA). Four separate wells with RNU6, along with
RNU44 and RNU48 were used in combination for an internal control.
For single assay microRNA quantification, specific 5X primers were used per
microRNA for reverse transcription to create cDNA, with specific 20X primers
used for qRT-PCR with Taqman® Universal Mastermix using a reaction
volume of 10 µL. The internal control used was RNU6, and all assays were
run in duplicate using a 96 well plate using a StepOne Plus RealTime-PCRSystem instrument (Applied Biosystems®, Foster City, CA). Like messenger
RNA analysis previously described, all microRNA data was analyzed using a
cycle threshold of 0.1 using the ΔΔCT method 112.
viii. Western Blot analysis
For intracellular protein quantification, monocyte cell culture tubes were
centrifuged for a given time point, the cell pellet lysed using RIPA buffer with a
1:1000 concentration of protease and phosphatase inhibitors (Thermo
Scientific, Rockford, IL) and stored at -80°C until subsequent analysis. For
protein extraction, lysed cells were then sonicated using a Sonifier 250
(Branson Ultrasonics, Danbury, CT). Protein concentrations were quantified
using a bicinchoninic acid (BCA) protein quantification assay (Thermo
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Scientific, Rockford, IL) against a standard curve using a SpectraMax Plus384
spectrophotometer at 540 nm.
Protein samples of 30 µg were loaded into gradient 4-12% Bis-Tris Plus 12
well gels in combination with 4X BoltTM LDS Running Buffer with 1:100 2mercaptoethanol. Gels were run in a BoltTM Mini Gel Tank in Bolt MES SDS
Running Buffer at 180 mV for 45 min (all from Thermo Scientific, Waltham,
MA). Each gel contained two wells loaded with a protein size standard to
identify the size of proteins of interest (Protein Western C Standard, Bio Rad,
Hercules, CA).
After gel electrophoresis, proteins were transferred to a nitrocellulose
membrane using iBlot Gel Transfer Stacks and an iBlot transfer device (Fisher
Scientific, Hampton, NH).
Membranes were then blocked with 5% non-fat dried milk in TBS-T (Tris base
9.68g, sodium chloride 32g and Tween-20 100 µL in 100 mL deionized water
adjusted to pH 7.6) for 1 h at room temperature to prevent non-specific
binding. Membranes were then incubated overnight with primary antibodies
(either rabbit or mouse anti-human) at room temperature. All antibodies were
purchased from Cell Signaling (Danvers, MA). Antibody concentrations were
as follows; Beta-actin 1:10,000, Vinculin 1:1000, NFκB p65 1:1000, IκB
1:1000, IκK-α 1:1000, IκK-β 1:1000, TAK-1 1:1000 diluted in 5% non-fat dried
milk with TBS-T. Phospho-IκK and phospho-TAK1 were diluted at 1:1000 in
5% Bovine Serum Albumin (BSA) in TBS-T (non-fat dried milk was not used
with phosphorylated antibodies to prevent casein interfering with sites of
phosphorylation). After incubation with the primary antibody, membranes were
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washed three times for 5 min in TBS-T before incubation with secondary
antibodies (goat anti-rabbit or horse anti-mouse as appropriate) at a
concentration of 1:1000 for 1 h at room temperature.
After a further three washes as above, membranes were finally incubated in
Pierce ECL Substrate for 5 min (Thermo Scientific, Waltham, MA). Finally, the
membrane was imaged using the ChemiDoc MP system (Bio Rad, Hercules,
CA, courtesy of Dr. Jason Smith) and protein densitometries measured using
ImageLab software (Bio Rad, Hercules, CA). For each protein of interest,
relative density units were expressed as a ratio over an internal loading
control from the same sample (either Beta Actin or Vinculin depending on the
molecular weight of the protein).
ix. Inhibition of IκK
To determine the direct role of IκK in monocyte function and dysfunction, a
small molecule specific inhibitor of IκK called IκK-16 was purchased (SigmaAldrich, St. Louis, MO). It was prepared in accordance with manufacturer’s
instructions. In brief, powder preparation was reconstituted in 180 µL of
dimethyl sulfoxide (DMSO) and aliquoted in stock 10 µL ampules and stored
at -80°C. For each experiment, IκK-16 was prepared fresh by a 1:50 dilution
with DMSO from stock and then diluted in 1:1000 with media (as described
under Monocyte Isolation) for use. Doses of IκK-16 were given at 100 nM
unless otherwise specified. For a 100 nM dose, 100 µL of IκK-16 was given
per mL of cultured cells. Preliminary experiments demonstrated that DMSO
had no effect on monocyte function or viability at such a substantial dilution.
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Loss of function of IκK phosphorylation is confirmed in the Results section of
Specific Aim 2 (see Figure 29).

x. Statistical analysis
Data are shown as mean ± standard error of the mean. For a given condition,
each donor was compared within the same individual. Therefore, in general
paired, related analyses were used. For individual comparisons, a two-tailed
paired t-test or Wilcoxon signed rank were used. Statistical analyses were
performed using SPSS version 21 (PASW Statistics, IBM, Chicago, IL).
Significance was determined with an alpha of 0.05. Sample size calculations,
power analyses and more complex statistical analyses are described in the
relevant sections.
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CHAPTER V
DEVELOPING A MODEL OF MONOCYTE IMPAIRMENT
INTRODUCTION

Monocyte impairment is estimated to occur in approximately 1 in 6 patients. It
is not clear whether these patients have a genetic predisposition limiting their
cellular responsiveness, or whether this is acquired from the insult itself.
Therefore, predicting which patients will have monocyte impairment is
challenging. The study of mechanisms and modulation of monocyte
impairment in surgical patients is complex and expensive. There are a large
number of additional factors which may influence these measurements such
as co-morbidity and the effect of interventions such as surgery, antimicrobial
drugs and adjunctive drugs such as heparin and fluid therapy. Therefore,
study of the human immunological response to a major insult in a consistent,
reproducible way requires an alternative solution.
Sepsis models in animals, such as mice, have been used to study
monocyte impairment in a variety of approaches. This often involves
intraperitoneal delivery of endotoxin, before either a further in-vivo challenge
or isolation of peritoneal macrophage or bone marrow derived cells for ex-vivo
LPS stimulation. The major limitation with this approach is whether the
findings can be extended to a human population. This was eloquently
discussed in the letter “Mice are not men” by the Glue Grant group in PNAS,
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2013 113. Cell lines have the benefit of being of human origin and are
reproducible, however, do not offer the genetic variability that exists in the
human population.
In this model, we use monocytes from healthy volunteers to preserve
the variability from person to person, that are impaired equally in standardized
fashion by an initial low dose of LPS (10ng/mL). The goal was to produce a
model where the cells with previous exposure to LPS have a reproducible d
ecrease in their capacity to produce TNF-α in response to a subsequent
challenge. TNF-α is the most defined and accepted marker that defines a
blunted monocyte response in high quality immunological studies. However,
IL-10 and HLA-DR expression represent important functions of the monocyte
which also bear clinical correlation and therefore were also measured.
RESULTS
Isolated Monocyte Culture – Cell Purity and Viability
Prior to isolation, leukocytes in whole blood can be seen in three broad
categories by flow cytometry which are neutrophils (polymorphonuclear cells),
lymphocytes and monocytes (circled, Figure 12A). Following CD14 magnetic
bead isolation, a single cell population can be observed (Figure 12B). A small
amount of debris can be seen in the bottom left hand corner of this scatterplot,
which is normal for cells after culture and multiple centrifugations. By gating
on the monocyte population (as per the circle in Figure 12B), consistently
over 95% these cells are highly positive for the monocyte markers CD14
(FITC) and HLA-DR (PE). A representative scatterplot is shown in Figure
12C. This confirms a pure single cell monocyte population for study.
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Figure 12. Monocyte purity following CD14 magnetic positive selection
technique from whole blood.
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Legend for Figure 12.

The distribution of monocytes in a three-part differential of leukocytes in whole
blood prior to monocyte isolation is shown in (A), based on its size (forward
scatter, FSC) and granularity (side scatter, SSC) properties. Following
isolation by magnetic bead positive selection technique, a single cell
population is identified in the gate circled (B). Material in the lower left hand
corner represents debris, normal for flow cytometry of such cells. Of the cells
isolated, 99.3% of gated cells are CD14 (FL1) and HLA-DR (FL2) positive
demonstrating a pure, viable monocyte population (C). This representative
sample is taken 33 hrs after isolation.
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Figure 13. Time course experiment of monocyte viability in cell culture.
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The viability of isolated monocytes were determined by culturing cells over
time and number of viable monocytes manually counted by standard
microscopy after Trypan blue staining. By 24 hours, cell loss is approximately
a third, reaching about half of the initial number of cells by 48 hours. N = 7.
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Figure 14. Experimental design of the impaired monocyte model.

After isolation of monocytes from healthy volunteers, cells are cultured and
divided into two conditions; naïve and impaired. After 1 h of rest, the naïve
cells remain in media only until 17 h. By comparison, low dose 10 ng/mL is
added to the impaired cell culture until 17 h. At 17 h, tubes of cell suspension
are centrifuged, and cells are washed and counted by microscopy and
resuspended to 0.5 x 10 6/mL concentration to ensure equal cell
concentrations across both naïve and impaired conditions. Cells are then
challenged with 100 ng/mL LPS to determine monocyte responsiveness at
various time points indicated.
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The viability of these cells in culture were studied over time, demonstrated in
Figure 13. It should be noted that there is a relatively consistent loss of
monocytes of approximately a third by 24 hours, reaching approximately a
half of cells by 48 hours after cell isolation.
Experimental design of the impaired monocyte model is described in
detail in the Methods section, but is summarized in Figure 14.
TNF-α production
The naïve cells in standard media without initial low dose LPS stimulation
secreted approximately 1500 pg/mL TNF-α by 17 hours (Figure 15). Low
dose LPS 10 ng/mL stimulated a trend towards increased TNF-α levels by 17
hours. After cells were washed and resuspended, both conditions were
cultured with a 100 ng/mL LPS challenge. In general, the TNF-α levels in both
conditions were lower at time points after 17 hours compared with those at the
end of the initial 17 hour interval. Critically, the naïve cells (illustrated in green)
were able to produce a consistently higher level of TNF-α after the 100 ng/mL
LPS challenge, compared to the impaired cells which demonstrated sustained
suppression of TNF-α production in response to such an 100 ng/mL LPS
challenge (seen maximally at 4 and 12 hours after the 100 ng/mL LPS
challenge).
IL-10 production
In contrast to TNF-α, IL-10 levels in general increased over time in culture for
both conditions (Figure 16). In response to the initial 10 ng/mL LPS, IL-10
trended to a lower level in the impaired cells compared to the naïve cells at 17
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hours, without reaching statistical significance. However, in response to the
100 ng/mL LPS challenge, the capacity for monocytes to produce IL-10 was
consistently suppressed in the impaired cells at 4, 12 and 24 hours after the
100 ng/mL LPS challenge.
HLA-DR expression
In both conditions, HLA-DR expression increased over the first 17 hours from
baseline levels after isolation. Low dose 10 ng/mL LPS caused a small but
consistent decrease in HLA-DR expression compared to the naïve cells
(Figure 17). This equated to impaired cells expressing approximately only 515% lower levels of HLA-DR compared to the naïve cells; however there was
a considerable amount of variability from donor to donor. There were no
differences in HLA-DR expression between conditions for the remaining time
points.
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Figure 15. TNF-α production in the impaired monocyte.
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Supernatant protein concentration of TNF-α, a pro-inflammatory cytokine, was
measured at various time points by ELISA to compare naïve cells (green)
against impaired cells (red). Low dose LPS 10 ng/mL at 1 h leads to a modest
increase in TNF-α production by 17 h in the impaired cells. However, in
response to a high dose 100 ng/mL LPS challenge given at 17 h, the same
impaired cells have a sustained suppression of TNF-α production thereafter
when compared to the naïve cells. Mean ± SEM. N = 7. * p < 0.05, † p = 0.07.
Wilcoxon signed rank test.
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Figure 16. IL-10 production in the impaired monocyte.
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The supernatant protein concentration of IL-10, an anti-inflammatory cytokine,
was measured at various time points by ELISA to compare naïve cells (green)
against impaired cells (red). Low dose 10 ng/mL LPS at 1 h leads to a minor
but not significant decrease in IL-10 concentration by 17 h in the impaired
cells. However, in response to a high dose 100 ng/mL LPS challenge given at
17 h, impaired cells have a sustained suppression of IL-10 production when
compared to the naïve cells. Mean ± SEM. N = 7. * p < 0.05, Wilcoxon signed
rank test.

81

40

IL-6 production
There was a slight trend of low dose 10 ng/mL LPS increasing IL-6 production
by 17 hours compared to naïve cells, but this did not reach statistical
significance. Subsequent to the 100 ng/mL LPS challenge, the impaired cells
had a sustained decrease in the ability to produce IL-6 when compared to the
naïve cells (Figure 18). This was most evident at 29 hours and 41 hours
(corresponding to 12 hours and 24 hours after the 100 ng/mL LPS challenge).
TNF-α gene expression (messenger RNA)
Figure 19 demonstrates differences in intracellular TNF-α messenger RNA
levels relative to the naïve monocyte, as measured by qRT-PCR. Low dose
10 ng/mL LPS in the impaired cells leads to a modest increase in TNF-α gene
expression seen at 2, 4 and 8 hours after isolation. This difference begins to
correspond to similar levels in the naïve monocyte by 17 hours. In response to
the 100 ng/mL LPS challenge, however, TNF-α gene expression is decreased
relative to the naïve monocyte. This difference is seen maximally at 19 hours
(2h after the 100 ng/mL LPS challenge).
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Figure 17. HLA-DR expression in the impaired monocyte.
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Legend for Figure 17.

Monocyte HLA-DR, a MHC II class surface marker critical for the function of
antigen presentation, was determined by flow cytometry at various time points
(A). Mean Fluorescence Intensity of HLA-DR was measured comparing naïve
cells (green) against impaired cells (red). Low dose 10 ng/mL LPS at 1 h led
to a small but consistent decrease in HLA-DR expression at 17 h in the
impaired cells. When both conditions were treated with a high dose 100
ng/mL LPS challenge at 17 h, no significant differences in HLA-DR expression
were observed between the naïve and impaired monocytes. Mean ± SEM. N
= 7. * p < 0.05, Wilcoxon signed rank test.
A histogram of HLA-DR expression in monocytes both naïve cells (white) and
impaired cells (gray) at 17 h is shown in (B). This is a representative sample
qualitatively demonstrating the decreased HLA-DR expression in impaired
conditions.
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Figure 18. IL-6 production in the impaired monocyte.
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IL-6 supernatant protein concentration was measured at various time points
by ELISA, comparing naïve cells (green) against impaired cells (red). Low
dose 10 ng/mL LPS given at 1 h led to a minor but not significant increase in
IL-6 production by 17 h in the impaired cells. However, in response to a high
dose 100 ng/mL LPS challenge given at 17 h, impaired cells appear to have a
sustained suppression of IL-6 production when compared to the naïve cells.
Mean ± SEM. N = 7. * p < 0.05, Wilcoxon signed rank test.
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TNF-α mRNA time course
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Figure 19. TNF-α gene expression (mRNA) in the impaired monocyte.
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Legend to Figure 19.

Intracellular TNF-α gene expression was examined in the naïve and impaired
monocyte by qRT-PCR. A time course experiment is shown in the top graph
using 4 donors (A). Low dose 10 ng/mL LPS upregulated TNF-α mRNA
expression rapidly over the first 4 to 8 hours after treatment, then began
“turning off” by 17 h. When both conditions were incubated with high dose 100
ng/mL LPS challenge at 17 h, the impaired cells demonstrated a decreased
level of mRNA expression relative to naïve cells. This genomic response early
after LPS stimulation corresponds with the sustained differences seen in TNFα protein (shown earlier in Figure 15). The maximal level of suppression of
TNF-α gene expression in the impaired monocyte is seen at 19 h, relative to
the naïve monocyte (2 h after the 100 ng/mL LPS challenge). N = 4.
The bottom figure represents qRT-PCR experiments focused at this 19 h time
point (B). Impaired monocytes (red) have a profound downregulation of TNF-α
mRNA relative to naïve cells. N = 8. Mean ± SEM. *p < 0.05, Wilcoxon signed
rank test.
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DISCUSSION

Monocytes have various critical immunological functions in orchestrating a
well-balanced response to an insult. Cytokine production is a highly regulated
set of small functional proteins allowing activation and differentiation of
leukocytes governing the immune response. TNF-α and IL-6 represent proinflammatory cytokines. These are produced early after a stimulus and
activate the innate and adaptive system to in turn produce further cytokines,
hence the term “cytokine cascade”. This pattern is demonstrated by our data,
where TNF-α and IL-6 are produced early and trend to an early increase in
the 10 ng/mL LPS treated cells.
TNF-α is secreted primarily from monocytes and macrophages often
within 30 min of an inciting event. As part of its autocrine function, it promotes
the activation and differentiation of macrophages, prolongs their survival and
increases their production from progenitor cells. Direct injection of TNF-α into
animals produces a shock-like state, which is also associated with increased
vascular permeability, pulmonary edema and activation of the coagulation
system. TNF-α has been described as the “master regulator” of inflammatory
cytokine production, but the blockade of TNF-α has been shown to improve
mortality in animal models 114.
The suppression of TNF-α in response to a second LPS exposure has
defined models of impaired monocyte function, or “endotoxin tolerance”,
throughout immunology literature 5,68,69. In our results utilizing this type of
model, there is a consistent depression of TNF-α production in cells with prior
LPS exposure, thus validating our model. This is in keeping with many other
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groups 7. Furthermore, the changes in TNF-α gene expression prove that the
suppressed response occurs at a level of intra-cellular genomic signaling
which is clearly different between the two conditions. These time course
experiments demonstrate that increased TNF-α observed in response to 10
ng/mL LPS is produced from newly synthesiszed messenger RNA, therefore
true production in response to a stimulus, rather than pre-formed TNF-α
released in impaired conditions compared with naïve monocyte. Contrast the
changes in TNF-α gene expression seen in Figure 19A to the clinical
scenario in Figure 1. We believe these similarities demonstrate the clinical
relevance of our model.
IL-10 is a centrally important anti-inflammatory cytokine which has an
important role in counterbalancing the pro-inflammatory response. In
excessive amounts, IL-10 can lead to monocyte deactivation, with high levels
related to the magnitude of injury. Our results show that IL-10 production,
representative of the anti-inflammatory response, is also impaired in cells
treated with prior 10 ng/mL LPS. This is in agreement with some groups 7,66,
although various in-vivo studies demonstrate higher IL-10 levels 68,115. This
difference may be related to the interaction between monocytes and T-cells
which is not preserved in our model of single cell suspension.
Monocyte HLA-DR expression is reported less often in the literature
than TNF-α in this type of experimental model. Our results show a decrease in
HLA-DR expression in response to low dose 10 ng/mL LPS, however this
difference is small and not seen at later time points by which both cellular
conditions have received LPS exposure. The magnitude of the HLA-DR
downregulation is less than expected, and may be that the small effect of low
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dose 10 ng/mL LPS in the context of cell activation by the process of isolation
and ex-vivo cell culture, as demonstrated by the increased size and
granularity properties of the monocytes compared to those seen in whole
blood prior (pre-isolation) (Figure 12A & B), and the higher than expected
levels of TNF-α in the naïve cells by 17 hours (Figure 15). This decrease in
HLA-DR expression in the impaired cells is however consistent and broadly in
keeping with literature findings 67,68.
Elevated levels of IL-6 have long been associated with mortality in
trauma and sepsis. IL-6 is a potent inducer of the acute phase response, with
pleiotropic effects on proliferation, differentiation and maturation of progenitor
cells as well as controlling cellular metabolic activities. These results
demonstrate that impaired monocytes have a decreased capacity to produce
IL-6 production in response to an LPS challenge. This is in keeping with
previous literature 7,66,68.
There were numerous difficulties in developing this model. Different
rest periods after isolation were evaluated, including no rest, 1 hour and 8
hours of rest. LPS doses of 2 ng/mL, 10 ng/mL and 100 ng/mL were tested as
the initial stimulus. Both 16 and 24 hours were used for the initial duration of
LPS exposure, and various monocyte cell concentrations were used. We
found that after 1 hour of rest after isolation, followed by an initial dose of 10
ng/mL LPS for 16 hours, led to the most consistent impairment of monocyte
function in response to a subsequent 100 ng/mL LPS challenge (Figure 14).
Therefore, the model appears to reproducibly produce monocytes
which have impaired functions of pro- and anti-inflammatory cytokine
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production as well as decreased antigen-presenting capacity, as measured by
HLA-DR expression. This model therefore allows for further study of the
underlying immunological mechanisms of impaired monocyte function, an
important factor in the outcome of surgical patients at risk of infection (Figure
20).
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Figure 20. Calculating host defense liabilities as a causative factor in the
probability of infection in the surgical patient.
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There are multiple and often unpredictable factors relating to whether a
surgical patient will be susceptible to nosocomial infection. This model of
impaired monocyte function allows for the study of the ‘Innate and Adaptive
Host Defenses’, and it’s ‘Acute Host Defense Liabilities’ in a reproducible
fashion.
Adapted from Fry DE, Surgical Infection Society Annual Meeting 2016, FL.
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CHAPTER VI
IκK SIGNALING IN THE IMPAIRED MONOCYTE
INTRODUCTION

The knowledge and understanding of molecular mechanisms governing the
immune response has improved considerably over the last 20 years. Various
dynamic and complex inflammatory pathways, such as NFκB, respond to
stimuli, but also have negative feedback regulation to counteract the proinflammatory response. If these are inadequate, persistent inflammation can
be harmful to the patient and can lead to multi-organ failure and death. By
comparison, an exaggerated compensatory anti-inflammatory response can
predominate which can lead to an impaired host response and insufficient
pathogen clearance.
The previous chapter demonstrated a decrease in the monocyte gene
expression of TNF-α in response to a subsequent LPS challenge. This
suggests that there may be a difference in NFκB signaling between naïve and
impaired conditions, as this is one of the critical mechanisms of proinflammatory signaling. Activation of NFκB signaling occurs in response to
TLR ligands like LPS, with a cascade of phosphorylation from its upstream
kinase, Inhibitor of κB Kinase (IκK). Subsequently, the release of the “brakes”
in the pathway, IκB, occurs which allows translocation of the active subunit
p65 to the nucleus to activate pro-inflammatory genes such as TNF-α.
Therefore, if this pathway is suppressed, this would account for the decreased
monocyte responsiveness seen both in the impaired monocyte model and in
the sick patient. Interestingly, various negative regulators are indeed
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downstream from NFκB and therefore when this pathway is activated, both
the pro-inflammatory cytokines are synthesized but also the slower acting
compensatory anti-inflammatory molecules are released.
The aim of this chapter is to first determine if there are alterations in
NFκB signaling between the naïve and impaired conditions. If this was the
case, we then could undertake a detailed study of IκK, upstream of NFκB, in
terms of the total concentration and levels of activation in the impaired
monocyte. This could then help elucidate the mechanisms underpinning a
possible cause and effect relationship between IκK suppression and the
diminished inflammatory response in the impaired monocyte.
RESULTS
NFκB signaling in the impaired monocyte
Monocytes cultured in low dose 10 ng/mL LPS for 16 hours were challenged
with an 100 ng/mL LPS challenge for 60 minutes. At this time point, impaired
monocytes, which had demonstrated an impaired response in the previous
chapter, had a lower protein concentration of p65, the active subunit of NFκB,
compared to naïve cells (Figure 21 A & B). In addition, a representative
histogram using phosflow technology demonstrated that these impaired cells
have a decrease in the level of phosphorylation at 30 minutes after the 100
ng/mL LPS challenge, compared to naïve monocytes (Figure 21C).
Levels of IκB, the “brakes” in the NFκB pathway, were similar at 17
hours. However, naïve cells achieved effective IκB degradation with low levels
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by 60 minutes after the 100 ng/mL LPS challenge (Figure 22B), compared to
the higher IκB levels in impaired cells (i.e. less effective degradation).
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Figure 21. NFκB (p65) signaling in the impaired monocyte.
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Legend to Figure 21.

Monocytes were cultured either in naïve (media only) or impaired (low dose
10 ng/mL LPS) conditions for 16 h. After resuspension in fresh media, cells in
both conditions were cultured with the 100 ng/mL LPS challenge for 60 min.
Cells were lysed and subsequently analyzed by Western Blot to determine the
concentration of p65, the active subunit of NFκB, between conditions. Beta
actin was used as a loading control. A representative blot is demonstrated
showing decreased p65 concentration in the impaired monocyte (A). This
reached statistical significance,* p < 0.05 (B). N = 6. A representative
phosflow histogram (C) demonstrates a higher peak of NFκB (p65)
phosphorylation in naïve cells (green) compared to impaired cells (red) at 30
min after a 100 ng/mL LPS challenge.
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Figure 22. IκB signaling in the impaired monocyte.
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Isolated monocytes were rested for 1 h and then treated either with media
only or low dose 10 ng/mL LPS for 16 h. Following washing and resuspending
in fresh media, cells in each condition were challenged with 100 ng/mL LPS
and NFκB was measured. Vinculin was used as a loading control.
Representative Western Blots (A) demonstrate the effective degradation of
IκB in naïve cells (green) by 60 min after the LPS challenge. By comparison,
the impaired cells were less effective in IκB degradation by 60 min (B, *
p<0.05, Wilcoxon Signed rank Test). N = 5.
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Total levels of IκK-α & -β in the impaired monocyte
Messenger RNA levels of the two critical catalytic subunits of IκK, -α and β,
were measured by qRT-PCR at 17 hours to examine for differences in gene
expression of IκK at the time of the LPS 100 ng/mL challenge (Figure 23).
Impaired monocytes had decreased IκK-α messenger RNA relative to naïve
monocyte. There were no differences between IκK-β gene expression
between naïve and impaired conditions.
Despite the decrease in IκK-α mRNA, Western blot measurements did not
show differences in total protein between naïve and impaired monocytes
(Figure 24). In addition, there were no differences in IκK-β protein between
naïve and impaired cells by Western Blot (Figure 24).
Immunofluorescence was used by qualitatively examining the fluorescence of
IκK-α and –β using Texas Red between naïve and impaired monocytes.
There were no clear differences between naïve and impaired monocytes
studied 30 minutes after the 100 ng/mL LPS challenge.
IκK phosphorylation in the impaired monocyte
Naïve and impaired monocytes were studied immediately before the 100
ng/mL LPS challenge, and then every 15 minutes for 120 minutes to
determine differences in IκK phosphorylation between conditions. In Figure
26, IκK phosphorylation in the naïve monocyte occurred maximally at 30 and
45 minutes, which then returned to unstimulated levels by 60 and 120 minutes
following the 100 ng/mL LPS challenge. By comparison, IκK phosphorylation
was decreased throughout the 120 minutes of study when compared against
the naïve response.
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Figure 23. IκK-α & -β gene expression in the impaired monocyte.
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Monocytes cultured in either naïve (media only) or impaired (10 ng/mL LPS)
conditions for 16 h following after an initial 1 h rest. At 17 h, which would
represent the time of 100 ng/mL LPS challenge, monocyte RNA was analyzed
for differences in the expression of IκK-α & IκK-β mRNA using qRT-PCR.
Impaired monocyte IκK mRNA levels were expressed relative to naïve cells.
These data show that IκK-α is downregulated in the impaired monocyte (p
<0.05, Wilcoxon-signed rank test). Gene expression of IκK-β did not differ
between naïve and impaired conditions. N = 7.
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Figure 24. IκK-α protein in the impaired monocyte.
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IκK-α protein levels were measured in naïve and impaired monocytes by
Western Blot, using beta-actin as an internal control. Monocytes were cultured
in either media only (naïve) or 10 ng/mL LPS (impaired) for 16 hrs. After
washing, cells were then treated with the 100 ng/mL LPS challenge. IκK-α
was measured by SDS-PAGE (Western Blot) at the time of isolation, at the
time of LPS challenge and 30 and 60 min after the LPS challenge (A). There
were no significant differences between naïve and impaired conditions in
terms of IκK-α protein concentration at the time of the LPS challenge (17 h)
(B).
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Figure 25. IκK-β protein in the impaired monocyte.
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IκK-β protein levels were measured in naïve and impaired monocytes by
Western Blot, using beta-actin as an internal control. Monocytes cultured with
either media only (naïve) or 10 ng/mL LPS (impaired) for 16 hrs. After
washing, cells were then treated with 100 ng/mL LPS challenge. IκK-β was
measured by SDS-PAGE (Western Blot) at the time of isolation, at the time of
LPS challenge and 30 and 60 min after the challenge (A). No significant
differences between naïve and impaired conditions in terms of IκK-β protein
concentration at the time of the LPS challenge (17 h) (B).
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Figure 26. IκK phosphorylation in the impaired monocyte.
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Monocytes were incubated in either naïve (media only) or impaired (10ng/mL
LPS) conditions for 16 h before washed and resuspended. At this point, 100
ng/mL LPS was given to both conditions and intracellular monocyte IκK
phosphorylation was measured by Western Blot (A). Beta actin was used as a
loading control for normalization. IκK phosphorylation was achieved in naïve
monocytes maximally at 30 min after the LPS challenge. By comparison, this
phosphorylation of IκK was not seen in cells pre-treated with 10 ng/mL LPS
(impaired). N = 4. Paired T-test.
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TAK-1 signaling in the impaired monocyte
Both phosphorylated and total levels of TAK-1 were measured over the same
15 minute intervals after the 100 ng/mL LPS challenge. There were no
consistent differences in the phosphorylated TAK-1 levels (expressed as a
percentage of total TAK-1) or total TAK-1 levels between naïve and impaired
monocytes (Figure 27).
Toll-like receptor signaling in the impaired monocyte
Naïve and impaired monocytes were profiled for dysregulated TLR signaling 2
hours after the 100 ng/mL LPS challenge. Two of the 44 genes examined
reached statistical significance and were both were downregulated in the
impaired monocyte when compared to the naïve cell (Figure 28). These
included TRAF-6, equating to approximately 5-fold downregulation, and
NFκBIE by 1.6-fold downregulation in the impaired monocyte.
Of interest, the gene for CD14 approached significance at p = 0.075, with 1.8fold downregulation. IκK-γ also decreased with a 1.5-fold downregulation (p =
0.078).
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Figure 27. TAK-1 signaling in the impaired monocyte.
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Monocytes were incubated in either naïve (media only) or impaired (LPS
10ng/mL) conditions for 16 h before 100 ng/mL LPS challenge. Intracellular
monocyte TAK-1 (phosphorylation and total) was then measured by Western
Blot every 15 min until 120 min (A). No differences between naïve and
impaired monocytes were elucidated in levels of TAK-1 activation, expressed
as a ratio of Phospho-TAK-1 over Total TAK-1 (after both were normalized
with beta actin). N = 5.
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Figure 28. Toll-like receptor signaling in the impaired monocyte.
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Monocytes were cultured in naïve (media only) or impaired (low dose 10
ng/mL LPS) conditions for 16 h. After resuspension in fresh media, cells in
each condition were stimulated for a further 2 hours with the 100 ng/mL LPS
challenge. Intracellular RNA was assessed for gene expression of TLR
signaling molecules (mRNA) using TLR profiling assays (qRT-PCR). 18S,
GAPDH and beta-2-microglobin were used as internal controls. N = 4. Each
dot represents a gene target. In this volcano plot, genes to the left of the
vertical 0.66 line were considered downregulated (equivalent to a fold
downregulation of 1.5) and those to the right of vertical 1.5 line were
considered upregulated in the impaired monocyte relative to naïve conditions
(control). On the y-axis, target genes above the horizontal line at 1.3 were
considered significant (thus above line equivalent to p < 0.05, Paired T-test).
The most consistently downregulated genes were TRAF-6 and NFκBIE.
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10

IκK-16 as an effective inhibitor of IκK phosphorylation
Following pre-treatment with either 100 nM IκK-16 (diluted in DMSO) or the
equivalent dilute DMSO control for 1 hour after isolation, monocytes were
stimulated with 100 ng/mL LPS. Time points for measurement of IκK
phosphorylation by Western Blot were taken at 1 hour (immediately before
100 ng/mL LPS) and then at 15 minute intervals for 120 minutes. Figure 29
demonstrates that control monocytes (with dilute DMSO only) responded to
the 100 ng/mL LPS challenge with a peak of IκK phosphorylation after 15
minutes. By comparison, levels of IκK phosphorylation were decreased in the
IκK-16 treated cells even prior to the addition of 100 ng/mL LPS, and
remained lower at 15 and 30 minutes after the 100 ng/mL LPS challenge as
compared to the control.
Monocyte viability was measured at 17 hours following a range of IκK-16
doses, ranging from a control without LPS, control (DMSO) with LPS, and
then 1 up to 1000 nM concentrations of IκK-16. There were no differences in
monocyte viability between conditions, with approximately 75% of cells viable
at 17 hours (Figure 30).
Effect of IκK-16 on cytokine production
Under the same conditions, levels of TNF-α were measured by ELISA to
determine if targeted IκK inhibition would decrease TNF-α production. Indeed,
with increasing doses from 1 to 1000 nM, TNF-α was incrementally decreased
compared to the DMSO control, reaching statistical significance at the 100 nM
and 1000 nM doses (Figure 31).
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The same inhibitory effect of IκK-16 was observed with respect to IL-10 levels.
There was more variability in IL-10 production between donors, but IκK-16
treatment decreased IL-10 production at doses of 100 nM (p = 0.078) and
1000 nM doses (p < 0.05) (Figure 32).
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Figure 29. Effect of IκK-16 on IκK phosphorylation.

A.

100 ng/mL LPS (DMSO control)

IκK-16
pre-treatment:

-

-

-

-

Mins after 17h 100ng/mL
LPS challenge:

0

15

30

45

-

100 ng/mL LPS + 100 nM IκK-16

-

60 120

+

+

+

+

+

+

0

15

30

45

60

120

Phospho-IκK α/β
(85-87 kDa)
Beta-actin
(42 kDa)

0.35

B.

Phospho-IKK / Beta-actin
(relative density units)

LPS 100 ng/mL

*

0.3

*

0.25
0.2

IκK phosphorylation
LPS 100 ng/mL + IκK-16

*

N=4

.

0.15
0.1
0.05
0
0

15

30

45

60

120

Minutes after 100 ng/mL LPS stimulation
IκK-16 is a selective inhibitor of IκK. Following isolation of monocytes, cells
were divided into either 100 nM IκK-16 (which is diluted into a very low
concentration of DMSO) or control with DMSO only for 1 h. IκK-α/β
phosphorylation was determined by Western Blot after the addition of 100
ng/mL LPS (given at 1 h). Beta-actin was used as a loading control. IκK-16
effectively decreases IκK phosphorylation, shown as a representative Blot (A)
and quantitatively using four different donors (B). * p < 0.05, Paired T-test.
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Percent of viable monocytes

Figure 30. Effect of IκK-16 on monocyte viability.
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Monocytes cultured with IκK-16 (diluted in DMSO) at various doses for 1 h,
then stimulated with 100 ng/mL LPS for 16 h. At this point, cells were stained
with Trypan Blue and manually counted by standard microscopy for number of
viable cells, expressed as a percentage of the initial cell number. This
experiment demonstrates that neither DMSO nor IκK-16 is toxic to human
monocytes. Four donors were used for these experiments. “ – “ denotes the
absence of a reagent, whereas “ + “ denotes the presence of it in cell culture.
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Figure 31. Effect of IκK-16 on TNF-α production.
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Monocytes were cultured with IκK-16 at various doses (diluted in DMSO) for 1
h, then stimulated with 100 ng/mL LPS until 17 h. At 17 h, cell culture
supernatant was measured for TNF-α protein concentration by ELISA. Both
100 nM and 1000 nM doses of IκK-16 were effective in decreasing TNF-α
production (p < 0.05, ANOVA with post-hoc Tukey Kramer test). N = 4.
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Figure 32. Effect of IκK-16 on IL-10 production.
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Monocytes were cultured with IκK-16 at various doses (diluted in DMSO) for 1
h, then stimulated with 100 ng/mL LPS until 17 h. At 17 h, cell culture
supernatant was measured for IL-10 protein concentration by ELISA.
Compared to 1 nM, the 1000nM dose decreased IL-10 levels (* p < 0.05). The
100 nM dose also appeared to decrease IL-10 levels compared with 1 nM,
approaching significance at 0.078 (#, ANOVA with post-hoc Tukey Kramer
test). N = 4.
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Effect of IκK-16 on HLA-DR expression
Isolated monocytes were stimulated with or without IκK-16 for 1 hour, before
the 100 ng/mL LPS challenge was added for 16 hours to determine the effect
of IκK on HLA-DR expression. We found no differences in the levels of HLADR expression between those treated with or without IκK-16, demonstrated in
Figure 33. This is clear from quantitative data from 6 donors, but also shown
qualitatively by scatterplots and histograms produced by flow cytometric
analyses.
MicroRNA expression in the impaired monocyte
Screening experiments were undertaken to examine the expression of 384
different microRNAs between the naïve and impaired monocyte. Initial
experiments were undertaken at the 33 hour time point (which equates to 16
hours after the 100 ng/mL LPS challenge). Significantly dyregulated miRNA’s
included miRNA-487a, -433, -655 and -450a. Those approaching significance
with biological significance included miRNA-210, -19b, -29b, -9, -7a, -221 and
-16. However, verification with single assay miRNA verification did not
demonstrate any of these to be significantly dysregulated (data not shown).
Further screening was undertaken at the earlier 17 h time point (i.e. the time
of the 100 ng/mL LPS challenge). These results revealed that miRNA-155
was the most consistently dysregulated, with miRNA-214 and miRNA-519e
also reaching statistical significance (Figure 34). Those approaching
statistical significance were therefore included for single assay experiments
and included miRNA-10a, -885-5p, -362-3p, -150, -133b, -138, and -212.
However, on single assay verification, only miRNA-155 was significantly
different between naïve and impaired monocytes at 17 hours (Figure 35).
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Both naïve and impaired monocyte expression of miRNA-155 was
upregulated when compared against baseline levels, but low dose 10 ng/mL
LPS resulted in a additive increase to a 12 fold increase compared to
baseline, pre-LPS levels.
Effect of IκK-16 on miRNA-155 expression
We have already shown that miRNA-155 expression increases in response to
LPS. When monocytes were treated with 100 nM IκK-16 for 1 hour prior to
100 ng/mL LPS stimulation, miRNA-155 was suppressed compared to control
(Figure 36).
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Monocyte HLA-DR expression

Figure 33A. Effect of IκK-16 on HLA-DR expression (i).
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Monocytes were cultured in conditions of either no IκK-16/no LPS, no IκK16/LPS or IκK-16/LPS for 17 h. Cells were analyzed using flow cytometry for
HLA-DR expression using a fluorescent PE stain (read on an FL2 channel).
Measurements were taken at the time of isolation and at 17 h. In standard cell
culture conditions, HLA-DR expression increases by 17 h from baseline
levels. Inhibition of IκK by IκK-16 does not influence HLA-DR expression (i). N
= 6. This is shown qualitatively (ii) with scatterplots comparing 100 ng/mL LPS
only vs. 100 ng/mL LPS + 100 nM IκK-16, and via a representative histogram
demonstrating no effect if IκK inhibition on HLA-DR (light gray = LPS only,
dark gray = IκK-16/LPS).
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Figure 33B. Effect of IκK-16 on HLA-DR expression (ii).
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Figure 34. MiRNA screening of the impaired monocyte.
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After 1 h rest, monocytes were cultured for 16 h in either media only (naïve) or
10 ng/mL LPS. At 17 h, cells were collected and lysed before RNA was
extracted. Following reverse transcription, Taqman Low Density Array cards
were used to measure the relative expression of 384 miRNAs by qRT-PCR. A
combination of RNU6, RNU44 and RNU48 were used as housekeeping genes
for normalization. MiRNA expression in the impaired monocytes were
compared to naïve monocytes as their control to express fold changes. Dots
to the right (red) represent upregulated miRNAs, whereas dots on the left
(green) represent downregulated miRNAs within the impaired monocyte.
Paired T-tests were used to generate –log10 p-values. A log10 p-value of 1.3 is
equivalent to 0.05, thus miRNAs above this level were considered significant.
N = 5.
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Figure 35. Verification of miRNA dysregulation in the impaired monocyte.
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MiRNAs that were significant and approaching significance from the miRNA
screening were included for single assay qRT-PCR analysis to verify
differences in expression between naïve and impaired monocytes at 17 h.
Fold changes here are calculated relative to the baseline level of miRNA
expression at isolation. MiRNA-155 is upregulated in both conditions during
the 17 h of cell culture, but low dose 10 ng/mL LPS results in even greater
increase (# p = 0.08). Other miRNAs assessed were not significantly different
between conditions.
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Figure 36. Effect of IκK-16 on miRNA-155 expression.
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Monocytes in culture following 1 h of rest were either stimulated with 100
ng/mL LPS only (green) or 100 ng/mL LPS in combination with 100 nM IκK-16
for 17 h. At 17h, monocyte intracellular RNA was extracted and miRNA-155
expression was determined by qRT-PCR. MiRNA-155 levels are expressed
relative to control (100 ng/mL LPS + dilute DMSO only). This shows that IκK16 blocks miRNA-155 production in response to LPS (* p <0.05, Paired Ttest). N = 4.
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DISCUSSION
This chapter aimed to understand the mechanisms underpinning how an initial
stimulus leads to a subsequent suppressed inflammatory response. The
hypothesis was that alteration of NFκB and IκK signaling account for how
impaired monocytes have suppressed immune responses. The first set of
experiments in this chapter demonstrate decreased levels of total p65, the
active subunit of NFκB, decreased p65 phosphorylation and critically,
impaired IκB degradation. The three sets of data examine different measures
of NFκB functionality and all demonstrate alterations in this important proinflammatory pathway. NFκB is known to be stimulated by LPS and other TLR
ligands in order to generate an inflammatory response. It has been
established that LPS activates NFκB to produce TNF-α, which occurs within
the first 17 hours. In response subsequent LPS challenge, the data presented
here show that cells with prior LPS exposure have suppressed NFκB
activation, decreased gene expression of TNF-α and decreased TNF-α
production. This suggests a negative feedback loop presumably evolved to
protect excessive, ongoing and potentially harmful responses. Recall the early
experiments by Beeson in the 1950’s, which showed that repeated endotoxin
injections to dogs produced less and less of a fever after each exposure.
NFκB suppression would also account for the decreased IL-6 and IL-10 levels
also seen in the previous chapter, as these genes are known to be
transcribed via this signaling pathway. It should be noted that other pathways
exist in pro-inflammatory responses. We have not examined MAPK or
ERK/JNK pathways which may also be suppressed.
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The most compelling experiments demonstrate decreased IκB
degradation in the impaired cells. This molecule represents “the brakes” within
this pathway, which in essence “are left on”. In a normal response, the brakes
are released by the upstream kinase, IκK. Therefore, these results imply that
there may be suppressed IκK function which might account for this defect.
Our experiments began focusing on the gene expression of the
catalytic subunits, IκK-α and –β. Recall that in the Glue Grant studies
discussed earlier, IκK-β was downregulated in trauma patients compared to
healthy controls. Our results do not show differences in IκK-β gene expression
or indeed protein levels in the impaired monocyte. Conversely, IκK-α was
consistently downregulated in the impaired monocyte in terms of gene
expression. However, this difference was not proven in the protein levels at 17
hours. Time course Western Blot experiments did not convincingly show
differences in IκK-α at later time points. It is not uncommon that differences in
messenger RNA are not always shown with the protein product. One possible
explanation for this may be the persistence or lack of degradation of the
existing protein product within the cells (in essence, changes in the production
but not changes in the degradation).
Given the lack of evidence for decreases in the total concentrations of
the catalytic subunits of IκK, the next experiments examined the level of
activation, i.e. level of phosphorylation of IκK, in response to the 100 ng/mL
LPS challenge. Western Blots every 15 minutes after the challenge revealed
clear suppression of IκK phosphorylation in cells with prior LPS exposure,
when compared to naïve cells that demonstrated dynamic IκK
phosphorylation peaking at 30 and 45 minutes after the LPS challenge.
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Indeed, these experiments address the hypothesis that IκK is suppressed in
the impaired cells. However, they demonstrate correlation, but do not in
themselves prove causation, which we will address later.
Given that the “chain of activation” via a cascade of
phosphorylation has been interrupted and prevented signals downstream, we
explored upstream mechanisms. TAK-1 is often described as an intermediate
signaling protein between TLR pathways and IκK. However, our experiments
do not show any differences in the phosphorylation or total levels of TAK-1
between naïve and impaired monocytes. One should note that TAK-1 is
known to be affected by ubiquitination in very complex biochemical protein
modifications, which we did not examine as this was beyond the scope of the
hypothesis. Furthermore, the input signals from upstream pathways to IκK are
redundant and involves more than 15 modifiers including a multitude of
kinases and phosphatases. Therefore, we adopted an approach of examining
a large amount of TLR related genes using gene expression profiling
experiments comparing the impaired monocyte to the naïve. We found that
TRAF-6, a gateway to numerous downstream pathways including NFκB, was
decreased. TRAF-6 has previously shown to be decreased in endotoxin
tolerance type studies, and more recently has been attributed to posttranslational modification by TNFAIP3 (A20) and miRNA-146a, and is thought
to be induced in response to the initial LPS stimulus. Even more interesting is
the findings of decreased TRAF-6 in the impaired monocyte in the TLR
profiling experiments. This may in fact reveal a signaling defect between
TRAF-6 and IκK independent of TAK-1.
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Other interesting trends included the downregulation of NFκBIA and
CD14. The former represents a gene coding for a subunit of the IκB complex.
This is in contrast to expected findings, as in albeit very different models
studying TNF signaling, IκB was in fact upregulated in response to external
TNF stimulation in order to limit later NFκB activation. However, a trend
towards decreased CD14 gene expression would correspond with decreased
responses to subsequent LPS stimulation, as CD14 is a co-receptor with MD2
and allows for TLR4 dimerization and signal transduction to MyD88. This
represents potentially multiple levels of negative feedback regulation, which
demonstrates the redundant nature of the innate immune system.
It should also be noted that there are various other explanations for the
decreased responsiveness to LPS. Rather than intra-cellular molecular
feedback mechanisms, an internalization of surface membranes and a
change in plasma membrane fluidity could result in the lack of available
external receptors for LPS, resulting in an impaired response. In addition, this
impairment could also be explained by a failure to recruit TLR4 receptors form
the cytosol, or other structural “machinery” which is exhausted. This was
certainly beyond the scope of this dissertation, but is an interesting area for
future research.
Our attention turned back to the role of IκK in monocyte function. There
is a correlation between decreased IκK phosphorylation, decreased proinflammatory cytokines and decreased HLA-DR expression in the impaired
monocyte. If monocyte impairment occurs as a result of IκK signaling, we
wanted to see if IκK inhibition would “turn a naïve monocyte into an impaired
monocyte”. For these experiments, IκK-16 was used to inhibit IκK
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phosphorylation. Other studies have demonstrated decreased IκK
phosphorylation in response to IκK-16. We confirm these findings in Figure
29, which demonstrates a true loss of function with use of this small molecule
selective inhibitor. This is of interest not only to demonstrate the mechanistic
role of IκK, but IκK-16 has been investigated as a potential therapy for
excessive inflammation in animal models of sepsis and hemorrhagic shock.
Importantly, any differences seen are due to pathway inhibition, rather than
toxicity to cells (Figure 30). Indeed, inhibition of IκK decreases both TNF-α
and IL-10 production, as seen in the impaired monocyte, in a dose-dependent
fashion. This proves a cause and effect relationship between the suppression
of IκK and pro-inflammatory cytokine production, as per the thesis hypothesis.
100 nM IκK-16 appears to be the minimal dose for therapeutic effect.
The same was not true for IκK inhibition and HLA-DR expression.
Despite exposure to the same dose of IκK-16 (100 nM) shown to effectively
decrease activation of IκK, there was no change in HLA-DR expression
compared to control. The expression of HLA-DR has been mostly attributed to
transcription of CIITA following JAK-STAT1 signaling, which is known to be
activated by IFN-γ. However, cross-talk between STAT and NFκB pathways
does exist, with LPS induced HLA-DR activation previously shown to also
depend on NFκB activation 116. Taken together, it is therefore possible that
there are defects of JAK-STAT signaling in impaired monocytes that
contribute to decreased HLA-DR expression, rather than a direct result of
decreased IκK and NFκB signaling. This has very interesting clinical
implications. The use of “blockers” of the inflammatory response of course
has concern, and this concern extends to the inhibition of IκK through IκK-16.
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However, these experiments suggest that IκK-16 has the potential to be used
as a “dimmer switch” to tune down inflammatory cytokine production but still
preserve antigen-presenting functions, as measured by HLA-DR expression.
These findings in combination with those by Li et al who found that IκK-16 did
not impair phagocytosis suggest that IκK-16 would decrease cytokine
responses by monocytes but not the other functions such as antigen
presentation and phagocytosis.
MiRNAs are small, non-coding single stranded RNA sequences in their
mature form which cause post-transcriptional inhibition of protein production.
There has been a great deal of research into the role of miRNA in a variety of
diseases including cancer and inflammation-related conditions. MiRNAs are
known to act as powerful regulators of toll-like receptor signaling, and other
groups have shown that miRNA-146a is increased in conditions of endotoxin
tolerance. In our findings, there was a slight increase in miRNA-146a in the
impaired monocytes, but this was not consistent and the magnitude of the
change was very small, which therefore did not qualify for single assay
verification. By comparison, miRNA-155 was upregulated in both naïve and
impaired conditions, but more so in the impaired condition. It has been shown
previously that miRNA-155 is increased in response to TLR ligands such as
LPS 117, but has not been associated with impaired monocyte function in the
same way as miRNA-146a. More commonly in the literature, miRNA-155 is
known for its early pro-inflammatory actions through suppressing its targets of
SHP1 and SOCS1 to promote TNF-α and other pro-inflammatory cytokines.
However, the delayed effects of miRNA-155 in decreasing the proinflammatory response have also previously been shown. Inflammation125

related targets also include RelA (p65), MyD88, TAB2 (part of the TAK-1
complex) and IκK-ε and would explain the role of miRNA-155 in dampening
inflammation. Of those targets measured in our experiments, p65 was
decreased as assessed by Western Blot at 60 minutes after the LPS
challenge, and IκK-ε trended downward in TLR profiling of the impaired
monocyte, in keeping with these miRNA-155 results. Given the higher
expression of miRNA-155 in the impaired monocyte and the decrease in
miRNA-155 targets, this could in part explain the suppression of IκK and
monocyte function in general. Nevertheless, miRNA-155 is associated with a
large number of inflammatory diseases and previous research in our lab
demonstrated the important role in cytokine regulation
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. MiRNA-based

therapy may be possible in the future, however, in the meantime
understanding how current therapeutics may influence miRNA expression as
a mechanism of action improves our understanding of positive and negative
effects of therapy. Our results demonstrate that IκK inhibition with IκK-16
decreases miRNA-155 expression. This demonstrates mechanistically that
miRNA-155 induction is IκK dependent, and that a likely feedback loop exists
in our model involving LPS stimulation of IκK and subsequent miRNA-155
induction in the first 17 hours, which in turn inhibits TLR, IκK and NFκB
activation in response to the LPS challenge through miRNA-155 mediated
inhibition of p65 and the other discussed targets. These results also imply that
IκK-16 therapy could limit excessive early inflammatory responses (via
decreasing the inhibition from SOCS1 and SHP1), and limit delayed
immunosuppression by preventing p65, MyD88 and TAB1 suppression.
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The miRNA screening experiments were designed to “throw the net
wide” in an unbiased fashion to find potentially novel miRNAs in the context of
monocyte impairment. However, this approach has some limitations. We
measured time zero (after isolation), at 17 hours and at 33 hours. It is possible
that we may have missed some miRNAs which were transiently changed
between these time points. Furthermore, the screening approach carries the
risk of both false positive and false negative results. Ideally, if there were a
higher number of donors used for screening with larger magnitudes of miRNA
differences, a false-discovery rate (FDR) correction such as the BenjaminiHochberg procedure or the method of Jung may have been appropriate to
limit the risk of type I error 118,119. Future studies with gain and loss of function
of miRNA-155 would be interesting, however this was beyond the scope of
this project and given the relatively small differences of miRNA-155
expression between conditions we turned our attentions downstream in the
pathway, as discussed in the next chapter.
In summary, this chapter has focussed on IκK signaling and
demonstrated that 1) Impaired monocytes have decreased NFκB activation,
2) Impaired monocytes have decreased IκK phosphorylation 3) naïve cells
can become “impaired” by IκK inhibition in terms of cytokine production 4) IκK
inhibition does not impair HLA-DR expression. These results demonstrate
cause and effect of IκK function and the capacity of the monocyte to produce
cytokines in response to an infective challenge.

127

CHAPTER VII
THE ROLE OF IΚK IN THE INFLAMMATORY RESPONSE
INTRODUCTION

Our data thus far demonstrates the critical role of IκK activation and the
monocyte inflammatory response. Our results have focused on TNF-α, IL-10
and HLA-DR as markers of monocyte function. However, as increasingly
complex assays are applied to studying sick surgical patients, a long list of
cytokines and markers have been associated with poor outcomes in the
surgical patient following trauma.
Certain patterns of cytokine and chemokine levels in patients following
major trauma have been shown to predict patient trajectories
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. In a study by

the Pittsburgh group, 44 patients who developed nosocomial infection after
trauma were compared to 44 patients who had an uncomplicated recovery.
Patient cohorts were matched by age, gender, injury severity score and
interventions. Both groups had increases in MCP-1 (CCL2), IL-6, IL-1RA and
HMGB1 compared to healthy volunteers, but levels were higher in the group
who became infected. Those who suffered later infection also had early and
sustained increases in IL-7, IL-5, IL-17A, IL-4, IL-13, MIP-1α (CCL3), MIP-1β
(CCL4), IFN-γ, IL-15, sIL-2Rα, GM-CSF and IP-10. In sequential observations
of both sets of trauma patients, levels of IFN-α, IL-1β, IL-2 and TNF-α were
low immediately after injury, but in the group who developed nosocomial
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infection, these levels gradually rose by 24 hours, with persistent elevation up
to 7 days after injury. It should be noted that in this study, the mean time to
developing infection was 7 days following injury (i.e. after the observed
cytokine changes), which suggests that the infection may be a consequence
of immune dysregulation, rather than the reverse.
The aims of this experiment were 1) to determine whether specific
cytokines were inhibited in the context of monocyte impairment, or whether a
global reduction in the capacity to produce cytokines occurs and 2) to
determine which cytokines and chemokines were modulated through IκK
inhibition, to offer a better understanding of this potential therapeutic target.
METHODS
Sample size considerations
Power calculations were undertaken based on prior pilot experiments with
data on TNF-α, IL-10 and IL-6 as representative cytokines. The effect size
was estimated based upon the mean differences and variability of that
difference between the naïve and impaired monocyte at 12 hours following
the 100 ng/mL LPS challenge (Table 5A). This was then used to estimate the
required sample size, depending on the minimal detectable difference for the
three cytokines (Table 5B). A representative power-sample size curve for IL10 is shown (Figure 37). Based on these calculations, 10 different donors
were used for these experiments in order to achieve a power of 0.80 (80%).
Non-parametric analysis was used to determine power and sample size
based on ranks (as non-parametric methods may be used to analyze
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subsequent data sets). This demonstrated increased power in the preliminary
data (70-85%).

Assay quality and detectability
Twenty-nine different cytokines and chemokines were measured in the
cell culture supernatant using a magnetic-bead based protein assay. Each of
the 96 wells tested had over 50 beads per cytokine, exceeding the minimal
count required for assay reliability. Two sets of quality controls were used to
measure expected levels for each of the 29 parameters, which all fell within
the expected range. Samples were run in duplicate. IL-3 levels were below
the lower limits of detection; IL-6 and MIP-1α concentrations were above the
upper limits of detection and could not accurately be interpreted. IL-6 was
therefore run separately as an individual ELISA. The experimental design is
illustrated in Figure 38.
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Table 5. Power and sample size calculations for the multiplex cytokine
analysis.
Table 5A.
Naïve Impaired
Mean
S.D. of
Effect
Power Power*
Mean
Mean
Difference Difference size
(1 – β) (ranks)
(pg/mL) (pg/mL)
(pg/mL)
(pg/mL)
(d)

Target

Sample
size

TNF-α

7

508.1

301.7

206.4

257.8

0.803

0.42

0.70

IL-10

7

981.5

586.8

394.7

380.1

1.038

0.63

0.85

IL-6

7

6659.1

3545.7

3113.4

3228.7

0.964

0.57

0.85

*Non-parametric power calculation based on Wilcoxon signed rank test &
subsequent Z-test on ranks.
Table 5B.

α
TNF-α
0.05
0.05
0.05
IL-10
0.05
0.05
0.05
IL-6
0.05
0.05
0.05

Power
(1 - β)

Difference
to detect
(pg/mL)

Effect
size
(d)

Sample
size
required

Sample
size
required*

0.80
0.80
0.80

If 100:
If 200:
If 300:

0.388
0.826
1.164

55
16
8

11.4

0.80
0.80
0.80

If 200:
If 400:
If 600:

0.526
1.052
1.578

31
10
6

4.6

0.80
0.80
0.80

If 1500:
If 3000:
If 4500:

0.464
0.929
1.393

39
12
7

4.6

*Non-parametric estimate of sample size based on noncentrality parameter
and expected differences from ranks.
Preliminary data of differences in TNF-α, IL-10 and IL-6 between naïve and
impaired monocytes at after the 100 ng/mL LPS challenge (12 hours) is
shown in Table 5A. The effect size from the preliminary experiments allows
for a sample size calculation, depending on how much of a difference is
detectable (Table 5B). Ten donors were used for the subsequent experiment.
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Figure 37. Power-sample size graph based on IL-10 differences between
naïve and impaired monocytes at 12 hours following 100 ng/mL LPS
challenge.

Sample size calculations were plotted against power. This representative plot
demonstrates the sample size for IL-10 at 12 hours following an LPS
challenge, comparing naïve and impaired monocytes. Note that as the sample
size increases, the power of the test obviously increases. A sample size of 10
donors would allow for an experiment to have a power of over 0.8 (80%).
A similar curve was created for non-parametric sample size calculations (not
shown).
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Figure 38. Experimental design of Multiplex cytokine experiments.

Monocytes were cultured in 4 conditions. In the first 17 hours, cells were
treated either with media only (1, unstimulated negative control and 2, naive),
low dose 10 ng/mL LPS (3, impaired) or with 100 nM IκK-16 (4, IκK inhibited)
all given at 1 hour after isolation. After 17 hours, cells were resuspended in
fresh media and were cultured either with media only (1, unstimulated
negative control) or 100 ng/mL LPS challenge (2, naïve, 3, impaired and 4,
IκK inhibited monocytes). At 29 hours (12 hours after 100 ng/mL LPS
challenge), concentrations of cytokines and chemokines in cell culture
supernatants were determined by a Milliplex Human Cytokine/Chemokine 29plex magnetic bead assay.
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RESULTS
Primary Analysis
Pro-inflammatory cytokines
In response to the 100 ng/mL LPS challenge, naïve monocytes produced
higher levels of TNF-α, IL-1β, IL-6 and IL-12 compared to the unstimulated
control (Figure 39). There were no increases in IL-8 production following LPS
treatment. Impaired monocytes, which had prior stimulation with low dose 10
ng/mL LPS, had a decreased capacity to produce TNF-α, IL-1β and IL-6
compared to the naïve control. There was also small reduction in IL-12p70
production by impaired monocytes.
IκK inhibition by IκK-16 treatment led to a decrease in TNF-α, IL-12 and IL-8,
with profound suppression of IL-1β and IL-6 levels compared to naïve cells.
One should note that IL-6 levels higher than the upper limits of detection of
the Milliplex assay were observed, and were therefore then separately tested
by individual IL-6 ELISA at an appropriately higher dilution and similarly
analyzed.
Anti-inflammatory cytokines
Levels of the anti-inflammatory cytokines IL-1RA and IL-10 were increased
with LPS stimulation in the naïve cells compared to the unstimulated negative
control, whereas levels of IL-4 and IL-13 were unchanged (Figure 40).
Monocyte impairment led to decreases in IL-10 production, but IL-1RA, IL-4
and IL-13 levels were similar between naïve and impaired conditions.
Inhibition of IκK decreased the levels of IL-10, IL-4 and IL-13. Levels of IL1RA were similar between naïve and IκK-16 treated monocytes.
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Figure 39. Effects of monocyte impairment and IκK inhibition on proinflammatory cytokine production.
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Legend for Figure 39.

Monocytes were cultured in either media only, low dose 10 ng/mL LPS or IκK16 (100 nM) for 16 hours. Cells then either remained unstimulated
(Unstimulated), or received 100 ng/mL LPS challenge (Naïve, Impaired, IκK16) for 12 hours after the LPS challenge. Cell culture supernatants were
measured using a Human Cytokine/Chemokine Milliplex assay. Results for
pro-inflammatory cytokines are shown using 10 donors, compared using
Wilcoxon Signed rank Test. * p <0.05, ** p < 0.01. Please note IL-6 was run
separately by individual ELISA due to high levels observed in the Milliplex
assay.
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Figure 40. Effect of monocyte impairment and IκK inhibition on antiinflammatory cytokine production.
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Monocytes were cultured in either media only, low dose 10 ng/mL LPS or IκK16 (100 nM) for 16 hours. Cells then either remained unstimulated
(Unstimulated), or received 100 ng/mL LPS challenge (Naïve, Impaired, IκK16) for 12 hours after the LPS challenge. Cell culture supernatants were
measured using a Human Cytokine/Chemokine Milliplex assay. Results for
anti-inflammatory cytokines are show using 10 donors, compared using
Wilcoxon Signed rank Test. * p <0.05, ** p < 0.01.
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Chemokines
MIP-1β levels increased in response to LPS in naïve cells, with a very small
increase in the levels of another chemokine called eotaxin (Figure 41). IP-10
levels were not increased by LPS stimulation and, interestingly, MCP-1 levels
actually decreased slightly compared to unstimulated monocytes.
10 ng/mL LPS treatment resulted in suppressed MIP-1β, MCP-1 and IP-10
levels in response to the 100 ng/mL LPS challenge, with eotaxin levels
unchanged in impaired cells compared with naive.
IκK-16 treatment decreased the levels of MIP-1β, MCP-1 and eotaxin
compared to naïve monocytes. Unexpectedly, monocytes with IκK inhibition
actually increased IP-10 production by approximately ten fold in response to
the 100 ng/mL LPS challenge compared with naïve monocytes.
MIP-1α levels were above the upper limits of detection of the Milliplex assay
and therefore were excluded from analysis.
Growth Factors
Naïve monocytes produced higher levels of G-CSF, GM-CSF and also VEGF
in response to 100 ng/mL LPS challenge, compared to unstimulated control
cells. In monocytes with low dose 10 ng/mL LPS impairment, the capacity to
produce GM-CSF, and to a degree VEGF, was reduced. Impaired monocytes
could produce equivalent concentrations of G-CSF and EGF.
IκK-16 treatment decreased the production of all four of these growth factors,
but G-CSF and GM-CSF were profoundly decreased (Figure 42).
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Figure 41. Effects of monocyte impairment and IκK inhibition on chemokine
N = 10
production.
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Monocytes were cultured in either media only, low dose 10 ng/mL LPS or IκK16 (100 nM) for 16 hours. Cells then either remained unstimulated
(Unstimulated), or received the 100 ng/mL LPS challenge (Naïve, Impaired,
IκK-16) for 12 hours. Cell culture supernatants were measured using a
Human Cytokine/Chemokine Milliplex assay. Results for chemokines are
shown using 10 donors, compared using Wilcoxon Signed rank Test. * p
<0.05, ** p < 0.01.
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Figure 42. Effect of monocyte impairment and IκK inhibition on growth factor
production.
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Monocytes were cultured in either media only, low dose 10 ng/mL LPS or IκK16 (100 nM) for 16 hours. Cells then either remained unstimulated
(Unstimulated), or received 100 ng/mL LPS challenge (Naïve, Impaired, IκK16) for 12 hours after the LPS challenge. Cell culture supernatants were
measured using a Human Cytokine/Chemokine Milliplex assay. Results for
growth factors are shown using 10 donors, compared using Wilcoxon Signed
rank Test. * p <0.05, ** p < 0.01.
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Other immunoregulatory cytokines
The 100 ng/mL LPS challenge increased the levels of IFN-α2, IL-2 and IL-7,
compared to unstimulated cells. Impaired monocytes produced decreased
levels of IFN-α2, IL-7 and TNF-β compared to naïve cells, whereas IFN-γ, IL15, IL-17 and IL-2 were unchanged between these naïve and impaired
conditions. Interestingly, IL-1α was the only cytokine or chemokine tested
which was elevated in the impaired cells compared to naïve conditions. IκK
inhibition led to a reduction in IFN-α2, IFN-γ, IL-15, IL-17, IL-1α, IL-2, IL-7 and
TNF-β levels compared to naïve monocytes (Figure 43). It should be noted
that in all four conditions (unstimulated, naïve, impaired and IκK-16 treated),
levels of IL-15, IL-17 and IL-2 were detectable but below 10 pg/mL. IL-5 levels
were below the minimal detectable concentration of 3.2 pg/mL, and IL-3 levels
were completely undetectable. Results for all cytokines/chemokines are
summarized for reference in Table 6.
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Figure 43. Effect of monocyte impairment and IκK inhibition on other
immunoregulatory cytokines.
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Monocytes were cultured in either media only, low dose 10 ng/mL LPS or IκK16 (100 nM) for 16 hours. Cells then either remained unstimulated
(Unstimulated), or received 100 ng/mL LPS challenge (Naïve, Impaired, IκK16) for 12 hours after the LPS challenge. Cell culture supernatants were
measured using a Human Cytokine/Chemokine Milliplex assay. Results for
other immunoregulatory cytokines are shown using 10 donors, compared
using Wilcoxon Signed rank Test. * p <0.05, ** p < 0.01.
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Secondary Analysis
An additional, more complex statistical analysis was undertaken on the
Milliplex cytokine/chemokine data. Given the large variability from donor to
donor for a given protein and the large variability between the actual raw
levels from protein to protein, this analysis was designed to address these
issues to allow cytokine patterns to be compared against one another.
In this analysis, the primary endpoint was the within-subject protein relative
change from the Naïve condition to the Impaired condition. Relative change
within subject samples was defined as:

. To

ensure the endpoint was approximately normally distributed, the endpoint was
log (base 2) transformed. Student’s t-test were then performed with the null
hypothesis that the average log relative change was equal to 0 (no difference
across condition) versus the alternative hypothesis that average log relative
change was not equal to 0. As multiple comparisons (proteins) were made, qvalues for preserving the False Discovery Rate (FDR) as opposed to the
familywise error rate (FWER) are reported. The FDR is defined as
where

represents expected value,

errors (false positives) and

is the number of Type I

is the number of rejected null hypotheses 121. As

an example, if differences with

are deemed “significant” then on

average 5% of these tests are false positives. Q-values were computed using
the method developed by Storey 122.
This data is shown in Figure 44 and demonstrates that TNF-α was the most
diminished of all cytokines and chemokines measured, and appeared to be
the most sensitive supernatant marker measured which reflects the changes
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resulting from monocyte impairment. In addition, the findings demonstrate that
numerous chemokines (green) which are significantly downregulated (i.e.
near the bottom of the plot), including IP-10, MCP-1 and MIP-1β.
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Figure 44. Relative change of cytokine & chemokine production in the
impaired monocyte compared to the naïve cells (Secondary analysis).

N = 10
The relative changes of each cytokine/chemokine from naïve to impaired
monocytes are summarized here. Each dot represents a within-subject
relative change. Stars denote statistical significance. *:q < 0.05 **: q < 0.01.
(Q-values are a measure of significance reflecting the false positive rate that
accounts for multiple comparisons). Colors denote the function of each protein
(e.g. pro-inflammatory). Proteins are ordered top to bottom based on the
relative change in the impaired monocyte, from most increased cytokine in the
impaired (IL-1α) down to the most decreased cytokine at the bottom (TNF-α).
Secondary analysis was with undertaken with the help of P. Trainor (PhD
candidate, Statistics).
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DISCUSSION
A critical balance is required to ensure a sufficient innate response to prevent
as well as clear infective challenges to the body, but also to limit an excessive
systemic inflammatory response to prevent ongoing damage and tissue
destruction. In the context of critical illness in the surgical patient, this balance
is often lost. Too much or too little of any aspect of the immunological system
has the potential for undesirable consequences. For that reason, the concept
of immune modulation carries a risk; “turning off” the immune system following
trauma or during sepsis risks nosocomial infection and failed pathogen
clearance, and “amplifying” the immune response could risk unnecessary
fever and systemic inflammation. This chapter deals with two of these
considerations; 1) during conditions of monocyte impairment resulting from
prior low dose endotoxin stimulation; which aspects of cytokine and
chemokine production are deficient, and which are preserved? 2) Focused,
specific inhibition of IκK may decrease TNF-α production but what other
cytokines and chemokines are dependent on this pathway? How similar are
these two phenomena?
The present experiments were designed with sample size calculations
based upon prior pilot experimental data. Ensuring a study is powered
sufficiently should reduce the risk of type II error and missing a potentially
significant result. Although these calculations were based on TNF-α, IL-10
and IL-6 from prior to the experiments, we cannot guarantee that all cytokines
assessed would be adequately powered. All experiments were based on 10
donors.
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Endotoxin stimulation of naïve monocytes resulted in a measurable
increase in over 15 inflammatory mediators, which included pro-inflammatory
and anti-inflammatory cytokines, as well as numerous chemokines. Some of
these, such as IL-2, IL-15 and IL-17 were low and although above the lower
limits of detection, should be interpreted with caution. By contrast, the levels
of production of IL-6 and MIP-1α by naïve monocytes were above the upper
limits of detection and therefore were excluded for analysis. IL-6 was
consequently tested separately by individual ELISA, and it is this IL-6 data
which is shown. In addition, whilst IL-8 was within range, I believe that these
should also be interpreted with caution as the unstimulated, naïve and
impaired conditions were similar at 14,000 pg/mL. It is possible that LPS
stimulation increased IL-8 levels beyond that of the unstimulated cells, and
levels from the impaired monocyte may be lower than naïve levels, which may
not be reflected in our results. It should be noted that similar to previous
experiments, the unstimulated monocytes have relatively high levels of many
inflammatory mediators which is likely a function of cellular stimulation from
the isolation procedure and centrifugation steps.
Prior results in this dissertation have indicated that TNF-α, IL-6 and IL10 were important inflammatory cytokines that were suppressed in the
impaired monocyte. In this different assay platform, TNF-α, IL-10 and IL-6
were again all decreased compared with naïve cells, which confirms the
previous results. These data show the impaired monocyte also has a
decreased capacity to produce IL-1β, IL-12p70, MIP-1β, MCP-1, GM-CSF,
VEGF, IFN-α2, TNF-β and IL-7. The identification of these inflammatory
mediators as suppressed in this model suggests that both chemokine and
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growth factor production by the monocyte are functions that are also to some
degree impaired. This would add further explanation to the decreased
pathogen clearance seen in such patients, due to decreased leukocyte
chemoattraction, as well as the lack of maturation and differentiation of new
circulating leukocytes such as myeloid-derived suppressor cells 123,124. Many
pro-inflammatory cytokines are produced in response to NFκB activation, thus
a reduction in all of these pro-inflammatory cytokine responses after IκK-16
was expected.
Anti-inflammatory cytokines are important mediators in resolving
inflammation after an initial insult, but excess levels can themselves suppress
other genes. LPS effectively increases IL-1RA and IL-10, but only IL-10 was
suppressed in the impaired monocyte compared to the naïve cells. This
supports the notion that global functions were impaired, rather than a
polarization of monocytes and macrophages toward an “M2” phenotype,
where higher IL-10 levels would be expected. The significance of the
decrease in anti-inflammatory cytokines following IκK inhibition (with IκK-16) is
that this may “maintain the balance” with the reduced pro-inflammatory
cytokines, preventing a dominance of these anti-inflammatory mediators.
There are some specific cytokines and chemokines worthy of attention.
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Figure 45. Summary of the effect of monocyte impairment and IκK inhibition
on cytokine and chemokine networks (as per the primary analysis).

Low dose LPS 10ng/mL results in monocytes having an impaired capacity to
produce a large number of cytokines and chemokines (red). Specific inhibition
of IκK, a central feature of monocyte impairment, results in decreased levels
of all cytokines and chemokines seen in blue. Those inflammatory mediators
which are decreased in both conditions are shown in the central region where
the two networks overlap. Cytokines that were undetectable are not shown.
MCP-1 is the only mediator which is decreased in monocyte impairment but
not influenced by IκK inhibition. IP-10 is also decreased in monocyte
impairment, but increases during specific IκK inhibition. IL-1α was the only
mediator which was increased in monocytes impaired by prior 10 ng/mL LPS
treatment, however, does appear to be dependent on IκK function.
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MCP-1, also known as monocyte chemoattractant protein-1 or CCL2,
yielded some interesting findings. MCP-1 has previously been described as
having a central role in injury-induced inflammation 125. This was the only
mediator to decrease in response to the 100 ng/mL LPS challenge, and was
the only cytokine decreased in the impaired monocyte but not regulated by
IκK signaling. MCP-1 is thought to be governed by JNK and MAPK p38
pathways, and therefore MCP-1 suppression may suggest alterations in these
pathways 126. It should be noted that the difference between naïve and IκK-16
treated monocytes was only p = 0.08.
IP-10 (interferon-gamma induced protein-10), also known as CXCL-10,
is generally secreted in response to IFN-γ with important roles in
chemoattraction for other leukocytes, and is thought to govern IL-10
production. In our results, this mediator showed an unexpected pattern. The
LPS challenge did not influence levels in the naïve monocyte relative to
unstimulated cells, but levels were decreased in the impaired monocyte.
Furthermore, it was the only parameter that consistently increased after IκK
inhibition. This may suggest that that other cytokines, either raised or
decreased in the first 17 hours, may modulate IP-10 levels rather than directly
from LPS stimulation. In addition, there is presumably an intermediate
molecule which normally suppresses IP-10, that is blocked by IκK-16 and thus
releasing IP-10 production (in other words, “the inhibitor is inhibited”). IP-10
had previously been thought to be NFκB-dependent; however these results
suggest that other pathways are involved in its production 127.
IL-1α was the only cytokine which significantly increased in the context
of monocyte impairment compared to naïve cells. This was an unexpected
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result, and to my knowledge has not been previously associated with
monocyte impairment or “endotoxin tolerance”. IL-1α has the capacity to
stimulate TNF-α, and both are synergistic in their interaction. In these results,
IL-1α upregulation is in contrast to TNF-α and to IL-1β, which has a similar
biochemical structure. Monocytes have a unique mechanism of inducible IL1α expression through a long non-coding RNA, but some evidence also
shows that cell death can lead to the passive leakage of cytosolic IL-1α.
Impaired monocytes have appeared to have similar rates of cell viability to
naïve cells according to our previous results, although we have not formally
measured apoptosis. A more likely explanation is that IL-1α is produced as a
result of the initial 10 ng/mL LPS stimulus in impaired cells, where its release
is persistent in a well-recognized, feed forward, “self-perpetuating”
inflammatory loop 124. This loop appears to be successfully interrupted by IκK
inhibition.
Taken together, the results from this set of experiments expand our
knowledge regarding the extent of impairment of monocyte function, with a
now extended range of inflammatory mediators in which impaired monocytes
have decreased capacity to produce and release. The pattern of change in
the impaired monocyte highlights those cytokines and chemokines are most
affected in impairment, as demonstrated by the secondary analysis (Figure
44). There is significant overlap between impaired monocyte function from
prior LPS exposure and monocytes inhibited by an IκK inhibitor, supporting
the role of IκK suppression in monocyte impairment (Figure 45). There are a
considerable number of mediators which are suppressed by IκK, but are not
decreased in the impaired monocyte, which suggests pleiotropic effects of
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LPS as a “sledgehammer” which may result in cross-talk between other
inflammatory pathways and redundant feedback loops preserving their
production through non-IκK mechanisms. Another important consideration is
the potential for “off-target” effects of IκK-16. While it is believed that this
inhibitor is specific for IκK, as with any drug, it may have unrecognized effects
such as the inhibition or activation of other pathways in the inflammatory
response. What is clear from these results is the broad spectrum of
inflammatory control governed by IκK activation. The Pittsburgh group have
associated the elevation of at least 15 cytokines or chemokines with later
nosocomial infection in trauma patients, that we have shown can be
decreased by IκK-16 120. The magnitude of the increase in pro- and antiinflammatory cytokines and chemokines, as well as the magnitude of the
decrease in adaptive immunity genes predicted poor outcomes in trauma
patients (Figure 46) 1. The results presented here demonstrate that IκK-16
has the capacity to attenuate many of these pro- and anti-inflammatory
cytokines and chemokines, but crucially without further impairment to HLA-DR
expression. This pattern of modulation makes IκK-16 an attractive therapeutic
avenue.
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Figure 46. The genomic response to trauma and potential role of IκK
inhibition.

IκK-16

The genomic response to trauma is not changed by a “second hit” but
nosocomial infection and mortality are predicted by the magnitude of the
change after injury. The larger the increase in innate immunity gene
expression (such as pro- and anti-inflammatory cytokines and chemokines) is
related to poorer outcomes. In addition, the level of downregulation in
adaptive immunity genes such as HLA-DR is also predictive of infection and
mortality. Taken together, our results show that IκK-16 attenuates the
response in pro- and anti-inflammatory cytokines and chemokines, without a
reduction in HLA-DR expression. This pattern of modulation makes IκK
inhibition an attractive therapeutic strategy (blue arrow). Adapted from Xaio,
2011 (as part of the Glue Grant studies) 1.
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Table 6. Effect of monocyte impairment and IκK inhibition on cytokine
production.

Unstimulated

Naïve

Impaired

IκK-16

P (1)
Impaired
vs. Naïve

P (1)
IκK-16
vs.
Naive

P (2)
Impaired
vs. Naïve

P (2)
IκK16 vs.
Naive

Pro-inflammatory cytokines
TNF-α

405.5 (86.6)

1325.8 (300.6)

671.3 (140.4)

509.8 (115.6)

↓0.002

↓0.002

<0.05

<0.05

IL-1α

1205.4 (280.2)

1419.3 (360.7)

2054.8 (522.9)

182.4 (42.5)

↑0.027

↓0.002

NS

<0.05

IL-1β

683.1 (134.8)

1245.9 (230.0)

1050.5 (253.1)

56.08 (13.8)

↓0.049

↓0.002

<0.05

<0.05

IL-12p70

12.2 (1.3)

15.8 (1.7)

14.0 (1.7)

8.63 (1.0)

↓0.010

↓0.002

NS

<0.05

IL-6

11310.1 (2949.1)

16899.2 (3288.1)

14384.4 (3066.9)

764.6 (314.9)

↓0.010

↓0.002

<0.05

<0.05

Anti-inflammatory cytokines
IL-10

4446.3 (1157.6)

6692.7 (1398.9)

4785.9 (1032.5)

1279.5 (272.1)

↓0.006

↓0.002

<0.05

<0.05

IL-1RA

200.8 (32.3)

252.6 (41.3)

215.1 (32.1)

218.3 (55.7)

0.084

0.322

NS

NS

Chemokines
MCP-1

7647.6 (1238.3)

6770.5 (1219.9)

5287.8 (1156.7)

5482.5 (1153.2)

↓0.002

0.084

<0.05

NS

MIP-1β

4699.8 (834.2)

7318.2 (1104.8)

5534.1 (835.6)

3524.4 (755.7)

↓0.004

↓0.004

<0.05

<0.05

IP-10

116.7 (30.2)

105.2 (31.9)

60.2 (12.9)

1582.2 (455.4)

↓0.020

↑0.004

<0.05

<0.05

Eotaxin

25.3 (1.4)

27.3 (1.7)

27.8 (2.1)

21.2 (1.6)

0.625

↓0.002

NS

<0.05

IL-8

14150.2 (462.5)

14283.3 (597.9)

14000.0 (833.5)

11606.2 (1097.0)

0.492

↓0.002

NS

<0.05

Growth factors
G-CSF

3987.7 (997.1)

5121.1 (1234.5)

5199.3 (1160.4)

162.9 (37.8)

0.250

↓0.008

NS

<0.05

GM-CSF

246.3 (78.8)

384.0 (86.2)

305.9 (69.2)

29.5 (7.5)

↓0.027

↓0.002

<0.05

<0.05

EGF

20.9 (1.3)

22.8 (1.7)

23.0 (1.4)

18.3 (1.4)

0.846

↓0.002

NS

<0.05

VEGF

148.3 (10.8)

175.0 (13.1)

160.1 (12.0)

121.1 (13.2)

↓0.020

↓0.002

<0.05

<0.05

Other immunoregulatory cytokines
IFN-α2

52.4 (4.9)

68.8 (6.0)

59.0 (5.1)

39.2 (4.1)

↓0.004

↓0.002

<0.05

<0.05

IFN-γ

34.9 (4.0)

38.8 (3.9)

38.0 (3.6)

19.5 (2.7)

0.695

↓0.002

NS

<0.05

IL-4

47.5 (4.5)

53.7 (4.8)

53.7 (5.0)

37.0 (3.5)

1.000

↓0.002

NS

<0.05

IL-7

26.5 (2.3)

30.7 (2.6)

28.2 (2.6)

19.0 (2.2)

↓0.037

↓0.002

<0.05

<0.05

Mean (SEM) shown. P-values (1) reflect Wilcoxon signed rank test. P-values (2) reflect
Repeated Measures ANOVA with Post Hoc Student Newman Keuls test. Arrows reflect the
direction of statistically significant differences in cytokines/chemokines between indicated
comparisons. Cytokines out-with upper and lower detection limits are excluded. IL-6 data
run as individual ELISA as described.
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PATHWAY ANALYSIS
Pathway analysis was undertaken to interpret the complex pattern of cytokine,
chemokine and surface receptor differences between the studied
experimental conditions representing monocyte functionality.
Specifically, the MetaCoreTM database (Thomson Reuters) was used to
determine signaling networks based on significant cytokines and chemokines
(p < 0.05 from Repeated Measures ANOVA with Post Hoc Student Newman
Keuls test between naïve and impaired monocytes) and HLA-DR (deemed to
be significantly different as per Specific Aim 1). The “Build a Network”
function was used, by entering the significantly different proteins (seed nodes)
based on our data. Then, a network was built and analyzed an algorithm for
up to 50 nodes. This yielded 30 networks, which were ranked in order of Zscore. The Z-score ranks the subnetworks according to the saturation of the
objects from the original list of seed nodes. The formula to calculate this is as

follows:

, where N is the total number of nodes in the

database, R is the number of network objects corresponding to significant
genes (i.e. cytokines, chemokines and surface markers entered), n is the
number of nodes in each small network generated from the output list, and r is
the number of nodes with data in each small network from the output list.
The results from this analysis are summarized in Table 7. The analysis
demonstrates that the highest ranking network generated is in fact “NFκB”,
the signaling pathway that has been the focus of this thesis. This yielded a pvalue of 7.78e46, with a Z-score of 323.72. It should be noted that this
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network achieved highest scores in terms of low p-value, high Z-score and
high G-score (the G-score is a modified Z-score based on how patterns relate
to Canonical Pathways in the database). Processes that this network were
associated with, based on the significant targets entered, included “positive
regulation of the immune system”, “cellular response to LPS”, “cellular
response to a molecule of bacterial origin”, “positive regulation of leukocyte
migration” and “leukocyte chemotaxis”.
The extent of the role of NFκB in how it relates to defective protein synthesis
is shown in Figure 47A. Each arrow (connection) is based on peer reviewed
literature evidence for a relationship between two targets, therefore, defective
inflammatory NFκB activation observed in the impaired monocyte could
explain differences in the linked cytokines and chemokines, but also low HLADR expression in the impaired monocyte relative to the naive.
Interestingly, the third and fourth most correlated networks were RelA (the
gene name for p65, the important active subunit of NFκB, and the NFκB
heterodimer p50/p65), respectively. These are all overlapping networks and
signify the importance of defective function of NFκB in the impaired monocyte.
A further discussion point is the highly scoring network of AP-1 (also known
as Activator Protein-1). AP-1 is a transcription factor which regulates the
gene expression of various proteins relating to differentiation, proliferation and
apoptosis. It is a heterodimer composed of proteins such as c-Fos, c-Jun and
ATF families. C-Jun is also the fifth most commonly involved network. In
Figure 48, it is clear that this transcription factor is activated by p38, ERK and
JNK, which are the critical upstream inflammatory signaling pathways
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involved in the monocyte inflammatory response. This cross-talk between
pathways implies that both NFκB and AP-1 (p38, ERK and JNK) have
overlapping roles in mounting a response to an infective stimulus. This again
highlights the redundancy of the innate immune response. We have shown
that indeed IκK and NFκB are suppressed, and could account for the network
of suppressed protein responses seen. However, given that these alternative
pathways culminating in AP-1 have not “compensated” for the decreases in
NFκB activation, this implies that these pathways are also similarly
suppressed.
A further conclusion from this pathway analysis is a potential explanation for
the pattern of MCP-1 levels (also known as CCL2) observed. This important
chemokine is regulated by both NFκB (As per Figure 47A), but also by AP-1
(Figure 48). Given that MCP-1 was not suppressed by an IκK-16 (a blocker of
IκK and subsequently NFκB) in the naïve monocyte, this suggests that MCP-1
production is an AP-1 mediated mechanism (presumably through MAPK p38,
ERK or JNK) in the context of monocyte impairment.
We also used the network analysis to consider some other anomalies seen in
our data. Firstly, we found that the impaired monocyte actually produced
consistently higher levels of IFN-α2 compared with the naïve monocyte. This
is in contrast to Shi et al, who found that IFN-α2 was decreased during
monocyte impairment, and replenishing IFN-α2 levels with an exogenous
source could abrogate this impairment 128.
Regulation of IFN-α2 production is governed by various mechanisms,
including the non-canonical NFκB pathway (involving TRAM-TRIF-TRAF3-
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TBK1/IκK-ε) through either interferon regulatory factor (IRF)-3 or IRF-7.
Therefore, given that IP-10 is also suppressed in the impaired monocyte but
IFN-α2 is elevated, this suggests that opposing effects of IRF function with
suppressed IRF-3 and elevated IRF-7 function may be occurring (Figure 48).
Through pathway analysis using MetaCoreTM, the two most consistent
pathways governing HLA-DR expression were NFκB and JAK-STAT1
signaling. The former is demonstrated in Figure 47A, and the latter is shown
in Figure 47B. In the impaired monocyte, HLA-DR expression is decreased,
which could be explained by deficiencies in either of these pathways.
However, when naïve cells were treated with IκK-16, which we know inhibits
IκK and NFκB functions, HLA-DR expression is unaffected. This suggests an
alternative pathway is being suppressed to cause the deficient HLA-DR
expression, and the literature and database pathway analysis is suggestive
that the JAK-STAT1 pathway is also suppressed in the impaired monocyte.
This is very likely as SOCS-1 (suppressor of cytokine signalling-1) is elevated
in impaired monocyte models, and is known to inhibit JAK-STAT1 signaling. In
fact, SOCS-1 is required for endotoxin tolerance.
In summary, pathway analysis reveals that the most consistent signaling
network corresponding to the data generated from our experiments is NFκB,
which accounts for almost all of the functional changes seen in the impaired
monocyte. Indeed, we have confirmed that the impaired monocyte does have
suppressed IκK and NFκB functionality. Our analysis has also revealed that
the pattern of change could also be explained by AP-1, particularly the pattern
of MCP-1 production, thus defects in MAPK p38/ERK/JNK signaling could
suppress AP-1 activity and contribute to monocyte impairment. Furthermore,
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the most likely cause for decreased HLA-DR expression out with NFκB
suppression is decreased JAK-STAT1 activation.
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Table 7. Top 5 networks involved in monocyte impairment based on pathway
analysis (MetacoreTM)

No.

Key

GO Processes

network

Total

Seed

Pathways

p-Value

zScore

gScore

nodes

nodes

12

11

0

7.78e-46

323.72

323.72

11

10

0

1.98e-41

307.38

307.38

11

10

0

1.98e-41

307.38

307.38

11

10

0

1.98e-41

307.38

307.38

10

9

0

4.27e-37

290.14

290.14

objects

1

NF-kB

positive regulation of immune system process
(100.0%), cellular response to lipopolysaccharide
(75.0%), cellular response to molecule of bacterial
origin (75.0%), positive regulation of leukocyte
migration (66.7%), leukocyte chemotaxis (66.7%)

2

AP-1

positive regulation of leukocyte migration (72.7%),
leukocyte chemotaxis (72.7%), leukocyte
migration (81.8%), regulation of leukocyte
migration (72.7%), positive regulation of
intracellular signal transduction (100.0%)

3

RelA (p65

cellular response to lipopolysaccharide (81.8%),

NF-kB

cellular response to molecule of bacterial origin

subunit)

(81.8%), positive regulation of leukocyte migration
(72.7%), cellular response to biotic stimulus
(81.8%), leukocyte chemotaxis (72.7%)

4

NF-kB

cellular response to lipopolysaccharide (81.8%),

p50/p65

cellular response to molecule of bacterial origin
(81.8%), positive regulation of leukocyte migration
(72.7%), cellular response to biotic stimulus
(81.8%), leukocyte chemotaxis (72.7%)

5

c-Jun

positive regulation of ERK1 and ERK2 cascade
(80.0%), positive regulation of leukocyte migration
(70.0%), regulation of ERK1 and ERK2 cascade
(80.0%), leukocyte chemotaxis (70.0%), leukocyte
migration (80.0%)
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Figure 47. Pathway analysis of the impaired monocyte.

A

B
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Legend to Figure 47.

Pathway analysis of the impaired monocyte. The most significantly affected
signaling network, and indeed the network with the highest Z-score was NFκB
This network, based on the differentially expressed cytokine/chemokine and
surface protein levels in the impaired monocyte, is demonstrated in Figure A.
Experimental evidence from the peer-reviewed literature and network analysis
demonstrates a proven causal link between the function of NFκB and each
downstream protein. The regulation of HLA-DR expression is primarily
governed by the class II transactivator (CIITA). Figure B demonstrates the
important role of the JAK-STAT pathway in promoting HLA-DR expression.
Decreased HLA-DR in the impaired monocyte, which does not appear to be
due to IκK/NFκB mediated suppression, but more likely decreases in the
function of JAK-STAT pathway.
Source for A: MetaCoreTM, Thomson-Reuters (from entering own data).
Source for B: Harding & Boom, Nature Reviews Microbiology 8, 296-307 129
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Figure 48. KEGG pathway of Toll-like Receptor Signaling.

CHAPTER VIII
ENHANCING IMPAIRED HOST DEFENCE MECHANISMS: AN
IMMUNOLOGICAL BASIS FOR ADJUVANT THERAPIES*2
INTRODUCTION

Surgical infection continues to plague the surgeon and the patient. Despite
various strategies to address this problem, surgical site infection (SSI) still
occurs in up to 17 per cent of patients, with post-operative infection of some
kind affecting 23 – 49 per cent of patients in high-risk groups.10 In particular,
major elective surgery acts as a significant physiological insult to some of our
patients.
Host defense impairment, and in particular, impairment of monocyte function,
is generally accepted as being predictive of nosocomial or secondary infection
after surgical trauma.4
Immunomodulatory agents have been studied clinically for many years,
particularly in the context of trauma and sepsis without definitive outcomes. 87
Some therapies appear to show promise by improving survival in murine
models of sepsis, such as cecal ligation and puncture. However, these mice
or rat models carry serious limitations: subjects are genetically homogenous
and various clinical factors observed in humans are not taken into account. 9
When these therapies are translated to humans, repeatedly the benefits in

2

We plan to will be submit the work of this chapter to a peer-reviewed journal in this calendar year
(2016).
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mortality are not consistently observed. In clinical practice, the majority of
patients will have relatively normal monocyte function and do not stand to
benefit from adjunctive therapy. A better understanding of how those with
impaired monocyte function will respond could allow for better translation to
the patient. The issue of monocyte impairment itself is hugely variable among
patients and often unpredictable, but approximately one in six trauma patients
have subnormal monocyte function. Thus, we have adopted an approach of
studying human monocytes ex-vivo. Low-dose stimulation of cells by LPS (10
ng/mL) recreates not just the initial pro-inflammatory response observed
clinically but also results in subsequent suppressed monocyte responsiveness
to LPS exposure. The use of different healthy volunteers introduces variation
from person to person, but permits the resulting impairment seen in some
patients in a reproducible fashion.7,8
In this study, we have examined the underlying immunological basis for
established and new adjuvant therapies using an ex-vivo model of impaired
human monocytes to determine their influence on key host defence
mechanisms. The immunomodulatory therapies we have focused on are
interferon-γ, GM-CSF and IκK-16 (an IκK inhibitor).
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METHODS
Techniques for monocyte isolation and cytokine analysis are detailed in
the main Methods section (page 61).
Flow cytometry
Monocyte samples (100 μL, 100,000 cells) were stained with fluorescein
isothiocyanate-labeled anti-human CD14, phycoerythrin-labeled anti-HLA-DR
antibodies (BD Biosciences, La Jolla, CA) and separately phycoerythrinlabeled anti-PD-L1 (BD Biosciences, La Jolla, CA) to measure monocyte
surface expression of these proteins. Manufacturer instructions were closely
followed. Monocytes were pelleted by centrifugation, washed with Dulbecco
Phosphate Buffered Saline (Sigma Aldrich, St. Louis, MO), and fixed in 300
μL of 1 per cent paraformaldehyde solution.
At the indicated time points, monocyte surface levels of CD14, HLA-DR
and PD-L1 expression were analysed using a FACS Calibur flow cytometer
(Becton Dickinson, San Diego, CA). A total of 5,000 gated events were
acquired. Mean fluorescence intensity (MFI) for each surface marker was
analysed on monocytes using Cell Quest software (Becton Dickinson, San
Diego, CA).
Adjuvant therapies
Human recombinant IFN-γ, GM-CSF and IκK-16 were purchased from Sigma
Aldrich, St. Louis (MO). Compounds were reconstituted from stock solution as
per manufacturer’s instructions and diluted in media to the appropriate
concentrations.Adjuvant therapy doses were as follows: 100 ng/mL rIFN-γ,
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100 ng/mL rGM-CSF and 50 nM IκK-16 as determined by dose-response
experiments (data not shown). Adjuvants rIFN-γ and rGM-CSF were then
added to cell culture 1 h after isolation, simultaneously with 10 ng/mL LPS for
a duration of 16 h (until 17 h post-isolation). IκK-16 was given at time zero for
1 h, cells were washed with PBS and re-suspended in fresh media then 10
ng/mL LPS was added to cell culture. No further doses of immunoadjuvants
were given at or after the 100 ng/mL LPS challenge at 17 h.
Statistical Analysis
Each donor was used as its own control. Wilcoxon-signed ranked test was
used for calculation of significant differences where appropriate. Naïve
conditions (no LPS 10ng/mL pre-treatment) and then each immunoadjuvant
therapy were compared to the impaired monocyte. Significance was set at P <
0.05. Preliminary experiments were used to estimate that a sample size of 7
was required to obtain a power of 0.8 (80%). SigmaPlot was used for
presentation of data and for statistical analysis (SyStat Software, Inc.,
Chicago, IL).
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Figure 49. Experimental protocol for adjuvant therapies in the impaired
monocyte.

Timeline of the experimental protocol. Following monocyte isolation from
healthy volunteers, following 1 hour of rest, cells are cultured either in media
only (naïve) or with low dose 10 ng/mL LPS for 16 hours. Monocytes are then
re-suspended in fresh media and challenged with high dose 100 ng/mL LPS
to assess the inflammatory response. Adjuvant strategies aim to modulate the
response to this 100 ng/mL LPS challenge.
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RESULTS
Monocyte impairment
Low-dose 10 ng/mL LPS stimulated ex-vivo human monocytes in culture to
produce higher levels of TNF-α at 17 h compared with its naïve control
(Figure 50). However, when these cells met a subsequent larger LPS
challenge of 100 ng/mL, they exhibited decreased levels of TNF-α when
compared to the naïve cells, most noticeably at 21 h. Monocytes impaired by
low-dose LPS exposure also exhibited a decreased ability to produce IL-10,
an anti-inflammatory cytokine, following the LPS challenge. This decrease in
IL-10 levels was sustained, reaching statistical significance at 21, 29 and 41 h
after the LPS challenge as seen in Figure 51. Monocyte surface HLA-DR
expression, a parameter reflecting antigen-presenting capacity measured by
flow cytometry, was modestly but consistently decreased in the LPS 10ng/mL
exposed monocyte at 17 h (Figure 52). CD14 and PD-L1 expression was
similar between naïve and impaired conditions.

IFN-γ treatment
Recombinant IFN-γ treatment increased the capacity for the monocyte to
produce TNF-α. In response to the initial 10 ng/mL LPS, TNF-α levels
increased in the impaired monocyte. Subsequent to 100 ng/mL LPS challenge
at 17 h, levels of TNF-α production were higher in IFN-γ treated monocytes at
21 and 29 h. IL-10 levels appeared to initially decrease in IFN-γ treated
monocytes at 17 h, but did not demonstrate significant differences. Compared
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to the impaired monocyte, HLA-DR expression was consistently sustained in
response to IFN-γ treatment at 21, 29 and 41 h. Monocyte CD14 expression
was decreased as a consequence of IFN-γ treatment, most noticeably at 41 h
(Figure 53). IFN-γ treated monocytes had markedly increased PD-L1
expression at every time point (Figure 54).
GM-CSF treatment
GM-CSF appeared to decrease TNF-α and increase IL-10 at 17 h, and then at
all subsequent time points following 100 ng/mL LPS. However, these
differences never reached statistical significance. GM-CSF did not have any
significant influence on monocyte HLA-DR, CD14 or PD-L1 expression.
IκK-16 treatment
Despite the short exposure to IκK-16, there was a consistent and sustained
decrease in TNF-α production when compared to the impaired monocyte,
most noticeable at 17 h and 41 h. Despite a decrease in TNF-α, there was no
decrease in IL-10 levels. In fact, monocytes treated with IκK-16 trended
towards an increased capacity to produce IL-10 following an LPS challenge
when compared with the impaired monocyte. IκK-16 also did not increase
monocyte HLA-DR or PD-L1 expression; however, CD14 expression was
progressively upregulated following the LPS challenge (Figure 53).
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Figure 50. Effect of immunoadjuvants on TNF-α production in the impaired
monocyte.
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Monocytes were cultured in naïve (media only) or impaired (10ng/mL)
conditions, with or without the three adjuvant regimes. Cells were then given
the 100 ng/mL LPS challenge. Supernatant TNF-α protein was measured by
ELISA. Mean ± S.E.M. N = 7. *p < 0.050.
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Figure 51. Effect of immunoadjuvants on IL-10 production in the impaired
monocyte.

B. Impaired without and with IFN-γ
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Monocytes were cultured in naïve (media only) or impaired (10ng/mL)
conditions, with or without the three adjuvant regimes. Cells were then given
the 100 ng/mL LPS challenge. Supernatant IL-10 protein was measured by
ELISA. Mean ± S.E.M. N = 7. *p < 0.050.
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Figure 52. Effect of immunoadjuvants on HLA-DR expression in the impaired
monocyte.

B. Impaired without and with IFN-γ
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Monocytes were cultured in naïve (media only) or impaired (10ng/mL)
conditions, with or without the three adjuvant regimes. Cells were then given
the 100 ng/mL LPS challenge. Surface HLA-DR expression was measured by
FACS. Mean ± S.E.M. N = 7. *p < 0.050.
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Figure 53. Effect of immunoadjuvants on surface CD14 expression in the
impaired monocyte.
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Monocytes were cultured in naïve (media only) or impaired (10ng/mL)
conditions, with or without the three adjuvant regimes. Cells were then given
the 100 ng/mL LPS challenge. Surface CD14 expression was measured by
FACS. Mean ± S.E.M. N = 7. *p < 0.050.
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Figure 54. Effect of IFN-γ on surface PD-L1 expression in the impaired monocyte.
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Legend for Figure 54.

Monocytes were cultured in naïve (media only) or impaired (10ng/mL)
conditions, with or without the three adjuvant regimens. Cells were then given
the 100 ng/mL LPS challenge. Surface PD-L1 expression was measured by
FACS. Mean ± S.E.M. N = 7. *p < 0.050.Figure E demonstrates a
representative histogram showing the increase in PD-L1 expression in
response to IFN-γ treatment.
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Figure 55. Effect of adjuvant treatments on monocyte viability.
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Monocytes were cultured on conditions of either naïve (media only), impaired
(low dose 10 ng/mL LPS), or impaired with adjuvant as previously described
for 16 hours, after an initial hour of rest. At 17 hours, cells were stained with
Trypan blue and were counted by standard microscopy to determine cell
viability between conditions. N.S., not statistically significant between groups
(Repeated Measures ANOVA).
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DISCUSSION
The purpose of this study was to understand how potential immunoadjuvant
therapies influence host defense mechanisms in a human ex-vivo model of
monocyte impairment. Firstly, our data demonstrate that the initial response to
endotoxin is a pro-inflammatory phenotype, but then impaired cytokine
production occurs in response to a further endotoxin challenge. These
findings are in agreement with many in-vitro and ex-vivo models in the
literature.5,46 Furthermore, this model is representative of both human
endotoxemia models and clinical studies examining the immune response
after major elective surgery, trauma and sepsis.

86

Specifically, the blunted

capacity of monocytes to express HLA-DR and to produce TNF-α has
repeatedly been shown to predict secondary infection and often death. This
has formed the basis for numerous randomized clinical trials designed to
enhance the monocyte inflammatory response.3,84
IFN-γ has been shown to act through the IFN-γ receptor and
subsequently via the JAK-STAT1 pathway to activate monocytes and
macrophages. Our results show that IFN-γ restores the capacity of the
monocyte to produce TNF-α and augment HLA-DR expression. These
findings are in keeping with previous in-vitro studies.47 In addition, these
positive effects by IFN-γ have been shown in-vivo with numerous clinical
studies.91
We have shown that IFN-γ also increases the expression of PD-L1 on
the surface of monocytes. Recent studies to understand the signaling and role
of this negative co-stimulatory receptor have shown that IFN-γ, through its
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activation of the JAK-STAT1 pathway, also leads to higher PD-L1 expression
in natural killer cells.130 We believe this likely represents a negative feedback
mechanism to suppress endogenous IFN-γ by T-cells in the context of highly
abundant exogenous sources. Future research is required to determine if PDL1 will be as clinically applicable as a marker or therapeutic target in the field
of surgical infection as it has been in oncology.
Our data has not demonstrated any significant modulatory effect of
GM-CSF on the impaired monocyte. Preliminary dose-determining studies
suggested that IL-10 production was augmented in the naïve monocyte;
however, this effect may be attenuated in the setting of monocyte impairment.
Surgical trials using GM-CSF have shown increased peri-operative HLA-DR
expression, and our results suggest that this effect may be through promotion
of myelopoeisis to produce new, functioning monocytes rather than
modulating existing circulating impaired monocytes. 93
IκK-16 is a small molecule inhibitor of IκK, acting to suppress this proinflammatory signaling pathway. “Glue Grant” studies of the genomic
response in surgical patients following trauma demonstrated that the
magnitude of both the pro- and anti-inflammatory response determined patient
outcome.1 Due to the presumed risks of persistent suppression of
inflammation, a short exposure of this therapy was used. Our results show
that, despite short exposure, decreases in TNF-α production are sustained.
Interestingly, levels of the anti-inflammatory cytokine IL-10 were restored
towards the level of the naïve monocyte. While the use of IκK-16 have
improved end organ function in pre-clinical models of hemorrhagic shock and
sepsis, tipping the balance in favor of IL-10 and decreasing TNF-α may in fact
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increase the risk of nosocomial infection in some patients.77 One unexpected
finding of the effect of IκK-16 was the augmentation of CD14 expression,
especially in the later stages after stimulation. CD14 acts as a receptor for
LPS, binding to TLR4 homodimers for signal transduction in the monocyte.
Studies in trauma patients have shown that the detachment of this receptor
following excessive stimulation, examined either by decreased monocyte
expression or increased soluble CD14, is a predictor of infection and
death.131,132 We believe that by decreasing the early and late responses to
LPS by limiting IκK activation, this might represent a mechanism to preserve
the capacity to respond to future exposure to pathogens and may warrant
further study.
This study does have some limitations. Due to the ex-vivo and
artefactual nature of this study, we cannot account for how other immune cells
might respond to these immunomodulatory agents. Furthermore, the
leukocyte response to LPS shares 88% of the same genomic response to
trauma, as demonstrated in high throughput Glue Grant studies. 1
In conclusion, IFN-γ is the most effective immunoadjuvant in terms of
increased TNF-α production and HLA-DR expression, which are two important
predictors of surgical infection. However, by modulating a different signaling
pathway, IκK-16 restored IL-10 production and augmented CD14 expression.
Correcting impaired host defenses is a key factor in preventing and surviving
surgical infection. We, as surgeons, are still trying to modulate pathologic
immune responses to improve rates of surgical infection and death in our
patients. Careful clinical judgment in terms of patient selection and timing is
required in successfully translating these studies to future clinical trials.
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CHAPTER IX
MONOCYTE FUNCTION IN THE INFECTED SURGICAL PATIENT
INTRODUCTION

Surgical patients are at risk from numerous different forms of
nosocomial infection during their hospital course. They may present with an
acute intra-abdominal infection such as diverticulitis, or from a contaminated
wound following trauma. The critically unwell patient often has invasive lines
which can act as a foreign body, and can be ventilated which carries a risk of
pneumonia. Finally, surgical site infection (SSI) is of political importance as a
potential measure of quality of care, and can range from superficial wound
infection to deep organ or cavity space infection. Patients with SSI’s often
require additional interventions, have a longer hospital stay and experience
greater morbidity. Previously in this dissertation, impaired host defense was
highlighted as a risk factor in the probability of surgical site infection, often
measured by low monocyte HLA-DR or low ex-vivo TNF-α production in
response to a stimulus. Few studies have examined the immune response in
surgical patients after the so called clinical “second hit” of infection.
In this chapter, surgical patients from a University Colon and Rectal
Surgery practice who were diagnosed with infection were studied. Patients
were selected based on being “in homeostasis with or tolerant of” their
infective source i.e. likely to bear the clinical phenotype of in-vivo monocyte
impairment previously described. This is distinct from other studies in sepsis
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where patients had a systemic inflammatory response with or without shock
and multi-organ failure.
The aims of this study was 1) to determine monocyte function in major
surgical patients with infection, as judged by HLA-DR expression and ex-vivo
cytokine production and 2) investigate the expression of intracellular negative
regulator molecules that could represent a potential marker or indeed driver of
suppressed monocyte function.
METHODS
Following IRB approval and written informed consent, peripheral blood
was obtained by phlebotomy. Blood samples were taken both during
episodes of infection and after clinical recovery (median 60 days after 1st
sample). As a comparator group, peripheral blood was also obtained from
healthy volunteers.
The majority of patients were hemodynamically stable and most were
diagnosed with deep surgical site infection, as defined by an abscess in an
organ or cavity space. The specific sources of infection included intraabdominal abscess (n=12), pneumonia (n=2), perineal abscess (n=1) and line
sepsis (n=1). Patients were aged 25-81 years, 6:10 (M:F). Healthy volunteers
were aged 19-32 years, 7:3 (M:F).
Peripheral blood was obtained using EDTA tubes, which prevented
clotting and allowed ex-vivo testing of the immune response. Monocyte HLADR expression (FACS) and cytokine levels (ELISA) were examined at
baseline 0 h (unstimulated) and following ex-vivo lipopolysaccharide (LPS)
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stimulation (100 ng/mL) for 4h (Fig. 56). Plasma samples were obtained after
centrifugation of whole blood, and stored at -80°C until later testing. Standard
individual ELISA assays were performed for TNF-α, IL-10 and IL-6 (as
described the main Methods section, from page 61). Flow cytometry was
performed on whole blood using the protocol described in the main Methods
section, from page 61. The main difference in protocol was that whole blood
was lysed with hypotonic lysis buffer to exclude RBCs from analysis. For the
gating strategy, the monocyte population was selected based on forward and
side scatter properties, and confirmed by gating only on CD14 positive cells .
Monocyte HLA-DR is expressed as mean fluorescence intensity (MFI). The
same antibodies for CD14 (FITC) and HLA-DR (PE) were used as described
in the main Methods section (from page 61), however, samples were run
using a BD LSRII flow cytometer (BD Biosciences, CA).
The remaining monocytes were isolated by magnetic bead positive
selection and mRNA was extracted and analyzed via qRT-PCR, to compare
the ratio of normalized mRNA expression (using 18S) between the patient and
healthy control samples (as described in the main Methods section, from
page 61). For statistical analysis, Mann-Whitney-U tests and Unpaired T-tests
were used where appropriate.
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Figure 56. Experimental design of clinical study of patients with surgical
infection.

Peripheral blood was taken from surgical patients with infection. Monocyte
function was determined by CD14 positive monocyte HLA-DR expression by
FACS, and ex-vivo LPS stimulation in whole blood for 4 hours. At 4 hours,
HLA-DR expression was measured again to determine the response, as well
as concentrations of plasma cytokines TNF-α, IL-10 and IL-6 by ELISA. In
addition, monocytes were isolated from patient samples using CD14 magnetic
bead isolation, and monocyte RNA was extracted and qRT-PCR was used to
determine the expression of various known negative regulators of monocyte
function. Further samples were taken from patients later in their course of
illness, presumably moving toward health after hospital discharge; healthy
volunteers were also studied.
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RESULTS
Monocyte HLA-DR expression
Patients had statistically significant lower baseline HLA-DR expression (0h,
unstimulated) compared to healthy volunteers (Figure 57). Following LPS
stimulation, healthy volunteers upregulated HLA-DR expression to MFI of
approximately 15,000 compared with only 8,000 in patients during their initial
sample (p<0.05). Levels of HLA-DR either prior to or after LPS stimulation did
not seem to improve in follow-up samples compared with initial patient
samples.
Cytokine production
Circulating levels of TNF-α were virtually undetectable in healthy volunteers
and patients (Figure 58). The levels of TNF-α appear slightly higher in
patients, however, these were below the lower limits of detection in the assay
and did not reach statistical significance. Decreased monocyte TNF-α
production was observed in patients in response to LPS stimulation,
compared with healthy volunteers. Follow-up samples from patients also had
lower levels of TNF-α production compared with health volunteers but also
appeared lower than initial patient samples.
Circulating levels of IL-10 were increased in patients compared to the
healthy controls (Figure 59, p<0.05). Levels of IL-10 did decrease in the
follow-up patient samples. After 4 hours of LPS stimulation, there were
minimal increases in all groups in IL-10 production. IL-10 levels after 4 hours
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of LPS stimulation remained higher in patients compared with healthy
volunteers.
Circulating plasma IL-6 levels (prior to stimulation) were elevated in the
initial patient samples compared to healthy volunteers, in which IL-6 levels
were below the lower limits of detection (Figure 60). Following 4 hours of exvivo LPS stimulation, this pattern was reversed. Healthy volunteers increased
their IL-6 levels to approximately 2,000 pg/mL, compared with a mean IL-6
level of less than 1,000 pg/mL in patients with infection. Follow-up samples for
IL-6 were not available for analysis at the time of writing.
Gene expression of negative regulators of the inflammatory response
Based on a thorough literature search, the expression of the following
negative regulator molecules were analysed; ATF3, IRAK-M, TNFAIP3 (A20),
SOCS-1, SOCS-3 and SHP-1. These were compared to 18S as the
housekeeping gene for normalization. Gene expression of IRAK-M, a known
negative regulator of inflammation, was consistently upregulated in patients
with infection as compared to healthy controls (p<0.05) (Figure 61). Data for
the other negative regulators were not significantly different (data not shown).
Interestingly, IRAK-M mRNA expression appeared to decrease after clinical
recovery (dark gray) although this did not reach statistical significance.
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Figure 57. Monocyte HLA-DR expression in patients with surgical infection.
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Monocyte HLA-DR expression was determined in both unstimulated blood
(baseline 0 h) and after 100 ng/mL LPS stimulation ex-vivo for 4 hours. HLADR expression using PE-tagged antibodies was determined on CD14 positive
monocytes using FACS. * p < 0.05, Mann-Whitney U test.
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Figure 58. Plasma TNF-α concentration in patients with surgical infection.
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Figure 59. Plasma IL-10 concentration in patients with surgical infection.
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Figure 60. Plasma IL-6 concentration in patients with surgical infection.
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Figure 61. Monocyte IRAK-M expression in patients with surgical infection.
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DISCUSSION

A proportion of surgical patients have a suppressed inflammatory response
which impairs their ability to clear infection. This can result in the permissive
escape of microbes from the chest, urine or wounds into the bloodstream,
leading to bacteremia. As a result, multi-organ failure and death is a
consequence in some patients. Prolonged or repeated physiological insults
through repeated operations, infection or trauma, and certain therapies can
lead to suppressed monocyte function. Such patients with “deactivated” host
defenses or “immunoparalysis” can tolerate infective sources, such as
abscesses, to persist without clearance. It was this clinical phenotype of
surgical patient that was selected for study in this chapter.
Firstly, we aimed to determine monocyte function within these patients.
Identification of such patients at higher risk for failure to clear infection is of
clinical interest. Furthermore, such a patient may benefit from a therapy that
could “reactivate” monocyte function. Much of the principle underpinning the
isolated monocyte model of impairment design in Specific Aim 1 held the
assumption that these patients had decreased ability to produce TNF-α in
response to LPS as well as decreased levels of HLA-DR expression. These
results confirm that the patients studied with surgical infection did have
suppressed monocyte function, compared to healthy volunteers. Not only was
monocyte HLA-DR expression decreased prior to stimulation, but the patient’s
monocytes were unable to upregulate HLA-DR expression in response to LPS
stimulation. These findings are in keeping with prior studies in sepsis and
trauma patients 4,24. TNF-α levels were decreased in response to LPS, but
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also the capacity to produce IL-6 was decreased. These data confirm the
validity of the impaired monocyte model.
Interestingly, circulating plasma levels of IL-6 and also IL-10 prior to
stimulation were elevated in patients compared with healthy controls. This is
in keeping with results from other groups 27,133. Mechanistically, this could in
part explain the decreased monocyte responsiveness. IL-10 is known to
decrease TNF-α gene expression and downregulate HLA-DR expression. IL10 has previously been discussed as a potential target to block and prevent
this loop of monocyte impairment 134.
A difference between the impaired monocyte model and the patient
observations is the increased IL-10 levels observed in infected patients. In our
model, the impaired monocyte consistently suppresses IL-10 production.
There are various explanations for this. Firstly, these samples were taken
from whole blood rather than a single cell suspension of monocytes. Other
documented sources of IL-10 in sick surgical patients include neutrophils and
T-cells that are polarized towards a Th2 phenotype, which would explain this
difference 135,136. Timing is a critical consideration. Our results indicate that
monocytes in culture increase IL-10 levels over time in regardless of
conditions. At 17 hours, fresh media is used to determine the responsiveness,
which is obviously not the case with the whole blood 100 ng/mL LPS
challenge. This could mask the increased IL-10 levels.
There are numerous limitations to this study. This thesis demonstrates
a high degree of variability in monocyte function from person to person in
healthy volunteers. In addition, there is considerable clinical variability
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between these patients. There is variability in the source and severity of
infection, in co-morbidity and treatments and critically, there were no specific
criteria of sampling times relative to the diagnosis of infection, rather these
patients were studied as targets of opportunity. This study was a spontaneous
experiment of surgical practice. Both initial and follow-up samples are likely to
be at different times within the clinical course from patient to patient, including
a few who appeared to have fully recovered. Other limitations include
potential selection bias with respect to patients, differences in age between
patients and healthy volunteers, and attrition bias in that every immune
parameter could not be measured in every patient. This is partly due to small
volumes of blood available for analysis.
Nevertheless, the patients at the time of infection had elevated levels of
IRAK-M expression relative to healthy volunteers, and this elevation appeared
to return towards the level of healthy volunteers after clinical recovery. These
data are similar to other groups studying patients with sepsis 137,138. IRAK-M is
likely to be involved in a negative feedback loop, induced by stimuli such as
LPS, which in turn suppress the assembly of IRAK 1/4 and decrease TRAF-6,
therefore suppressing the inflammatory response through IκK and NFκB
inhibition (Figure 62). In fact, various groups in experimental models have
shown that silencing or knockout of IRAK-M results in an abrogation of
impairment with increased cytokine production
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Figure 62. Proposed mechanism of IRAK-M mediated suppression of
monocyte function in patients with surgical infection.
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Monocytes in surgical patients will likely have initial stimulation such as from
an operation, infection or soiling of the peritoneal cavity resulting in the
stimulation of inflammatory pathways such as IκK, and resulting upregulation
of IRAK-M. This negative regulator is known to suppress TLR signaling,
resulting in a suppressed inflammatory response.
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In summary, this small observational study demonstrates that patients with
surgical infection have impaired monocyte function, as judged by decreased
TNF-α production in response to ex-vivo LPS stimulation and decreased HLADR expression. These results confirm to some extent the in-vitro impaired
monocyte model. Upregulation of IRAK-M in infected patients may provide a
potential mechanism of suppressed IκK activation and impaired responses
and may be a potential marker and/or target of immunomodulation.
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CHAPTER X
CONCLUSIONS AND OVERVIEW

Impaired monocyte function is a central component to an immune
suppression of host defense mechanisms following major trauma, surgery or
infection. Although this occurs in only a subset of patients, this is predictive of
poor outcomes and remains an attractive therapeutic target.
This model of isolated monocytes from healthy volunteers allows for a
pure population of reproducibly impaired monocytes to be studied for
underlying mechanisms and potential therapy. This is characterized by a
reduced capacity to produce many cytokines and chemokines (such as TNF-α
and IL-10), and reduced HLA-DR expression, as a result of low dose LPS
exposure. This constellation of defects is representative of the patient with
impaired host defenses.
The focus of this thesis has been to understand the effects of such
impairment on NFκB and IκK signaling. While other pathways may also be
involved, NFκB which is an important pro-inflammatory signaling pathway is
indeed altered in its function in the context of monocyte impairment. Our
results reflect decreased p65 protein, diminished p65 phosphorylation and
decreased IκB degradation in response to a subsequent challenge,
demonstrating suppressed NFκB activation in the impaired monocyte. The
total levels of the IκK subunits studied do not actually change but there is
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suppressed IκK phosphorylation. This is seen most evidently within 30
minutes after the LPS challenge. This suppression of IκK activation
corresponds with the decreased TNF-α and IL-10 production as a result of
impairment. This defect is likely to be a result of a negative feedback loop that
is limiting upstream signaling pathways, where we found downregulated gene
expression of TRAF-6. TRAF-6 is considered the gatekeeper of toll-like
receptor signaling, and its suppression in the impaired monocyte, in part,
explains how decreased IκK activation occurs.
Loss of function studies with a novel, specific IκK inhibitor
demonstrated cause and effect relationship of the IκK pathway, by
recapitulating the impaired monocyte as measured by decreases in TNF-α
and IL-10 production. This occurred in a dose-dependent fashion, proving the
hypothesis that decreased IκK activity leads to impaired monocyte function.
Interestingly, HLA-DR expression was not influenced by IκK inhibition, and is
likely to be governed by other altered signaling pathways. Interestingly,
miRNA-155 appeared to increase in response to LPS, but decreased with IκK
inhibition. This negative effect of IκK inhibition on miRNA-155 may provide an
additional mechanism to limit early inflammation, and perhaps late
immunosuppression, which may offer clinical benefit. Early inhibition of IκK
may be useful in some clinical settings, such as major trauma and shock, by
limiting an excessive cytokine and chemokine response which is also
associated with poor outcomes, without decreasing HLA-DR expression.
However, it is likely that profound or prolonged IκK inhibition would likely be
detrimental in a sick surgical patient.
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Understanding how our findings correspond with in-vivo monocyte
impairment would be worthy of further study. One limitation of the study was
that while single cell suspension allows focused mechanistic and signaling
studies, the interaction of monocytes with other cells and organs in an in-vivo
system, such as in an animal model, could not be elucidated. However, during
the time of this thesis, we did study monocyte function in surgical patients with
infection. We found that they had decreased TNF-α and HLA-DR expression,
which confirms the validity and clinical relevance of the in-vitro model. Further
observations in animal models or humans following trauma to examine IκK
function and downstream cytokine networks could better inform and translate
these findings at a systemic physiological level. This may also aid the
understanding of negative feedback loops involved in upstream signaling
dynamics, and how adjuvants like IκK-16 and IFN-γ modulate the monocyte
inflammatory response in a positive way for the “high risk” surgical patient.
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Figure 63. Summary of thesis hypothesis.
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Legend to Figure 63.

We hypothesized that monocyte impairment occurred as a result of feedback
inhibition of IκK. First, we developed a model of decreased monocyte function,
as judged by decreased TNF-α and decreased IL-10 in response to an LPS
challenge. Impaired monocytes also had decreased HLA-DR
expression.*Decreased IL-10 production in the impaired monocyte was
contrary to the hypothesis. In impaired cells previously exposed to low dose
10 ng/mL LPS, decreased IκK phosphorylation was observed. Manipulation of
this pathway with an IκK inhibitor resulted in decreased TNF-α and IL-10
production, as seen in the impaired monocyte. HLA-DR was not decreased by
IκK inhibition. Therefore, we conclude that decreased cytokine production of
the impaired monocyte occurs as a result inhibition of IκK, although
decreased HLA-DR likely occurs due to non-IκK related pathways.
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Royal College of Surgeons, Edinburgh

2013

Masters in Surgical Sciences (MSc)
2010 - 2013
Edinburgh Surgical Sciences Qualification (ESSQ)
Part time distance learning degree
Dissertation: “MBL and the acute phase response: A factor in post-operative infection following liver
resection?”
Achieved Distinction
University of Edinburgh/Royal College of Surgeons Edimburgh.
Doctor of Philosophy in Physiology (PhD)
2014 - 2016
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Prizes & Awards
Distinction and Commendation
Clinical Medicine, May 2010, MBChB, University of Glasgow

223

Distinction
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2014 - Present
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qPCR, Flow cytometry, Western Blot, Immunofluorescence microscopy.
Supervision of high school, undergraduate and medical students in mentoring and teaching
scientific technique.
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As a member of the Department of Surgery, this involved regular attendance at weekly teaching
trauma rounds, grand rounds, morbidity and mortality meetings and examining medical student
surgical exams.
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General Surgery, Western Isles Hospital, Stornoway, Isle of Lewis
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Society for Surgery of the Alimentary Tract (SSAT) 2016
Surgical Infection Society (SIS) 2016
Association of Surgeons in Training (ASiT) 2014
Royal College of Surgeons, Edinburgh 2013
General Medical Council (GMC) 2010

Courses and Meetings Attended












Academic Surgical Congress, Las Vegas, 2017 (Registered)
Surgical Infection Society Annual Meeting, West Palm Beach, 2016
Academic Surgical Congress, Jacksonville, FL, 2016
Academic Surgical Congress, Las Vegas, 2015
ASC Grant Writing Course, ASC Congress, Las Vegas, 2015
Train the Trainers, Royal College of Surgeons England, 2013
Care of the Critically Ill Surgical Patient (CCrISP), Liverpool, 2013
ATLS, Raigmore Hospital, Inverness. 2012
ALS, 17th Jan 2012
Basic Surgical Skills, Royal College of Physicians and Surgeons, Glasgow, 2011.
ILS, University of Glasgow, 2010.

Audit


Fluid prescription in Surgical Patients by Junior Doctors
Working with Mr Hugh Paterson, Consultant Colorectal Surgeon, Western General Hospital,
2012.
An audit consisting of surveying FY1 doctors on their fluid prescription regimes in various
scenarios in combination with clinical data of fluid prescription in surgical patients. Resulted in
regular fluid teaching program, with re-audit complete.



Audit of Compliance with VTE Prophylaxis including Reassessment in WIH
Western Isles Hospital, Stornoway, Isle of Lewis, 2012.
Conceptualised, designed, collected data for & presented at a local meeting. Resulted in a change
of practice, with new documentation and the second cycle is about to begin.



Audit of Surgical Management of Abscesses in the Colorectal Unit.
Western General Hospital, Dec 2013.
Audit of time/inpatient stay from admission to drainage, and whether this was undertaken “out
of hours”, presented to the regional Colorectal Morbidity & Mortality meeting.



Audit of Risk assessment & Appropriate Heparin/TED prescription in the Urology Unit,
WGH.
Western General Hospital, Edinburgh, 2014
I supervised an FY1 doctor in the design, collection and data analysis. We presented the first
cycle, with a view to implementing an intervention through stickers and for re-audit.



Loop ileostomy patient education in an American Colorectal Unit.
University Hospital, Louisville, Kentucky, 2016.
An initial audit revealed a high rate of readmission following loop ileostomy formation due to
dehydration and partial small bowel obstruction. An intervention of a patient orientated
educational card was provided to all patients undergoing a new loop ileostomy formation to
educate them on monitoring ileostomy output, do’s and don’ts of appropriate foods and what to
do if concerns regarding ileostomy output. The current status of this project is in the progress of
analysis of outcomes after the intervention to close the audit cycle loop.
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Parnaby CN, Galbraith N, O'Dwyer PJ. Experience in identifying the venous drainage of the adrenal
gland during laparoscopic adrenalectomy. Clin Anat. 2008 Oct; 21(7): 660-5.
Papers in progress:
Galbraith NJ, Walker SP, Cahill M, Bishop C, Manek S, Reid M, Polk HC. Enhancing impaired host
defense mechanisms: An immunological basis for adjuvant therapies.
Submitted to Journal of Leukocyte. Biology, December 2016
Galbraith NJ, Carter JV, Netz U, McCafferty M, Yang D, Fry DE, Galandiuk S. A contemporary metaanalysis of laparoscopic lavage for perforated diverticulitis.
Submitted to JAMA Surgery, November 2016
Walker SP, Galbraith NJ, Bishop C, Reid M, Gardner SA, Polk HC. Interferon-gamma enhances
monocyte function and increases PD-L1 expression.
Accepted for oral presentation at ASC, 2017, Las Vegas. Target journal: PLoS One.
Galbraith NJ, Walker SP, Carter JV, Gardner SA, Galandiuk S, Polk HC. The role and regulation of IκK
in relation to impaired monocyte function.
Accepted for presentation at ASC, 2017, Las Vegas. Target journal: Surgery
Galbraith NJ, Walker SP, Gardner SA, Carter JV, Manek S, Galandiuk S, Polk HC. Surgical patients with
infection have suppressed monocyte function and increased IRAK-M expression.
Accepted for presentation at ASC, 2017, Las Vegas. Target journal: Journal of Immunology
Galbraith NJ, Walker SP, Carter JV, Gardner SA, Galandiuk S, Smith JW, Barnes SL, Polk HC.
Major trauma causes microRNA changes associated with pro-inflammatory cytokine signaling. Target
journal: Annals of Surgery.
Galbraith NJ, Netz U, Carter JV, Polk HC Jr., Galandiuk S. Long term outcomes in patients diagnosed
with Indeterminate Colitis – a retrospective case review.
“Radiofrequency ablation for breast cancer liver metastasis: A case of tumour progression”
Galbraith NJ, Wigmore SJ.
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“MBL and the acute phase response: A factor in post-operative infection following liver resection”
Galbraith NJ, Wigmore SJ.
“Key Factors affecting Compensatory Renal Hypertrophy following Live Kidney Donation”
Galbraith NJ, Clancy MJ.
Presentations
Poster presentation, Surgical Infection Society Annual Meeting, West Palm Beach, FL. May 2016.
“Dysregulation of NFκB in the impaired human monocyte leads to a blunted TNF-α response”
Oral presentation, Academic Surgical Congress, Jacksonville, FL. February 2016 (First Author & Presenter)
“MicroRNA dysregulation associated with function of the impaired monocyte”
Price Seminar, Price Institute of Surgical Research, Department of Surgery, University of Louisville, March
2015
“Drug prophylaxis and other adjunctive therapies for septic complications in the surgical patient”
Oral presentation, Academic Surgical Congress, Las Vegas February 2015 (First Author & Presenter)
“TRPA1 mediates the effects of hypothermia on the monocyte inflammatory response”
Oral presentation (Vascular/Transplant Section), Association of Surgeons of Great Britain & Ireland,
Harrogate, 2014 (First Author & Presenter)
“Factors affecting Compensatory Renal Hypertrophy following Live Kidney Donation”
Poster, Association of Surgeons of Great Britain & Ireland, Harrogate, 2014 (First Author & Presenter)
“MBL and the acute phase response: A factor in post-operative infection following liver resection.”
Poster, Association of Surgeons in Training, 2014 (First Author & Presenter)
“Key Factors affecting Compensatory Renal Hypertrophy following Live Kidney Donation”
ePoster, ESSQ MSc, University of Edinburgh, 2013 (First Author & Presenter)
“MBL and the acute phase response: A factor in post-operative infection following liver resection”
Poster, European Society for Coloprotology (ESCP), Vienna, 2012 (First Author)
“Fluid prescription in Surgical Patients by Junior Doctors”
Poster, European Society of Organ Transplantation (ESOT), 2011 (Third Author)
"Compensatory Renal Hypertrophy Following Laparoscopic Live Kidney Donation: No Reduction
Compared with Open Techniques"
Poster, ASGBI International Surgical Congress, 2010 (Second Author)
"Patient Outcome Following Laparoscopic Adrenalectomy for Adrenal Metastasis"
Poster, British Association of Endocrine and Thyroid Surgeons Annual Meeting, 2009 (Presenter and First
Author)
“Laparoscopic adrenalectomy in metastatic renal cell carcinoma.”
Oral presentation, Scottish Renal Association Meeting, 2009 (Presenter and First Author)
“Renal function in patients following live donor nephrectomy.”
Oral presentation at the Winter Meeting of the British Association of Clinical Anatomists, 2007 (Second
Author)
“Importance of adrenal vein anatomy during laparoscopic adrenalectomy.”

Book Chapters
Galbraith NJ, Wiemann TJ, Polk HC.
The Prevention and Treatment of the Diabetic Foot
Fischer’s Mastery of Surgery, 7th Edition.
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Book Reviews
“How to Pass the MRCS OSCE Volume 1 (Oxford Specialty Training: Revision Texts)” by Pradip K.
Datta, Chris Bulstrode, Vasha Kaur
Reviewed by P. Cullis & NJ. Galbraith
Published at British Journal of Surgery (BJS) Online: Book Reviews
“Fundamentals of Surgical Practice (3rd Edition) by Andrew Kingsnort and Douglas Boweley
Reviewed by P. Cullis & NJ. Galbraith
Published 24th Feb 2014 in Surgeons News, Royal College of Surgeons, Edinburgh

Teaching
I am registered for my third consecutive year as an eTutor for the Edinburgh Surgical Sciences
Qualification MSc programme, teaching junior doctors in the Colorectal & Urology modules through Case
Based Discussion enforcing basic science principles and formally assessing them (2013 – present).
I have carried out teaching to medical students including bed side teaching, lectures and interactive
tutorials.
There has been ample opportunity to teach within the academic foundation programme. Recent teaching
sessions included:
 Surgical emergencies for the FY1
 Topics in Gastroenterology (3rd year medical students) including inflammatory bowel disease,
upper GI bleeds and colorectal cancer.
In my recent clinical year before leaving Edinburgh, I was an examiner in the 3 rd year OSCE’s for their GI
block with the University of Edinburgh.
Since my time in Louisville, I have regularly taken part as an examiner in the 3rd year medical student
surgical oral exams, as well as regular attendance on Dr. Polk’ teaching trauma rounds.

Management, Leadership & Teamwork
Following on from heavy involvement in the audit process, following a successful presentation of our VTE
audit in the Western Isles Hospital, I attended meetings with the Medicines Management team to establish
new guidelines based on our audit, which was highly successful.
Since then, I have organized X-Ray meetings, the Stone meeting in my current Urology rotation, and
recently presented a paper at our departmental Journal Club in the Colorectal Surgery.
As a research fellow in the Price Institute of Surgical Research, I was responsible for up to 5 students in
the lab at any time. This involved leadership in pioneering and delegating individual projects, supervising
experimental technique, assisting in data analysis and presentation of results. Leadership of this team
provided a challenge in ensuring all members of the team benefited. This was a highly successful endeavor
resulting in a medical student presenting at the Research Louisville symposium (2016) and a prospective
medical student presenting our work at national level. This role also involved the organising the weekly lab
meeting and coordinating with other research fellows and lab staff to ensure successful collaboration.
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Non – Academic Achievements









Louisville Half Marathon
Edinburgh Marathon
Loch Ness Marathon
Students for Kids International Projects (SKIP), Llongwe, Malawi
Mount Kilimanjaro, Tanzania
50/50 Charity Event, University of Glasgow
Certificate of Excellence for Selection in Home International Hill Race
Giffnock North Athletics Club
Level 1 Athletics Coaching Certificate, UK Athletics

2016
2012
2010
2008
2008
2006
2004
2004

Interests
I feel it is important to balance a busy work and academic life with social and physical activities. In
particular, I train and compete regularly in distance running. This has been at school, club, university and
international levels over the past 10 years. I have broadened my range of running to include both hill
running such as the Kintyre Way Relay, and long distance running including the Loch Ness Marathon.
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